Human glp-1 mimetibodies, compositions, methods and uses

ABSTRACT

The present invention relates to at least one improved human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority of the benefits of the filing of U.S.Provisional Application Ser. No. 60/831,704, filed Jul. 18, 2006. Thecomplete disclosures of the aforementioned related U.S. patentapplication is hereby incorporated herein by reference for all purposes.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to improved mammalian GLP-1 mimetibodies,specified portions and variants specific for biologically activeproteins, fragment or ligands, GLP-1 mimetibody encoding andcomplementary nucleic acids, host cells, and methods of making and usingthereof, including therapeutic formulations, administration and devices.

2. Related Art

Recombinant proteins are an emerging class of therapeutic agents. Suchrecombinant therapeutics have engendered advances in protein formulationand chemical modification. Such modifications can potentially enhancethe therapeutic utility of therapeutic proteins, such as by increasinghalf lives (e.g., by blocking their exposure to proteolytic enzymes),enhancing biological activity, or reducing unwanted side effects. Onesuch modification is the use of immunoglobulin fragments fused toreceptor proteins, such as enteracept. Therapeutic proteins have alsobeen constructed using the Fc domain to attempt to provide a longerhalf-life or to incorporate functions such as Fc receptor binding,protein A binding, and complement fixation.

Diabetes is a growing epidemic that is estimated to affect over 300million people by the year 2025 pending an effective pharmaceuticalcure. Type 2 diabetes accounts for 90-95% of all cases. Complicationsresulting from sustained elevated plasma glucose levels includecardiovascular disease, nephropathy, neuropathy, and retinopathy. Inaddition, the β-cells of the pancreas die and therefore cease to secreteinsulin during the later stages of type 2 diabetes. Current treatmentsfor diabetes are associated with a variety of deleterious side effectsincluding hypoglycemia and weight gain. In addition, current treatmentsfor type 2 diabetes do not cure the disease but simply prolong the timeuntil patients require insulin therapy.

Glucagon like peptide-1 (GLP-1) is a 37-amino acid peptide secreted fromthe L-cells of the intestine following an oral glucose challenge. Asubsequent endogenous cleavage between the 6th and 7th position producesthe biologically active GLP-1 (7-37) peptide. The GLP-1 (7-37) peptidesequence can be divided into 2 structural domains. The amino terminaldomain of the peptide is involved in signaling while the remainder ofthe peptide appears to bind to the extracellular loops of the GLP-1receptor in a helical conformation. In response to glucose, the activeGLP-1 binds to the GLP-1 receptor on the pancreas and causes an increasein insulin secretion (insulinotropic action). In addition, it has beenshown that GLP-1 reduces gastric emptying which decreases the bolus ofglucose that is released into the circulation and may reduce foodintake. These actions in combination lower blood glucose levels. GLP-1has also been shown to inhibit apoptosis and increase proliferation ofthe β-cells in the pancreas. Thus, GLP-1 is an attractive therapeutic tolower blood glucose and preserve the β-cells of the pancreas of diabeticpatients. In addition, GLP-1 activity is controlled by blood glucoselevels. When blood glucose levels drop to a certain threshold level,GLP-1 is not active. Therefore, there is no risk of hypoglycemiaassociated with treatment involving GLP-1.

The viability of GLP-1 therapy has been demonstrated in the clinic. Asix-week GLP-1 infusion lowered fasting and 8-hour mean plasma glucoselevels effectively in type 2 diabetic patients. GLP-1 therapy alsoresulted in an improvement in β-cell function. Exenatide is a GLP-1analogue currently in clinical trials. Exenatide was first identified inthe saliva of the gila monster lizard, and is 53% identical to GLP-1.Exenatide can bind the GLP-1 receptor and initiate the signaltransduction cascade responsible for the numerous activities that havebeen attributed to GLP-1 (7-37). To date, it has been shown to reduceHbA1c levels and serum fructosamine levels in patients with type 2diabetes. In addition, it delayed gastric emptying and inhibited foodintake in healthy volunteers.

However, GLP-1 is rapidly inactivated in vivo by the proteasedipeptidyl-peptidase IV (DPP-IV). Therefore, the usefulness of therapyinvolving GLP-1 peptides has been limited by their fast clearance andshort half-lives. For example, GLP-1 (7-37) has a serum half-life ofonly 3 to 5 minutes. GLP-1 (7-36) amide has a time action of about 50minutes when administered subcutaneously. Even analogs and derivativesthat are resistant to endogenous protease cleavage, do not havehalf-lives long enough to avoid repeated administrations over a 24 hourperiod. For example, exenatide is resistant to DPP-IV, yet it stillrequires twice daily preprandial dosing because of the short half-lifeand significant variability in in vivo pharmacokinetics. NN2211, anothercompound currently in clinical trials, is a lipidated GLP-1 analogue. Itis expected to be dosed once daily.

Fast clearance of a therapeutic agent is inconvenient in cases where itis desired to maintain a high blood level of the agent over a prolongedperiod of time since repeated administrations will then be necessary.Furthermore, a long-acting compound is particularly important fordiabetic patients whose past treatment regimen has involved taking onlyoral medication. These patients often have an extremely difficult timetransitioning to a regimen that involves multiple injections ofmedication. A GLP-1 therapy that has an increased half-life would have asignificant advantage over other GLP-1 peptides and compounds indevelopment.

Accordingly, there is a need to provide improved and/or modifiedversions of GLP-1 therapeutic proteins, which overcome one more of theseand other problems known in the art. The mimetibody technology providesa novel delivery platform for peptide therapeutics. A GLP-1 mimetibodymay provide a means of delivering the GLP-1 peptide in a sustainedmanner, providing an improvement over GLP-1 peptides currently indevelopment. Furthermore, based upon its dimeric structure and itstissue distribution characteristics, a GLP-1 mimetibody could havedifferentiable features with regard to insulin secretion, β-cellpreservation, and food intake.

SUMMARY OF THE INVENTION

The present invention provides improved human GLP-1 mimetibodies,including modified immunoglobulins, cleavage products and otherspecified portions and variants thereof, as well as GLP-1 mimetibodycompositions, encoding or complementary nucleic acids, vectors, hostcells, compositions, formulations, devices, transgenic animals,transgenic plants, and methods of making and using thereof, as describedand/or enabled herein, in combination with what is known in the art.

Preferably, such GLP-1 mimetibodies are improved for expression,purification and/or stability by changing O-linked glycosylation sites(such as but not limited to Val-Xaa-Ser) to N-linked glycosylation sites(such as, but not limited to, Asn-Xaa-Ser or Gln-Xaa-Ser). The presentinvention provides such improvements to GLP-1 CH1 deleted mimetibodies(e.g., alanine) or o-glycosylation sites, such as but not limited to thesequence Val-Xaa-Ser, can be substituted with N-glycosylation sites,such as Asn-Xaa-Ser or Gln-Xaa-Ser, as may be preferred, e.g., but notlimited to, as done at the following residues presented in the SequenceListing: Val-Xaa-Ser (O-glycosylation site) changes to N-glycosylationsite Asn-Xaa-Ser at: position 44 in SEQ ID NOS:2, 4, 7-14, position 64in SEQ ID NOS:43, 45, position 82 in SEQ ID NOS:44, 46 and 51; position88 in SEQ ID NOS:48, 50, 53-55, position 89 in SEQ ID NO:47, position 90in SEQ ID NO:49; position 103 and/or 185 in SEQ ID NOS:56 and 63; orposition 39 in SEQ ID NOS:60 and 61; position 79 in SEQ ID NO:64 or anyother suitable position as disclosed herein or as known in the art).

The present invention also provides at least one isolated GLP-1mimetibody or specified portion or variant as described herein and/or asknown in the art. The GLP-1 mimetibody can optionally comprise at leastone CH3 region directly linked with at least one CH2 region directlylinked with at least one portion of at least one hinge region orfragment thereof (H), directly linked with at least one partial variableregion (V), directly linked with an optional linker sequence (L),directly linked to at least one GLP-1 therapeutic peptide (P).

In a preferred embodiment a pair of a CH3-CH2-hinge-partial V regionsequence-linker-therapeutic peptide sequence, the pair optionally linkedby association or covalent linkage, such as, but not limited to, atleast one Cys-Cys disulfide bond or at least one CH4 or otherimmunoglobulin sequence. In one embodiment, a GLP-1 mimetibody comprisesformula (I):

(P(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t),

wherein P is at least one bioactive GLP-1 peptide, variant orderivative, L is at least one linker sequence, which can be apolypeptide that provides structural flexibility by allowing themimetibody to have alternative orientations and binding properties, V isat least one portion of a C-terminus of an immunoglobulin variableregion, H is at least one portion of an immunoglobulin variable hingeregion, CH2 is at least a portion of an immunoglobulin CH2 constantregion, CH3 is at least a portion of an immunoglobulin CH3 constantregion, n is an integer from 1 to 10, and o, p, q, r, s, and t can beindependently an integer from 0 to 10, mimicking different types ofimmunoglobulin molecules e.g., but not limited to IgG1, IgG2, IgG3,IgG4, IgA1, IgA2, IgM, IgD, IgE, or any subclass thereof, and the like,or any combination thereof.

The variable region of the antibody sequence can be, but not limited to,at least one portion of at least one of SEQ ID NOS:47-55, or fragmentthereof as described in Table 1 or SEQ ID NOS:47-64, further optionallycomprising at least one substitution, insertion or deletion as furtherdescribed in FIGS. 1-9 of PCT publication WO 05/05604 (PCT US04/19898)filed Jun. 24, 2004 and published Jan. 20, 2005, with corresponding SEQID NOS:1-9. The CH2, CH3 and hinge region can be, but not limited to, atleast one portion of at least one of SEQ ID NOS:56-64, or fragmentthereof as described in Table 1, further optionally comprising at leastone substitution, insertion or deletion as further described in FIGS.32-40 of PCT publication WO 05/05604 (PCT US04/19898) filed Jun. 24,2004 and published Jan. 20, 2005, with corresponding SEQ ID NOS:32-40.

Thus, a GLP-1 mimetibody of the present invention mimics at least aportion of an antibody or immunoglobulin structure or function with itsinherent properties and functions, while providing a GLP-1 therapeuticpeptide and its inherent or acquired in vitro, in vivo or in situproperties or activities. The various portions of the antibody andtherapeutic peptide portions of GLP-1 mimetibody of the presentinvention can vary as described herein in combination with what is knownin the art.

The present invention also provides at least one isolated GLP-1mimetibody or specified portion or variant that has at least oneactivity, such as, but not limited to known biological activities of atleast one bioactive GLP-1 peptide or polypeptide corresponding to the Pportion of formula (I), as described herein or known in the art.

In one aspect, the present invention provides at least one isolatedhuman GLP-1 mimetibody comprising at least one polypeptide sequence ofSEQ ID NO:1, or optionally with one or more substitutions, deletions orinsertions as described herein or as known in the art. In anotheraspect, at least one GLP-1 mimetibody or specified portion or variant ofthe invention mimics the binding of at least one GLP-1 peptide orpolypeptide corresponding to the P portion of the mimetibody in formula(I), to at least one epitope comprising at least 1-3, to the entireamino acid sequence of at least one ligand, e.g., but not limited to, aGLP-1 receptor, or fragment thereof, wherein the ligand binds to atleast a portion of SEQ ID NO:1, or optionally with one or moresubstitutions, deletions or insertions as described herein or as knownin the art. The at least one GLP-1 mimetibody can optionally bind GLP-1receptor with an affinity of at least 10⁻⁷, at least 10⁻⁸, at least 10⁻⁹M, at least 10⁻¹⁰ M, at least 10⁻¹¹ M, or at least 10⁻¹² M. A GLP-1mimetibody can thus be screened for a corresponding activity accordingto known methods, such as, but not limited to the binding activitytowards a receptor or fragment thereof.

The present invention further provides at least one anti-idiotypeantibody to at least one GLP-1 mimetibody of the present invention. Theanti-idiotype antibody or fragment specifically binds at least one GLP-1mimetibody of the present invention. The anti-idiotype antibody includesany protein or peptide containing molecule that comprises at least aportion of an immunoglobulin molecule, such as but not limited to atleast one complimetarity determining region (CDR) of a heavy or lightchain or a ligand binding portion thereof, a heavy chain or light chainvariable region, a heavy chain or light chain constant region, aframework region, or any portion thereof, that competitively binds aGLP-1 ligand binding region of at least one GLP-1 mimetibody of thepresent invention. Such idiotype antibodies of the invention can includeor be derived from any mammal, such as but not limited to a human, amouse, a rabbit, a rat, a rodent, a primate, and the like.

The present invention provides, in one aspect, isolated nucleic acidmolecules comprising, complementary, having significant identity orhybridizing to, a polynucleotide encoding at least one GLP-1 mimetibodyor GLP-1 mimetibody anti-idiotype antibody, or specified portions orvariants thereof, comprising at least one specified sequence, domain,portion or variant thereof. The present invention further providesrecombinant vectors comprising at least one of said isolated GLP-1mimetibody or GLP-1 mimetibody anti-idiotype antibody encoding nucleicacid molecules, host cells containing such nucleic acids and/orrecombinant vectors, as well as methods of making and/or using suchGLP-1 mimetibody or GLP-1 mimetibody anti-idiotype antibody nucleicacids, vectors and/or host cells.

Also provided is an isolated nucleic acid encoding at least one isolatedmammalian GLP-1 mimetibody or GLP-1 mimetibody anti-idiotype antibody;an isolated nucleic acid vector comprising the isolated nucleic acid,and/or a prokaryotic or eukaryotic host cell comprising the isolatednucleic acid. The host cell can optionally be at least one selected fromCOS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa,myeloma, or lymphoma cells, or any derivative, immortalized ortransformed cell thereof.

The present invention also provides at least one method for expressingat least one GLP-1 mimetibody or GLP-1 mimetibody anti-idiotypeantibody, or specified portion or variant in a host cell, comprisingculturing a host cell as described herein and/or as known in the artunder conditions wherein at least one GLP-1 mimetibody or GLP-1mimetibody anti-idiotype antibody, or specified portion or variant isexpressed in detectable and/or recoverable amounts. Also provided is amethod for producing at least one GLP-1 mimetibody or GLP-1 mimetibodyanti-idiotype antibody, comprising translating the GLP-1 mimetibody orGLP-1 mimetibody anti-idiotype antibody encoding nucleic acid underconditions in vitro, in vivo or in situ, such that the GLP-1 mimetibodyor GLP-1 mimetibody anti-idiotype antibody is expressed in detectable orrecoverable amounts.

Also provided is a method for producing at least one isolated humanGLP-1 mimetibody or GLP-1 anti-idiotype antibody of the presentinvention, comprising providing a host cell or transgenic animal ortransgenic plant capable of expressing in recoverable amounts the GLP-1mimetibody or GLP-1 anti-idiotype antibody.

Further provided in the present invention is at least one GLP-1mimetibody produced by the above methods.

The present invention also provides at least one composition comprising(a) an isolated GLP-1 mimetibody or specified portion or variantencoding nucleic acid and/or GLP-1 mimetibody as described herein; and(b) a suitable carrier or diluent. The carrier or diluent can optionallybe pharmaceutically acceptable, according to known methods. Thecomposition can optionally further comprise at least one furthercompound, protein or composition.

Also provided is a composition comprising at least one isolated humanGLP-1 mimetibody and at least one pharmaceutically acceptable carrier ordiluent. The composition can optionally further comprise an effectiveamount of at least one compound or protein selected from at least one ofa detectable label or reporter, an anti-infective drug, a diabetes orinsuling metabolism related drug, a cardiovascular (CV) system drug, acentral nervous system (CNS) drug, an autonomic nervous system (ANS)drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, ahormonal drug, a drug for fluid or electrolyte balance, a hematologicdrug, an antineoplactic, an immunomodulation drug, an ophthalmic, oticor nasal drug, a topical drug, a nutritional drug, a TNF antagonist, anantirheumatic, a muscle relaxant, a narcotic, a non-steroidanti-inflammatory drug (NTHE), an analgesic, an anesthetic, a sedative,a local anesthetic, a neuromuscular blocker, an antimicrobial, anantipsoriatic, a corticosteriod, an anabolic steroid, an erythropoietin,an immunization, an immunoglobulin, an immunosuppressive, a growthhormone, a hormone replacement drug, a radiopharmaceutical, anantidepressant, an antipsychotic, a stimulant, an asthma medication, abeta agonist, an inhaled steroid, an epinephrine or analog, a cytokine,or a cytokine antagonist.

The present invention also provides at least one composition, deviceand/or method of delivery of a therapeutically or prophylacticallyeffective amount of at least one GLP-1 mimetibody or specified portionor variant, according to the present invention.

The present invention further provides at least one GLP-1 mimetibodymethod or composition, for administering a therapeutically effectiveamount to modulate or treat at least one GLP-1 related condition in acell, tissue, organ, animal or patient and/or, prior to, subsequent to,or during a related condition, as known in the art and/or as describedherein.

The present invention further provides at least one GLP-1 mimetibody,specified portion or variant in a method or composition, whenadministered in a therapeutically effective amount, for modulation, fortreating or reducing the symptoms of, at least one metabolic, immune,cardiovascular, infectious, malignant, and/or neurologic disease in acell, tissue, organ, animal or patient and/or, as needed in manydifferent conditions, such as but not limited to, prior to, subsequentto, or during a related disease or treatment condition, as known in theart.

The present invention further provides at least one GLP-1 mimetibody,specified portion or variant in a method or composition, whenadministered in a therapeutically effective amount, for modulation, fortreating or reducing the symptoms of at least one of a diabetes orinsuling metabolism related disorder, a bone and joint disorder,cardiovascular disorder, a dental or oral disorder, a dermatologicdisorder, an ear, nose or throat disorder, an endocrine or metabolicdisorder, a gastrointestinal disorder, a gynecologic disorder, a hepaticor biliary disorder, a an obstetric disorder, a hematologic disorder, animmunologic or allergic disorder, an infectious disease, amusculoskeletal disorder, a oncologic disorder, a neurologic disorder, anutritional disorder, an opthalmologic disorder, a pediatric disorder, apoisoning disorder, a psychiatric disorder, a renal disorder, apulmonary disorder, or any other known disorder, (See, e.g., The MerckManual, 17th ed., Merck Research Laboratories, Merck and Co., WhitehouseStation, N.J. (1999), entirely incorporated herein by reference), asneeded in many different conditions, such as but not limited to, priorto, subsequent to, or during a related disease or treatment condition,as known in the art.

The present invention also provides at least one composition, deviceand/or method of delivery, for diagnosing GLP-1 related conditions, ofat least one GLP-1 mimetibody, according to the present invention.

The present invention further provides at least one GLP-1 mimetibodymethod or composition, for diagnosing at least one GLP-1 relatedcondition in a cell, tissue, organ, animal or patient and/or, prior to,subsequent to, or during a related condition, as known in the art and/oras described herein.

Also provided is a method for diagnosing or treating a disease conditionin a cell, tissue, organ or animal, comprising: (a) contacting oradministering a composition comprising an effective amount of at leastone isolated human GLP-1 mimetibody of the invention with, or to, thecell, tissue, organ or animal. The method can optionally furthercomprise using an effective amount of 0.001-50 mg/kilogram of the cells,tissue, organ or animal per 0-24 hours, 1-7 days, 1-52 weeks, 1-24months, 1-30 years or any range or value therein. The method canoptionally further comprise using the contacting or the administratingby at least one mode selected from parenteral, subcutaneous,intramuscular, intravenous, intrarticular, intrabronchial,intraabdominal, intracapsular, intracartilaginous, intracavitary,intracelial, intracelebellar, intracerebroventricular, intracolic,intracervical, intragastric, intrahepatic, intramyocardial, intraosteal,intrapelvic, intrapericardiac, intraperitoneal, intrapleural,intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal,intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical,bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.The method can optionally further comprise administering, prior,concurrently or after the (a) contacting or administering, at least onecomposition comprising an effective amount of at least one compound orprotein selected from at least one of a detectable label or reporter, ananti-infective drug, a diabetes or insuling metabolism related drug, acardiovascular (CV) system drug, a central nervous system (CNS) drug, anautonomic nervous system (ANS) drug, a respiratory tract drug, agastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid orelectrolyte balance, a hematologic drug, an antineoplactic, animmunomodulation drug, an ophthalmic, otic or nasal drug, a topicaldrug, a nutritional drug, a TNF antagonist, an antirheumatic, a musclerelaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), ananalgesic, an anesthetic, a sedative, a local anesthetic, aneuromuscular blocker, an antimicrobial, an antipsoriatic, acorticosteriod, an anabolic steroid, an erythropoietin, an immunization,an immunoglobulin, an immunosuppressive, a growth hormone, a hormonereplacement drug, a radiopharmaceutical, an antidepressant, anantipsychotic, a stimulant, an asthma medication, a beta agonist, aninhaled steroid, an epinephrine or analog, a cytokine, or a cytokineantagonist.

Also provided is a medical device, comprising at least one isolatedhuman GLP-1 mimetibody of the invention, wherein the device is suitableto contacting or administering the at least one GLP-1 mimetibody by atleast one mode selected from parenteral, subcutaneous, intramuscular,intravenous, intrarticular, intrabronchial, intraabdominal,intracapsular, intracartilaginous, intracavitary, intracelial,intracelebellar, intracerebroventricular, intracolic, intracervical,intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic,intrapericardiac, intraperitoneal, intrapleural, intraprostatic,intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal,intrasynovial, intrathoracic, intrauterine, intravesical, bolus,vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

Also provided is an article of manufacture for human pharmaceutical ordiagnostic use, comprising packaging material and a container comprisinga solution or a lyophilized form of at least one isolated human GLP-1mimetibody of the present invention. The article of manufacture canoptionally comprise having the container as a component of a parenteral,subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial,intraabdominal, intracapsular, intracartilaginous, intracavitary,intracelial, intracelebellar, intracerebroventricular, intracolic,intracervical, intragastric, intrahepatic, intramyocardial, intraosteal,intrapelvic, intrapericardiac, intraperitoneal, intrapleural,intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal,intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical,bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermaldelivery device or system.

The present invention further provides any invention described herein.

DESCRIPTION OF THE FIGURES

FIG. 1 illustrates the nucleotide (SEQ ID NO: 75) and peptide (SEQ IDNO: 76) sequences of GLP-1 MMB in an IgG4scaffold showing importantfunctional domains.

FIGS. 2A-2C illustrate FACS binding assays of GLP-1 MMB. FIG. 2A showsthat GLP-1 MMB binds to HEK293 cells over-expressing the GLP-1R. Greyarea: GLP-1 MMB but no secondary; grey line: secondary only; dottedline, negative control MMB and secondary; black line: GLP-1 MMB andsecondary. FIG. 2B shows that the GLP-1 MMB does not bind to the controlHEK293 cells. Grey area: GLP-1 MMB but no secondary; black line:secondary only; grey line: GLP-1 MMB and secondary. FIG. 2C shows that aGLP-1 peptide analogue (A2S) is able to compete with GLP-1 MMB forbinding to HEK293 cells over-expressing the GLP-1R. Grey area: GLP-1 MMBbut no secondary; black line: GLP-1 MMB and secondary; break line: GLP-1MMB, 0.2 nM competitor, secondary; dotted line: GLP-1 MMB, 20 nMcompetitor, secondary; grey line: GLP-1 MMB, 100 nM competitor,secondary).

FIGS. 3A-3E illustrate cAMP assays of GLP-1 MMB. FIG. 3A: wt GLP-1 MMBin IgG1 scaffold; FIG. 3B: GLP-1 peptide; FIG. 3C: GLP-1 (A2G) MMB inIgG4 (Ala/A1a, Ser->Pro) scaffold; FIG. 3D: GLP-1 (A2S) MMB in IgG4(Ala/Ala, Ser->Pro) scaffold; FIG. 3E: wt GLP-1 MMB in IgG4 (Ala/Ala,Ser->Pro) scaffold.

FIG. 4 illustrates the resistance of GLP-1 MMB to DPP-IV cleavage.

FIG. 5 shows the stability of GLP-1 MMB in serum.

FIG. 6 demonstrates that GLP-1 MMBs cause insulin secretion in RINmcells.

FIG. 6A shows that GLP-1 (7-36) peptide and exendin-4 peptide stimulatesinsulin release in RINm cells. FIG. 6B shows that GLP-1 (A2S) MMB ineither IgG1 or IgG4 (Ala/Ala, Ser->Pro) scaffold, or GLP-1 (A2G) MMB inIgG4 (Ala/Ala, Ser->Pro) scaffold are active in stimulating insulinsecretion in RINm cells.

FIG. 7 demonstrates that GLP-1 MMB lowers glucose (FIG. 7A) in adose-dependent manner (FIG. 7B).

FIG. 8 shows the pharmacokinetic profile of four GLP-1 MMBs (A2G, A2S,Ex-cap and wild-type) in cynomolgus monkey.

FIG. 9 shows the effects of GLP-1 MMB during an oral glucose tolerancetest in diabetic mice.

FIG. 10 shows the effects of GLP-1 MMB on fasting blood glucose duringchronic dosing to diabetic mice.

FIG. 11 shows the effects of GLP-1 MMB on oral glucose tolerance testafter chronic dosing to diabetic mice.

FIG. 12 shows the effects of GLP-1 MMB on reducing HbA1c after chronicdosing to diabetic mice.

FIG. 13 shows the effects of GLP-1 MMB on blood glucose (FIG. 13A) andinsulin (FIG. 13B) levels in an oral glucose tolerance test in normalcynomolgus monkeys.

FIG. 14 shows the effects of GLP-1 MMB on insulin staining in islets ofdiabetic mice after a single dose.

FIG. 15 demonstrates that GLP-1 MMB delays gastric emptying in normaldogs.

FIG. 16 demonstrates that GLP-1 MMB lowers blood glucose following anoral glucose tolerance test in diet induced obese mice.

FIG. 17 demonstrates that GLP-1 MMB lowers blood glucose (FIG. 17A) andlowers insulin level (FIG. 17B) in an intraperitoneal glucose tolerancetest in diabetic mice.

FIG. 18A demonstrates cAMP response in rat INS-1E cells to increasingconcentrations of GLP-1MMB. The data were fit to a hyperbola providingan EC₅₀ of 8.7 nM and a maximal amount of secreted cAMP of 48.3 nM.

FIG. 18B demonstrates cAMP response in rat INS-1E cells to increasingconcentrations of GLP-1 peptide. The data were fit to a hyperbolaproviding an EC₅₀ of 0.11 nM and a maximal amount of secreted cAMP of46.7 nM.

FIG. 19 demonstrates insulin secretion in rat INS-1E cells at increasingconcentrations of GLP-1MMB.

FIG. 20A demonstrates GLP-1MMB levels in rat plasma following single ivand sc administration (3 mg/kg).

FIG. 20B demonstrates GLP-1MMB levels in monkey plasma following singleiv administration (1 mg/kg).

FIG. 21A demonstrates ipGTT in DIO mice dosed with GLP-1MMB.

FIG. 21B demonstrates calculated area under the curve (AUC) for ipGTTpresented in FIG. 1

FIG. 21C demonstrates the data from FIG. 2 were fit to a hyperbola,providing an ED₅₀ of 15 μg/kg.

FIGS. 22A and B demonstratre 24 hour cumulative food intake in wild type(A) and GLP-1R−/− (B) mice treated with a single iv dose of CNTO1996 (1mg/kg), exendin-4 (0.07 mg/kg) and GLP-1 MMB (1 mg/kg). Values representmean±SE; *p<0.05 vs. CNTO1996-treated group.

FIGS. 23A, B, and C, demonstrate glucose tolerance test in wild type (A)and GLP-1R−/− (B) mice following a single iv dose of CNTO1996 (1 mg/kg),exendin-4 (0.07 mg/kg) and GLP-1 MMB (1 mg/kg). (C) Area under the curvefor ipGTT tests in wild type (black bar) and GLP-1R−/− (grey bar) mice.Values represent mean±SE; *p<0.05 vs. CNTO1996-treated group.

FIG. 24 demonstrates stomach content in wild type (black bars) andGLP-1R−/− (grey bars) mice treated with CNTO1996 (1 mg/kg), exendin-4(0.07 mg/kg) and GLP-1 MMB (1 mg/kg). Values represent mean±SE; *p<0.05vs. CNTO1996-treated group.

FIG. 25 demonstrates glucose tolerance test in DIO mice performed atvarious time points following single iv administration of a GLP-1 MMB (1mg/kg).

FIG. 26 demonstrates the area under the curve for data obtained duringthe ipGTT in DIO mice (FIG. 25).

FIG. 27 demonstrates GLP-1 MMB levels in DIO mice plasma followingsingle iv administration (1 mg/kg).

FIG. 28 demonstrates the area under the curve for the glucose tolerancetest following single iv administration of a GLP-1 MMB (1 mg/kg) plottedas a function of the GLP-1 MMB plasma concentration immediately afterthe glucose tolerance test.

DESCRIPTION OF THE INVENTION

The present invention provides isolated, recombinant and/or syntheticmimetibodies or specified portions or variants, as well as compositionsand encoding nucleic acid molecules comprising at least onepolynucleotide encoding at least one GLP-1 mimetibody. Such mimetibodiesor specified portions or variants of the present invention comprisespecific GLP-1 mimetibody sequences, domains, fragments and specifiedvariants thereof, and methods of making and using said nucleic acids andmimetibodies or specified portions or variants, including therapeuticcompositions, methods and devices.

Preferably, such GLP-1 mimetibodies are improved for expression,purification and/or stability by changing O-linked glycosylation sites(such as but not limited to Val-Xaa-Ser) to N-linked glycosylation sites(such as, but not limited to, Asn-Xaa-Ser or Gln-Xaa-Ser). The presentinvention provides such improvements to GLP-1 CH1 deleted mimetibodies.

The present invention also provides at least one isolated GLP-1mimetibody or specified portion or variant as described herein and/or asknown in the art. The GLP-1 mimetibody can optionally comprise at leastone CH3 region directly linked with at least one CH2 region directlylinked with at least one hinge region or fragment thereof (H), directlylinked with at least one partial variable region (V), directly linkedwith an optional linker sequence (L), directly linked to at least oneGLP-1 therapeutic peptide (P).

In a preferred embodiment a GLP-1 mimetibody comprises formula (I):

((P(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t),

where P is at least one bioactive GLP-1 polypeptide, L is at least onelinker sequence, which can be a polypeptide that provides structuralflexibility by allowing the mimetibody to have alternative orientationsand binding properties, V is at least one portion of a C-terminus of animmunoglobulin variable region, H is at least one portion of animmunoglobulin variable hinge region, CH2 is at least a portion of animmunoglobulin CH2 constant region, CH3 is at least a portion of animmunoglobulin CH3 constant region, m, n, o, p, q, r, s and t can beindependently an integer between and including 0 and 10, mimickingdifferent types of immunoglobulin molecules, e.g., but not limited toIgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM, IgD, IgE, or any subclassthereof, and the like, or any combination thereof.

Preferably, such GLP-1 mimetibodies are improved for expression,purification and/or stability by changing O-linked glycosylation sites(such as but not limited to Val-Xaa-Ser) to N-linked glycosylation sites(such as, but not limited to, Asn-Xaa-Ser or Gln-Xaa-Ser). The presentinvention provides such improvements to GLP-1 CH1 deleted mimetibodies.

Thus, a GLP-1 mimetibody of the present invention mimics an antibodystructure with its inherent properties and functions, while providing atherapeutic peptide and its inherent or acquired in vitro, in vivo or insitu properties or activities. In a preferred embodiment where t=1, themonomer CH3-CH2-hinge-partial J sequence-linker-therapeutic peptide canbe linked to other monomers by association or covalent linkage, such as,but not limited to, a Cys-Cys disulfide bond. The various portions ofthe antibody and the GLP-1 therapeutic peptide portions of at least oneGLP-1 mimetibody of the present invention can vary as described hereinin combination with what is known in the art.

The portion of CH3-CH2-hinge may be extensively modified to form avariant in accordance with this invention, provided binding to thesalvage receptor is maintained. In such variants, one may remove one ormore native sites that provide structural features or functionalactivity not required by the fusion molecules of this invention. One mayremove these sites by, for example, substituting or deleting residues,inserting residues into the site, or truncating portions containing thesite. The inserted or substituted residues may also be altered aminoacids, such as peptidomimetics or D-amino acids. A variant ofCH3-CH2-hinge may lack one or more native sites or residues that affector are involved in (1) disulfide bond formation, (2) incompatibilitywith a selected host cell, (3) heterogeneity upon expression in aselected host cell, (4) glycosylation, (5) interaction with complement,(6) binding to an Fc receptor other than a salvage receptor, or (7)antibody-dependent cellular cytotoxicity (ADCC). Exemplary CH3-CH2-hingevariants include molecules and sequences in which: 1. Sites involved indisulfide bond formation are removed. Such removal may avoid reactionwith other cysteine-containing proteins present in the host cell used toproduce the molecules of the invention. For this purpose, the cysteineresidues may be deleted or substituted with other amino acids (e.g.,alanyl, seryl). Even when cysteine residues are removed, the singlechain CH3-CH2-hinge domains can still form a dimeric CH3-CH2-hingedomain that is held together non-covalently; 2. The CH3-CH2-hinge regionis modified to make it more compatible with a selected host cell. Forexample, when the molecule is expressed recombinantly in a bacterialcell such as E. coli, one may remove the PA sequence in the hinge, whichmay be recognized by a digestive enzyme in E. coli such as prolineiminopeptidase; 3. A portion of the hinge region is deleted orsubstituted with other amino acids to prevent heterogeneity whenexpressed in a selected host cell; 4. One or more glycosylation sitesare removed. Residues that are typically glycosylated (e.g., valine orasparagine) may confer cytolytic response. Such residues may be deletedor substituted with unglycosylated residues (e.g., alanine) oro-glycosylation sites, such as but not limited to the sequenceVal-Xaa-Ser, can be substituted with N-glycosylation sites, such asAsn-Xaa-Ser or Gln-Xaa-Ser, as may be preferred, e.g., as done at thefollowing residues presented in the Sequence Listing Val-Xaa-Ser(O-glycosylation site) changes to N-glycosylation site Asn-Xaa-Ser at:position 44 in SEQ ID NOS:2, 4, 7-14, position 64 in SEQ ID NOS:43, 45,position 82 in SEQ ID NOS:44, 46 and 51; position 88 in SEQ ID NOS:48,50, 53-55, position 89 in SEQ ID NO:47, position 90 in SEQ ID NO:49;position 103 and/or 185 in SEQ ID NOS:56 and 63; or position 39 in SEQID NOS:60 and 61; position 79 in SEQ ID NO:64 or any other suitableposition as disclosed herein or as known in the art); 5. Sites involvedin interaction with complement, such as the C1q binding site, areremoved. Complement recruitment may not be advantageous for themolecules of this invention and so may be avoided with such a variant;6. Sites are removed that affect binding to Fc receptors other than asalvage receptor. The CH3-CH2-hinge region may have sites forinteraction with certain white blood cells that are not required for thefusion molecules of the present invention and so may be removed; 7. TheADCC site is removed. ADCC sites are known in the art; see, for example,Molec. Immunol. 29 (5): 633-9 (1992) with regard to ADCC sites in IgG1.These sites, as well, are not required for the fusion molecules of thepresent invention and so may be removed.

Linker polypeptide provides structural flexibility by allowing themimetibody to have alternative orientations and binding properties. Whenpresent, its chemical structure is not critical. The linker ispreferably made up of amino acids linked together by peptide bonds.Thus, in preferred embodiments, the linker is made up of from 1 to 20amino acids linked by peptide bonds, wherein the amino acids areselected from the 20 naturally occurring amino acids. Some of theseamino acids may be glycosylated, as is well understood by those in theart. In a more preferred embodiment, the 1 to 20 amino acids areselected from glycine, alanine, serine, proline, asparagine, glutamine,and lysine. Even more preferably, a linker is made up of a majority ofamino acids that are sterically unhindered, such as glycine and alanine.Thus, preferred linkers are poly(Gly-Ser), polyglycines (particularly(Gly)₄ (SEQ ID NO: 73), (Gly)₅ (SEQ ID NO: 74)), poly(Gly-Ala), andpolyalanines. Other specific examples of linkers are: (Gly)₃Lys(Gly)₄(SEQ ID NO:65), (Gly)₃AsnGlySer(Gly)₂ (SEQ ID NO:66), (Gly)₃Cys(Gly)₄(SEQ ID NO:67), and GlyProAsnGlyGly (SEQ ID NO:68).

To explain the above nomenclature, for example, (Gly)₃Lys(Gly)₄ (SEQ IDNO: 65) means Gly-Gly-Gly-Lys-Gly-Gly-Gly-Gly (SEQ ID NO: 65).Combinations of Gly and Ala are also preferred. The linkers shown hereare exemplary; linkers within the scope of this invention may be muchlonger and may include other residues.

Non-peptide linkers are also possible. For example, alkyl linkers suchas —NH—(CH₂)s-C(O)—, wherein s=2-20 could be used. These alkyl linkersmay further be substituted by any non-sterically hindering group such aslower alkyl (e.g., C₁-C₆) lower acyl, halogen (e.g., Cl, Br), CN, NH2,phenyl, etc. An exemplary non-peptide linker is a PEG linker which has amolecular weight of 100 to 5000 kD, preferably 100 to 500 kD. Thepeptide linkers may be altered to form derivatives in the same manner asdescribed above.

As used herein, a “GLP-1 peptide,” or “GLP-1 peptide, variant, orderivative” can be at least one GLP-1 peptide, GLP-1 fragment, GLP-1homolog, GLP-1 analog, or GLP-1 derivative. A GLP-1 peptide has fromabout twenty-five to about forty-five naturally occurring ornon-naturally occurring amino acids that have sufficient homology tonative GLP-1 (7-37) such that they exhibit insulinotropic activity bybinding to the GLP-1 receptor on β-cells in the pancreas. GLP-1 (7-37)has the amino acid sequence of SEQ ID NO:15:

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Glu-Trp-Leu-Val-Lys-Gly-Arg-Gly.

A GLP-1 fragment is a polypeptide obtained after truncation of one ormore amino acids from the N-terminus and/or C-terminus of GLP-1 (7-37)or an analog or derivative thereof. A GLP-1 homolog is a peptide inwhich one or more amino acids have been added to the N-terminus and/orC-terminus of GLP-1 (7-37), or fragments or analogs thereof. A GLP-1analog is a peptide in which one or more amino acids of GLP-1 (7-37)have been modified and/or substituted. A GLP-1 analog has sufficienthomology to GLP-1 (7-37) or a fragment of GLP-1 (7-37) such that theanalog has insulinotropic activity. A GLP-1 derivative is defined as amolecule having the amino acid sequence of a GLP-1 peptide, a GLP-1homolog or a GLP-1 analog, but additionally having chemical modificationof one or more of its amino acid side groups, α-carbon atoms, terminalamino group, or terminal carboxylic acid group.

Numerous active GLP-1 fragments, analogs and derivatives are known inthe art and any of these analogs and derivatives can also be part of theGLP-1 mimetibody of the present invention. Some GLP-1 analogs and GLP-1fragments known in the art are disclosed in U.S. Pat. Nos. 5,118,666,5,977,071, and 5,545,618, and Adelhorst, et al., J. Biol. Chem. 269:6275(1994). Examples include, but not limited to, GLP-1 (7-34), GLP-1(7-35), GLP-1 (7-36), Gln9-GLP-1 (7-37), D-Gln9-GLP-1 (7-37),Thr16-Lys18-GLP-1 (7-37), and Lys18-GLP-1 (7-37).

A “GLP-1 mimetibody,” “GLP-1 mimetibody portion,” or “GLP-1 mimetibodyfragment” and/or “GLP-1 mimetibody variant” and the like has, mimics orsimulates at least one biological activity, such as but not limited toligand binding, in vitro, in situ and/or preferably in vivo, of at leastone GLP-1 peptide, variant or derivative, such as but not limited to atleast one of SEQ ID NO:1. For example, a suitable GLP-1 mimetibody,specified portion, or variant can also modulate, increase, modify,activate, at least one GLP-1 receptor signaling or other measurable ordetectable activity.

GLP-1 mimetibodies useful in the methods and compositions of the presentinvention are characterized by suitable affinity binding to proteinligands, for example, GLP-1 receptors, and optionally and preferablyhaving low toxicity. In particular, a GLP-1 mimetibody, where theindividual components, such as the portion of variable region, constantregion (without a CH1 portion) and framework, or any portion thereof(e.g., a portion of the J, D or V regions of the variable heavy or lightchain; at least a portion of at least one hinge region, the constantheavy chain or light chain, and the like) individually and/orcollectively optionally and preferably possess low immunogenicity, isuseful in the present invention. The mimetibodies that can be used inthe invention are optionally characterized by their ability to treatpatients for extended periods with good to excellent alleviation ofsymptoms and low toxicity. Low immunogenicity and/or high affinity, aswell as other undefined properties, may contribute to the therapeuticresults achieved. “Low immunogenicity” is defined herein as raisingsignificant HAMA, HACA or HAHA responses in less than about 75%, orpreferably less than about 50, 45, 40, 35, 30, 35, 20, 15, 10, 9, 8, 7,6, 5, 4, 3, 2, and/or 1% of the patients treated and/or raising lowtitres in the patient treated (less than about 300, preferably less thanabout 100 measured with a double antigen enzyme immunoassay) (see, e.g.,Elliott et al., Lancet 344:1125-1127 (1994)).

Utility. The isolated nucleic acids of the present invention can be usedfor production of at least one GLP-1 mimetibody, fragment or specifiedvariant thereof, which can be used to effect in an cell, tissue, organor animal (including mammals and humans), to modulate, treat, alleviate,help prevent the incidence of, or reduce the symptoms of, at least oneprotein related condition, selected from, but not limited to, at leastone of a diabetes related disorder, an insulin metabolism relateddisorder, an immune disorder or disease, a cardiovascular disorder ordisease, an infectious, malignant, and/or neurologic disorder ordisease, as well as other known or specified protein related conditions.

Such a method can comprise administering an effective amount of acomposition or a pharmaceutical composition comprising at least oneGLP-1 mimetibody or specified portion or variant to a cell, tissue,organ, animal or patient in need of such modulation, treatment,alleviation, prevention, or reduction in symptoms, effects ormechanisms. The effective amount can comprise an amount of about 0.0001to 500 mg/kg per single or multiple administration, or to achieve aserum concentration of 0.01-5000 μg/ml serum concentration per single ormultiple administration, or any effective range or value therein, asdone and determined using known methods, as described herein or known inthe relevant arts.

Citations. All publications or patents cited herein are entirelyincorporated herein by reference as they show the state of the art atthe time of the present invention and/or to provide description andenablement of the present invention. Publications refer to anyscientific or patent publications, or any other information available inany media format, including all recorded, electronic or printed formats.The following references are entirely incorporated herein by reference:Ausubel, et al., ed., Current Protocols in Molecular Biology, John Wiley& Sons, Inc., NY, N.Y. (1987-2003); Sambrook, et al., Molecular Cloning:A Laboratory Manual, 2^(nd) Edition, Cold Spring Harbor, N.Y. (1989);Harlow and Lane, Antibodies, a Laboratory Manual, Cold Spring Harbor,N.Y. (1989); Colligan, et al., eds., Current Protocols in Immunology,John Wiley & Sons, Inc., NY (1994-2003); Colligan et al., CurrentProtocols in Protein Science, John Wiley & Sons, NY, N.Y., (1997-2003).

Mimetibodies of the Present Invention. The GLP-1 mimetibody canoptionally comprise at least one CH3 region directly linked with atleast one CH2 region directly linked with at least one portion of atleast one hinge region fragment (H), such as comprising at least onecore hinge region, directly linked with at least one partial variableregion (V), directly linked with an optional linker sequence (L),directly linked to at least one GLP-1 therapeutic peptide (P). In apreferred embodiment, a pair of a CH3-CH2-H-V-L-P can be linked byassociation or covalent linkage, such as, but not limited to, a Cys-Cysdisulfide bond. Thus, a GLP-1 mimetibody of the present invention mimicsan antibody structure with its inherent properties and functions, whileproviding a therapeutic peptide and its inherent or acquired in vitro,in vivo or in situ properties or activities. The various portions of theantibody and therapeutic peptide portions of at least one GLP-1mimetibody of the present invention can vary as described herein incombination with what is known in the art.

Mimetibodies of the present invention thus provide at least one suitableproperty as compared to known proteins, such as, but not limited to, atleast one of increased half-life, increased activity, more specificactivity, increased avidity, increased or decreased off rate, a selectedor more suitable subset of activities, less immunogenicity, increasedquality or duration of at least one desired therapeutic effect, lessside effects, and the like.

Fragments of mimetibodies according to Formula (I) can be produced byenzymatic cleavage, synthetic or recombinant techniques, as known in theart and/or as described herein. Mimetibodies can also be produced in avariety of truncated forms using antibody genes in which one or morestop codons have been introduced upstream of the natural stop site. Thevarious portions of mimetibodies can be joined together chemically byconventional techniques, or can be prepared as a contiguous proteinusing genetic engineering techniques. For example, a nucleic acidencoding at least one of the constant regions of a human antibody chaincan be expressed to produce a contiguous protein for use in mimetibodiesof the present invention. See, e.g., Ladner et al., U.S. Pat. No.4,946,778 and Bird, R. E. et al., Science, 242: 423-426 (1988),regarding single chain antibodies.

As used herein, the term “human mimetibody” refers to an antibody inwhich substantially every part of the protein (e.g., GLP-1 peptide,C_(H) domains (e.g., C_(H)2, C_(H)3), hinge, V) is expected to besubstantially non-immunogenic in humans with only minor sequence changesor variations. Such changes or variations optionally and preferablyretain or reduce the immunogenicity in humans relative to non-modifiedhuman antibodies, or mimetibodies of the present invention. Thus, ahuman antibody and corresponding GLP-1 mimetibody of the presentinvention is distinct from a chimeric or humanized antibody. It ispointed out that the GLP-1 mimetibody can be produced by a non-humananimal or cell that is capable of expressing human immunoglobulins(e.g., heavy chain and/or light chain) genes.

Human mimetibodies that are specific for at least one protein ligandthereof can be designed against an appropriate ligand, such as anisolated GLP-1 receptor, or a portion thereof (including syntheticmolecules, such as synthetic peptides). Preparation of such mimetibodiesare performed using known techniques to identify and characterize ligandbinding regions or sequences of at least one protein or portion thereof.

In a preferred embodiment, at least one GLP-1 mimetibody or specifiedportion or variant of the present invention is produced by at least onecell line, mixed cell line, immortalized cell or clonal population ofimmortalized and/or cultured cells. Immortalized protein producing cellscan be produced using suitable methods. Preferably, the at least oneGLP-1 mimetibody or specified portion or variant is generated byproviding nucleic acid or vectors comprising DNA derived or having asubstantially similar sequence to, at least one human immunoglobulinlocus that is functionally rearranged, or which can undergo functionalrearrangement, and which further comprises a mimetibody structure asdescribed herein, e.g., but not limited to Formula (I), wherein portionsof C-terminal variable regions can be used for V, hinge regions for H,CH2 for CH2 and CH3 for CH3, as known in the art.

The term “functionally rearranged,” as used herein refers to a segmentof nucleic acid from an immunoglobulin locus that has undergone V(D)Jrecombination, thereby producing an immunoglobulin gene that encodes animmunoglobulin chain (e.g., heavy chain), or any portion thereof. Afunctionally rearranged immunoglobulin gene can be directly orindirectly identified using suitable methods, such as, for example,nucleotide sequencing, hybridization (e.g., Southern blotting, Northernblotting) using probes that can anneal to coding joints between genesegments or enzymatic amplification of immunoglobulin genes (e.g.,polymerase chain reaction) with primers that can anneal to coding jointsbetween gene segments. Whether a cell produces a GLP-1 mimetibody orportion or variant comprising a particular variable region or a variableregion comprising a particular sequence (e.g., at least one P sequence)can also be determined using suitable methods.

Mimetibodies, specified portions and variants of the present inventioncan also be prepared using at least one GLP-1 mimetibody or specifiedportion or variant encoding nucleic acid to provide transgenic animalsor mammals, such as goats, cows, horses, sheep, and the like, thatproduce such mimetibodies or specified portions or variants in theirmilk. Such animals can be provided using known methods as applied forantibody encoding sequences. See, e.g., but not limited to, U.S. Pat.Nos. 5,827,690; 5,849,992; 4,873,316; 5,849,992; 5,994,616; 5,565,362;5,304,489, and the like, each of which is entirely incorporated hereinby reference.

Mimetibodies, specified portions and variants of the present inventioncan additionally be prepared using at least one GLP-1 mimetibody orspecified portion or variant encoding nucleic acid to provide transgenicplants and cultured plant cells (e.g., but not limited to tobacco andmaize) that produce such mimetibodies, specified portions or variants inthe plant parts or in cells cultured therefrom. As a non-limitingexample, transgenic tobacco leaves expressing recombinant proteins havebeen successfully used to provide large amounts of recombinant proteins,e.g., using an inducible promoter. See, e.g., Cramer et al., Curr. Top.Microbol. Immunol. 240:95-118 (1999) and references cited therein. Also,transgenic maize or corn have been used to express mammalian proteins atcommercial production levels, with biological activities equivalent tothose produced in other recombinant systems or purified from naturalsources. See, e.g., Hood et al., Adv. Exp. Med. Biol. 464:127-147 (1999)and references cited therein. Antibodies have also been produced inlarge amounts from transgenic plant seeds including antibody fragments,such as single chain mimetibodies (scFv's), including tobacco seeds andpotato tubers. See, e.g., Conrad et al., Plant Mol. Biol. 38:101-109(1998) and references cited therein. Thus, mimetibodies, specifiedportions and variants of the present invention can also be producedusing transgenic plants, according to know methods. See also, e.g.,Fischer et al., Biotechnol. Appl. Biochem. 30:99-108 (October, 1999), Maet al., Trends Biotechnol. 13:522-7 (1995); Ma et al., Plant Physiol.109:341-6 (1995); Whitelam et al., Biochem. Soc. Trans. 22:940-944(1994); and references cited therein. The above references are entirelyincorporated herein by reference.

The mimetibodies of the invention can bind human protein ligands with awide range of affinities (K_(D)). In a preferred embodiment, at leastone human GLP-1 mimetibody of the present invention can optionally bindat least one protein ligand with high affinity. For example, at leastone GLP-1 mimetibody of the present invention can bind at least oneprotein ligand with a K_(D) equal to or less than about 10⁻⁷ M or, morepreferably, with a K_(D) equal to or less than about 0.1-9.9 (or anyrange or value therein)×10⁻⁷, 10⁻⁸, 10⁻⁹, 10⁻¹⁰, 10⁻¹¹, 10⁻¹², or 10⁻¹³M, or any range or value therein.

The affinity or avidity of a GLP-1 mimetibody for at least one proteinligand can be determined experimentally using any suitable method, e.g.,as used for determining antibody-antigen binding affinity or avidity.(See, for example, Berzofsky, et al., “Antibody-Antigen Interactions,”In Fundamental Immunology, Paul, W. E., Ed., Raven Press: New York, N.Y.(1984); Kuby, Janis Immunology, W. H. Freeman and Company: New York,N.Y. (1992); and methods described herein). The measured affinity of aparticular GLP-1 mimetibody-ligand interaction can vary if measuredunder different conditions (e.g., salt concentration, pH). Thus,measurements of affinity and other ligand-binding parameters (e.g.,K_(D), K_(a), K_(d)) are preferably made with standardized solutions ofGLP-1 mimetibody and ligand, and a standardized buffer, such as thebuffer described herein or known in the art.

Nucleic Acid Molecules. Using the information provided herein, such asthe nucleotide sequences encoding at least 90-100% of the contiguousamino acids of at least one of SEQ ID NOS:1 and 6, as well as at leastone portion of an antibody, wherein the above sequences are inserted asthe P sequence of Formula (I) to provide a GLP-1 mimetibody of thepresent invention, further comprising specified fragments, variants orconsensus sequences thereof, or a deposited vector comprising at leastone of these sequences, a nucleic acid molecule of the present inventionencoding at least one GLP-1 mimetibody or specified portion or variantcan be obtained using methods described herein or as known in the art.

Nucleic acid molecules of the present invention can be in the form ofRNA, such as mRNA, hnRNA, tRNA or any other form, or in the form of DNA,including, but not limited to, cDNA and genomic DNA obtained by cloningor produced synthetically, or any combination thereof. The DNA can betriple-stranded, double-stranded or single-stranded, or any combinationthereof. Any portion of at least one strand of the DNA or RNA can be thecoding strand, also known as the sense strand, or it can be thenon-coding strand, also referred to as the anti-sense strand.

Isolated nucleic acid molecules of the present invention can includenucleic acid molecules comprising an open reading frame (ORF),optionally with one or more introns, nucleic acid molecules comprisingthe coding sequence for a GLP-1 mimetibody or specified portion orvariant; and nucleic acid molecules which comprise a nucleotide sequencesubstantially different from those described above but which, due to thedegeneracy of the genetic code, still encode at least one GLP-1mimetibody as described herein and/or as known in the art. Of course,the genetic code is well known in the art. Thus, it would be routine forone skilled in the art to generate such degenerate nucleic acid variantsthat code for specific GLP-1 mimetibody or specified portion or variantsof the present invention. See, e.g., Ausubel, et al., supra, and suchnucleic acid variants are included in the present invention.

As indicated herein, nucleic acid molecules of the present inventionwhich comprise a nucleic acid encoding a GLP-1 mimetibody or specifiedportion or variant can include, but are not limited to, those encodingthe amino acid sequence of a GLP-1 mimetibody fragment, by itself; thecoding sequence for the entire GLP-1 mimetibody or a portion thereof;the coding sequence for a GLP-1 mimetibody, fragment or portion, as wellas additional sequences, such as the coding sequence of at least onesignal leader or fusion peptide, with or without the aforementionedadditional coding sequences, such as at least one intron, together withadditional, non-coding sequences, including but not limited to,non-coding 5′ and 3′ sequences, such as the transcribed, non-translatedsequences that play a role in transcription, mRNA processing, includingsplicing and polyadenylation signals (for example—ribosome binding andstability of mRNA); an additional coding sequence that codes foradditional amino acids, such as those that provide additionalfunctionalities. Thus, the sequence encoding a GLP-1 mimetibody orspecified portion or variant can be fused to a marker sequence, such asa sequence encoding a peptide that facilitates purification of the fusedGLP-1 mimetibody or specified portion or variant comprising a GLP-1mimetibody fragment or portion.

Polynucleotides Which Selectively Hybridize to a Polynucleotide asDescribed Herein. The present invention provides isolated nucleic acidsthat hybridize under selective hybridization conditions to apolynucleotide disclosed herein, or others disclosed herein, includingspecified variants or portions thereof. Thus, the polynucleotides ofthis embodiment can be used for isolating, detecting, and/or quantifyingnucleic acids comprising such polynucleotides.

Low or moderate stringency hybridization conditions are typically, butnot exclusively, employed with sequences having a reduced sequenceidentity relative to complementary sequences. Moderate and highstringency conditions can optionally be employed for sequences ofgreater identity. Low stringency conditions allow selectivehybridization of sequences having about 40-99% sequence identity and canbe employed to identify orthologous or paralogous sequences.

Optionally, polynucleotides of this invention will encode at least aportion of a GLP-1 mimetibody or specified portion or variant encoded bythe polynucleotides described herein. The polynucleotides of thisinvention embrace nucleic acid sequences that can be employed forselective hybridization to a polynucleotide encoding a GLP-1 mimetibodyor specified portion or variant of the present invention. See, e.g.,Ausubel, supra; Colligan, supra, each entirely incorporated herein byreference.

Construction of Nucleic Acids. The isolated nucleic acids of the presentinvention can be made using (a) recombinant methods, (b) synthetictechniques, (c) purification techniques, or combinations thereof, aswell-known in the art.

The nucleic acids can conveniently comprise sequences in addition to apolynucleotide of the present invention. For example, a multi-cloningsite comprising one or more endonuclease restriction sites can beinserted into the nucleic acid to aid in isolation of thepolynucleotide. Also, translatable sequences can be inserted to aid inthe isolation of the translated polynucleotide of the present invention.For example, a hexa-histidine marker sequence provides a convenientmeans to purify the proteins of the present invention. The nucleic acidof the present invention—excluding the coding sequence—is optionally avector, adapter, or linker for cloning and/or expression of apolynucleotide of the present invention.

Additional sequences can be added to such cloning and/or expressionsequences to optimize their function in cloning and/or expression, toaid in isolation of the polynucleotide, or to improve the introductionof the polynucleotide into a cell. Use of cloning vectors, expressionvectors, adapters, and linkers is well known in the art. See, e.g.,Ausubel, supra; or Sambrook, supra.

Recombinant Methods for Constructing Nucleic Acids. The isolated nucleicacid compositions of this invention, such as RNA, cDNA, genomic DNA, orany combination thereof, can be obtained from biological sources usingany number of cloning methodologies known to those of skill in the art.In some embodiments, oligonucleotide probes that selectively hybridize,under suitable stringency conditions, to the polynucleotides of thepresent invention are used to identify the desired sequence in a cDNA orgenomic DNA library. The isolation of RNA, and construction of cDNA andgenomic libraries, is well known to those of ordinary skill in the art.(See, e.g., Ausubel, supra; or Sambrook, supra).

Synthetic Methods for Constructing Nucleic Acids. The isolated nucleicacids of the present invention can also be prepared by direct chemicalsynthesis by known methods (see, e.g., Ausubel, et al., supra). Chemicalsynthesis generally produces a single-stranded oligonucleotide, whichcan be converted into double-stranded DNA by hybridization with acomplementary sequence, or by polymerization with a DNA polymerase usingthe single strand as a template. One of skill in the art will recognizethat while chemical synthesis of DNA can be limited to sequences ofabout 100 or more bases, longer sequences can be obtained by theligation of shorter sequences.

Recombinant Expression Cassettes. The present invention further providesrecombinant expression cassettes comprising a nucleic acid of thepresent invention. A nucleic acid sequence of the present invention, forexample a cDNA or a genomic sequence encoding a GLP-1 mimetibody orspecified portion or variant of the present invention, can be used toconstruct a recombinant expression cassette that can be introduced intoat least one desired host cell. A recombinant expression cassette willtypically comprise a polynucleotide of the present invention operablylinked to transcriptional initiation regulatory sequences that willdirect the transcription of the polynucleotide in the intended hostcell. Both heterologous and non-heterologous (i.e., endogenous)promoters can be employed to direct expression of the nucleic acids ofthe present invention.

In some embodiments, isolated nucleic acids that serve as promoter,enhancer, or other elements can be introduced in the appropriateposition (upstream, downstream or in intron) of a non-heterologous formof a polynucleotide of the present invention so as to up or downregulate expression of a polynucleotide of the present invention. Forexample, endogenous promoters can be altered in vivo or in vitro bymutation, deletion and/or substitution, as known in the art. Apolynucleotide of the present invention can be expressed in either senseor anti-sense orientation as desired. It will be appreciated thatcontrol of gene expression in either sense or anti-sense orientation canhave a direct impact on the observable characteristics. Another methodof suppression is sense suppression. Introduction of nucleic acidconfigured in the sense orientation has been shown to be an effectivemeans by which to block the transcription of target genes.

Vectors And Host Cells. The present invention also relates to vectorsthat include isolated nucleic acid molecules of the present invention,host cells that are genetically engineered with the recombinant vectors,and the production of at least one GLP-1 mimetibody or specified portionor variant by recombinant techniques, as is well known in the art. See,e.g., Sambrook, et al., supra; Ausubel, et al., supra, each entirelyincorporated herein by reference.

The polynucleotides can optionally be joined to a vector containing aselectable marker for propagation in a host. Generally, a plasmid vectoris introduced into a cell using suitable known methods, such aselectroporation and the like, other known methods include the use of thevector as a precipitate, such as a calcium phosphate precipitate, or ina complex with a charged lipid. If the vector is a virus, it can bepackaged in vitro using an appropriate packaging cell line and thentransduced into host cells.

The DNA insert should be operatively linked to an appropriate promoter.The expression constructs will further contain sites optionally for atleast one of transcription initiation, termination and, in thetranscribed region, a ribosome binding site for translation. The codingportion of the mature transcripts expressed by the constructs willpreferably include a translation initiating at the beginning and atermination codon (e.g., UAA, UGA or UAG) appropriately positioned atthe end of the mRNA to be translated, with UAA and UAG preferred formammalian or eukaryotic cell expression.

Expression vectors will preferably but optionally include at least oneselectable marker. Such markers include, e.g., but not limited to,methotrexate (MTX), dihydrofolate reductase (DHFR, U.S. Pat. Nos.4,399,216; 4,634,665; 4,656,134; 4,956,288; 5,149,636; 5,179,017,ampicillin, neomycin (G418), mycophenolic acid, or glutamine synthetase(GS, U.S. Pat. Nos. 5,122,464; 5,770,359; 5,827,739) resistance foreukaryotic cell culture, and tetracycline or ampicillin resistance genesfor culturing in E. coli and other bacteria or prokaryotics (the abovepatents are entirely incorporated hereby by reference). Appropriateculture mediums and conditions for the above-described host cells areknown in the art. Suitable vectors will be readily apparent to theskilled artisan. Introduction of a vector construct into a host cell canbe effected by calcium phosphate transfection, DEAE-dextran mediatedtransfection, cationic lipid-mediated transfection, electroporation,transduction, infection or other known methods. Such methods aredescribed in the art, such as Sambrook, supra, Chapters 1-4 and 16-18;Ausubel, supra, Chapters 1, 9, 13, 15, 16.

At least one GLP-1 mimetibody or specified portion or variant of thepresent invention can be expressed in a modified form, such as a fusionprotein, and can include not only secretion signals, but also additionalheterologous functional regions. For instance, a region of additionalamino acids, particularly charged amino acids, can be added to theN-terminus of a GLP-1 mimetibody or specified portion or variant toimprove stability and persistence in the host cell, during purification,or during subsequent handling and storage. Also, peptide moieties can beadded to a GLP-1 mimetibody or specified portion or variant of thepresent invention to facilitate purification. Such regions can beremoved prior to final preparation of a GLP-1 mimetibody or at least onefragment thereof. Such methods are described in many standard laboratorymanuals, such as Sambrook, supra, Chapters 17.29-17.42 and 18.1-18.74;Ausubel, supra, Chapters 16, 17 and 18.

Those of ordinary skill in the art are knowledgeable in the numerousexpression systems available for expression of a nucleic acid encoding aprotein of the present invention. Illustrative of cell cultures usefulfor the production of the mimetibodies, specified portions or variantsthereof, are mammalian cells. Mammalian cell systems often will be inthe form of monolayers of cells although mammalian cell suspensions orbioreactors can also be used. A number of suitable host cell linescapable of expressing intact glycosylated proteins have been developedin the art, and include the COS-1 (e.g., ATCC CRL 1650), COS-7 (e.g.,ATCC CRL-1651), HEK293, BHK21 (e.g., ATCC CRL-10), CHO (e.g., ATCC CRL1610, DG-44) and BSC-1 (e.g., ATCC CRL-26) cell lines, hepG2 cells,P3X63Ag8.653, SP2/0-Ag14, 293 cells, HeLa cells and the like, which arereadily available from, for example, American Type Culture Collection,Manassas, Va. Preferred host cells include cells of lymphoid origin suchas myeloma and lymphoma cells. Particularly preferred host cells areP3X63Ag8.653 cells (ATCC Accession Number CRL-1580) and SP2/0-Ag14 cells(ATCC Accession Number CRL-1851).

Expression vectors for these cells can include one or more of thefollowing expression control sequences, such as, but not limited to anorigin of replication; a promoter (e.g., late or early SV40 promoters,the CMV promoter (e.g., U.S. Pat. Nos. 5,168,062; 5,385,839), an HSV tkpromoter, a pgk (phosphoglycerate kinase) promoter, an EF-1 alphapromoter (e.g, U.S. Pat. No. 5,266,491), at least one humanimmunoglobulin promoter; an enhancer, and/or processing informationsites, such as ribosome binding sites, RNA splice sites, polyadenylationsites (e.g., an SV40 large T Ag poly A addition site), andtranscriptional terminator sequences. See, e.g., Ausubel et al., supra;Sambrook, et al., supra. Other cells useful for production of nucleicacids or proteins of the present invention are known and/or available,for instance, from the American Type Culture Collection Catalogue ofCell Lines and Hybridomas (www.atcc.org) or other known or commercialsources.

When eukaryotic host cells are employed, polyadenlyation ortranscription terminator sequences are typically incorporated into thevector. An example of a terminator sequence is the polyadenlyationsequence from the bovine growth hormone gene. Sequences for accuratesplicing of the transcript can also be included. An example of asplicing sequence is the VP1 intron from SV40 (Sprague, et al., J.Virol. 45:773-781 (1983)). Additionally, gene sequences to controlreplication in the host cell can be incorporated into the vector, asknown in the art.

Purification of a GLP-1 mimetibody or specified portion or variantthereof. A GLP-1 mimetibody or specified portion or variant can berecovered and purified from recombinant cell cultures by well-knownmethods including, but not limited to, protein A purification, ammoniumsulfate or ethanol precipitation, acid extraction, anion or cationexchange chromatography, phosphocellulose chromatography, hydrophobicinteraction chromatography, affinity chromatography, hydroxylapatitechromatography and lectin chromatography. High performance liquidchromatography (“HPLC”) can also be employed for purification. See,e.g., Colligan, Current Protocols in Immunology, or Current Protocols inProtein Science, John Wiley & Sons, NY, N.Y., (1997-2003), e.g.,Chapters 1, 4, 6, 8, 9, 10, each entirely incorporated herein byreference.

Mimetibodies or specified portions or variants of the present inventioninclude naturally purified products, products of chemical syntheticprocedures, and products produced by recombinant techniques from aeukaryotic host, including, for example, yeast, higher plant, insect andmammalian cells. Depending upon the host employed in a recombinantproduction procedure, the GLP-1 mimetibody or specified portion orvariant of the present invention can be glycosylated or can benon-glycosylated, with glycosylated preferred. Such methods aredescribed in many standard laboratory manuals, such as Sambrook, supra,Sections 17.37-17.42; Ausubel, supra, Chapters 10, 12, 13, 16, 18 and20, Colligan, Protein Science, supra, Chapters 12-14, all entirelyincorporated herein by reference.

MIMETIBODIES, SPECIFIED FRAGMENTS AND/OR VARIANTS. The isolatedmimetibodies of the present invention comprise a GLP-1 mimetibody orspecified portion or variant encoded by any one of the polynucleotidesof the present invention as discussed more fully herein, or any isolatedor prepared GLP-1 mimetibody or specified portion or variant thereof.

Preferably, the GLP-1 mimetibody or ligand-binding portion or variantbinds at least one GLP-1 protein ligand and thereby provides at leastone GLP-1 biological activity of the corresponding protein or a fragmentthereof. Different therapeutically or diagnostically significantproteins are well known in the art and suitable assays or biologicalactivities of such proteins are also well known in the art.

Non-limiting examples of suitable GLP-1 peptides, variants andderivatives for this invention appear as SEQ ID NO:1:His-Xaa2-Xaa3-Gly-Thr-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Ser-Xaa 12-Tyr-Xaa14-Glu-Xaa 16-Xaa 17-Xaa 18-Xaa19-Lys-Xaa21-Phe-Xaa23-Ala-Trp-Leu-Xaa27-Xaa28-Gly-Xaa30-Xaa31, wherein:Xaa2 is Ala, Gly, Ser, Thr, Leu, Ile, Val, Glu, Asp, or Lys; Xaa3 isGlu, Asp, or Lys; Xaa6 is Phe, His, Trp, or Tyr; Xaa7 is Thr or Asn;Xaa8 is Ser, Ala, Gly, Thr, Leu, Ile, Val, Glu, Asp, or Lys; Xaa9 is Aspor Glu; Xaa10 is Val, Gln, His, Glu, or Lys; Xaa12 is Ser, Val, Ala,Gly, Thr, Leu, Ile, Glu, Asp or Lys; Xaa14 is Leu, Gln, His, Glu, orLys; Xaa16 is Gly, Ala, Ser, Thr, Leu, Ile, Val, Gln, Asn, Arg, Cys,Glu, Asp or Lys; Xaa17 is Gln, Asn, Arg, His, Glu, Asp or Lys; Xaa18 isAla, Gly, Ser, Thr, Leu, Ile, Val, Glu, Asp or Lys; Xaa19 is Ala, Gly,Ser, Thr, Leu, Ile, Val, Glu, Asp or Lys; Xaa21 is Glu, Leu, Ala, His,Phe, Tyr, Trp, Arg, Gln, Thr, Ser, Gly, Asp or Lys; Xaa23 is Ile, Ala,Val, Leu or Glu; Xaa27 is Val, Gln, His, Glu, or Lys; Xaa28 is Lys, Asn,Arg, His, Glu or Asp; Xaa30 is Arg, His, Thr, Ser, Trp, Tyr, Phe, Glu,Asp or Lys; and Xaa31 is Gly, Ala, Ser, Thr, Leu, Ile, Val, Arg, Trp,Tyr, Phe, His, Glu, Asp, Lys or Pro.

Another preferred group of GLP-1 peptides, variants or derivatives areexemplified in SEQ ID NO:6:His-Xaa2-Xaa3-Gly-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Ser-Xaa12-Xaa13-Xaa14-Glu-Xaa16-Xaa 17-Xaa 18-Xaa19-Lys-Xaa21-Phe-Xaa23-Xaa24-Trp-Leu-Xaa27-Xaa28-Gly-Xaa30, wherein:Xaa2 is Ala, Gly, or Ser; Xaa3 is Glu or Asp; Xaa5 is a variable aminoacid; Xaa6 is His, Trp, Phe or Tyr; Xaa7 is Thr or Asn; Xaa8 is Ser, Thror Ala; Xaa9 is Asp or Glu; Xaa10 is Val, Gln, His, Glu, or Lys; Xaa12is Ser or Lys; Xaa13 is Tyr, Gln, His, Glu or Lys; Xaa14 is Leu, Gln,His, Glu, or Lys; Xaa16 is Gly, Ala, Glu or Asp; Xaa17 is Gln or Glu;Xaa18 is Ala or Lys; Xaa19 is Ala, Val, Ile, Leu or Met; Xaa21 is Glu orLeu; Xaa23 is Ile, Ala, Val, Leu or Glu; Xaa 24 is Ala, Gln, His, Glu,or Lys; Xaa27 is Val, Gln, His, Glu, or Lys; Xaa28 is Lys or Asn; andXaa30 is Arg or Glu.

These peptides can be prepared by methods disclosed and/or known in theart. The Xaas in the sequence (and throughout this specification, unlessspecified otherwise in a particular instance) include specified aminoacid residues, derivatives or modified amino acids thereof. Because theenzyme, dipeptidyl-peptidase IV (DPP-IV), may be responsible for theobserved rapid in vivo inactivation of administered GLP-1, GLP-1peptides, homologs, analogs and derivatives that are protected from theactivity of DPP-IV in the context of mimetibody are preferred

A GLP-1 mimetibody, or specified portion or variant thereof, thatpartially or preferably substantially provides at least one GLP-1biological activity, can bind the GLP-1 ligand and thereby provide atleast one activity that is otherwise mediated through the binding ofGLP-1 to at least one ligand, such as a GLP-1 receptor, or through otherprotein-dependent or mediated mechanisms. As used herein, the term“GLP-1 mimetibody activity” refers to a GLP-1 mimetibody that canmodulate or cause at least one GLP-1 dependent activity by about20-10,000%, preferably by at least about 60, 70, 80, 90, 91, 92, 93, 94,95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190,200, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 2000,3000, 4000, 5000, 6000, 7000, 8000, 9000% or more, depending on theassay.

The capacity of a GLP-1 mimetibody or specified portion or variant toprovide at least one protein-dependent activity is preferably assessedby at least one suitable protein biological assay, as described hereinand/or as known in the art. A human GLP-1 mimetibody or specifiedportion or variant of the invention can be similar to any class (IgG,IgA, IgM, etc.) or isotype and can comprise at least a portion of akappa or lambda light chain. In one embodiment, the human GLP-1mimetibody or specified portion or variant comprises IgG heavy chainvariable fragments, hinge region, CH2 and CH3 of, at least one ofisotypes, e.g., IgG1, IgG2, IgG3 or IgG4.

At least one GLP-1 mimetibody or specified portion or variant of theinvention binds at least one ligand, subunit, fragment, portion or anycombination thereof. The at least one GLP-1 peptide, variant orderivative of at least one GLP-1 mimetibody, specified portion orvariant of the present invention can optionally bind at least onespecified epitope of the ligand. The binding epitope can comprise anycombination of at least one amino acid sequence of at least 1-3 aminoacids to the entire specified portion of contiguous amino acids of thesequences of a protein ligand, such as a GLP-1 receptor or portionthereof.

Such mimetibodies can be prepared by joining together the variousportions of Formula (I) of the GLP-1 mimetibody using known techniques,by preparing and expressing at least one nucleic acid molecules thatencode the GLP-1 mimetibody, using known techniques of recombinant DNAtechnology or by using any other suitable method, such as chemicalsynthesis.

Mimetibodies that bind to human GLP-1 ligands, such as receptors, andthat comprise a defined heavy or light chain variable region or portionthereof, can be prepared using suitable methods, such as phage display(Katsube, Y., et al., Int J Mol. Med, 1(5):863-868 (1998)) or methodsthat employ transgenic animals, as known in the art. The GLP-1mimetibody, specified portion or variant can be expressed using theencoding nucleic acid or portion thereof in a suitable host cell.

The invention also relates to mimetibodies, ligand-binding fragments andimmunoglobulin chains comprising amino acids in a sequence that issubstantially the same as an amino acid sequence described herein.Preferably, such mimetibodies or ligand-binding fragments thereof canbind human GLP-1 ligands, such as receptors, with high affinity (e.g.,K_(D) less than or equal to about 10⁻⁷ M). Amino acid sequences that aresubstantially the same as the sequences described herein includesequences comprising conservative amino acid substitutions, as well asamino acid deletions and/or insertions. A conservative amino acidsubstitution refers to the replacement of a first amino acid by a secondamino acid that has chemical and/or physical properties (e.g., charge,structure, polarity, hydrophobicity/hydrophilicity) that are similar tothose of the first amino acid. Conservative substitutions includereplacement of one amino acid by another within the following groups:lysine (K), arginine (R) and histidine (H); aspartate (D) and glutamate(E); asparagine (N), glutamine (Q), serine (S), threonine (T), tyrosine(Y), K, R, H, D and E; alanine (A), valine (V), leucine (L), isoleucine(I), proline (P), phenylalanine (F), tryptophan (W), methionine (M),cysteine (C) and glycine (G); F, W and Y; C, S and T.

Amino Acid Codes. The amino acids that make up mimetibodies or specifiedportions or variants of the present invention are often abbreviated. Theamino acid designations can be indicated by designating the amino acidby its single letter code, its three letter code, name, or threenucleotide codon(s) as is well understood in the art (see Alberts, B.,et al., Molecular Biology of The Cell, Third Ed., Garland Publishing,Inc., New York, 1994).

SINGLE THREE THREE LETTER LETTER NUCL CODE CODE NAME CODON(S) A AlaAlanine GCA, GCC, GCG, GCU C Cys Cysteine UGC, UGU D Asp Aspartic acidGAC, GAU E Glu Glutamic acid GAA, GAG F Phe Phenylanine UUC, UUU G GlyGlycine GGA, GGC, GGG, GGU H His Histidine CAC, CAU I Ile IsoleucineAUA, AUC, AUU K Lys Lysine AAA, AAG L Leu Leucine UUA, UUG, CUA, CUC,CUG, CUU M Met Methionine AUG N Asn Asparagine AAC, AAU P Pro ProlineCCA, CCC, CCG, CCU Q Gln Glutamine CAA, CAG R Arg Arginine AGA, AGG,CGA, CGC, CGG, CGU S Ser Serine AGC, AGU, UCA, UCC, UCG, UCU T ThrThreonine ACA, ACC, ACG, ACU V Val Valine GUA, GUC, GUG, GUU W TrpTryptophan UGG Y Tyr Tyrosine UAC, UAU

A GLP-1 mimetibody or specified portion or variant of the presentinvention can include one or more amino acid substitutions, deletions oradditions, either from natural mutations or human manipulation, asspecified herein. Such or other sequences that can be used in thepresent invention, include, but are not limited to the followingsequences presented in Table 1, as shown corresponding to specifiedportions of SEQ ID NOS:47-64, where the partial variable region of theantibody sequence can be, but is not limited to, at least one portion ofat least one of SEQ ID NOS:47-55, or fragment thereof as described inTable 1, further optionally comprising at least one substitution,insertion or deletion as further described in FIGS. 1-9 of PCTpublication WO 05/05604 (PCT US04/19898) filed Jun. 24, 2004 andpublished Jan. 20, 2005, with corresponding SEQ ID NOS:1-9. The CH2, CH3and hinge region can be, but not limited to, at least one portion of atleast one of SEQ ID NOS:56-64, or fragment thereof as described in Table1, further optionally comprising at least one substitution, insertion ordeletion as further described in FIGS. 32-40 of PCT publication WO05/05604 (PCT US04/19898) filed Jun. 24, 2004 and published Jan. 20,2005, with corresponding SEQ ID NOS:32-40. Of course, the number ofamino acid substitutions a skilled artisan would make depends on manyfactors, including those described above. Generally speaking, the numberof amino acid substitutions, insertions or deletions for at least one ofa GLP-1 mimetibody will not be more than 40, 30, 20, 19, 18, 17, 16, 15,14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 amino acids, such as 1-30or any range or value therein, as specified herein.

In formula I of the present invention((P(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), the V, H, CH2, CH3 portionsaccording to Formula I can be any suitable human or human compatiblesequence, e.g., as presented in Table 1, where the partial variableregion of the antibody sequence can be, but is not limited to, at leastone portion of at least one of SEQ ID NOS:47-55, or fragment thereof asdescribed in Table 1, further optionally comprising at least onesubstitution, insertion or deletion as further described in FIGS. 1-9 ofPCT publication WO 05/05604 (PCT US04/19898) filed Jun. 24, 2004 andpublished Jan. 20, 2005, with corresponding SEQ ID NOS:1-9; and wherethe CH2, CH3 and hinge region can be, but not limited to, at least oneportion of at least one of SEQ ID NOS:56-64, or fragment thereof asdescribed in Table 1, further optionally comprising at least onesubstitution, insertion or deletion as further described in FIGS. 32-40of PCT publication WO 05/05604 (PCT US04/19898) filed Jun. 24, 2004 andpublished Jan. 20, 2005, with corresponding SEQ ID NOS:32-40, or asknown in the art, or any combination or consensus sequence thereof, orany fusion protein thereof, preferably of human origin or engineered tominimize immunogenicity when administered to humans.

The P portion can comprise at least one GLP-1 therapeutic peptide knownin the art or described herein, such as, but not limited to thosepresented in SEQ ID NO:1, or any combination or consensus sequencethereof, or any fusion protein thereof. In a preferred embodiment, the Pportion can comprise at least one GLP-1 peptide having the sequence ofat least one of SEQ ID NO:6, or any combination or consensus sequencethereof, or any fusion protein thereof.

The optional linker sequence can be any suitable peptide linker as knownin the art. Preferred sequences include any combination of G and S.e.g., X1-X2-X3-X4- . . . -Xn, where X can be G or S, and n can be 5-30.Non-limiting examples include GS, GGS, GGGS (SEQ ID NO:16), GSGGGS (SEQID NO:17), GGSGGGS (SEQ ID NO:18), GGSGGGSGG (SEQ ID NO:19) andGGGSGGGSGG (SEQ ID NO:20); and the like.

Amino acids in a GLP-1 mimetibody or specified portion or variant of thepresent invention that are essential for function can be identified bymethods known in the art, such as site-directed mutagenesis oralanine-scanning mutagenesis (e.g., Ausubel, supra, Chapters 8, 15;Cunningham and Wells, Science 244:1081-1085 (1989)). The latterprocedure introduces single alanine mutations at every residue in themolecule. The resulting mutant molecules are then tested for biologicalactivity, such as, but not limited to at least one protein relatedactivity, as specified herein or as known in the art. Sites that arecritical for GLP-1 mimetibody or specified portion or variant bindingcan also be identified by structural analysis such as crystallization,nuclear magnetic resonance or photoaffinity labeling (Smith, et al., J.Mol. Biol. 224:899-904 (1992) and de Vos, et al., Science 255:306-312(1992)).

Mimetibodies or specified portions or variants of the present inventioncan comprise as the P portion of Formula (I), e.g. but not limited to,at least one portion of at least one of SEQ ID NOS:1 and 6. A GLP-1mimetibody or specified portion or variant can further optionallycomprise at least one functional portion of at least one polypeptide asP portion of Formula (I), at least 90-100% of at least on of SEQ IDNOS:1 and 6. Non-limiting variants that can enhance or maintain at leastone of the listed activities above include, but are not limited to, anyof the above polypeptides, further comprising at least one mutationcorresponding to at least one substitution, insertion or deletion thatdoes not significantly affect the suitable biological activities orfunctions of said GLP-1 mimetibody.

In one embodiment, the P amino acid sequence, or portion thereof, hasabout 90-100% identity (i.e., 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,100 or any range or value therein) to the corresponding amino acidsequence of the corresponding portion of at least one of SEQ ID NOS:1and 6. Preferably, 90-100% amino acid identity (i.e., 90, 91, 92, 93,94, 95, 96, 97, 98, 99, 100 or any range or value therein) is determinedusing a suitable computer algorithm, as known in the art.

Mimetibodies or specified portions or variants of the present inventioncan comprise any number of contiguous amino acid residues from a GLP-1mimetibody or specified portion or variant of the present invention,wherein that number is selected from the group of integers consisting offrom 10-100% of the number of contiguous residues in a GLP-1 mimetibody.Optionally, this subsequence of contiguous amino acids is at least about2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100, 110,120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250 ormore amino acids in length, or any range or value therein. Further, thenumber of such subsequences can be any integer selected from the groupconsisting of from 1 to 20, such as at least 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more.

As those of skill will appreciate, the present invention includes atleast one biologically active GLP-1 mimetibody or specified portion orvariant of the present invention. Biologically active mimetibodies orspecified portions or variants have a specific activity at least 20%,30%, or 40%, and preferably at least 50%, 60%, or 70%, and mostpreferably at least 80%, 90%, or 95%-1000% of that of the native(non-synthetic), endogenous or related and known inserted or fusedprotein or specified portion or variant. Methods of assaying andquantifying measures of enzymatic activity and substrate specificity arewell known to those of skill in the art.

In another aspect, the invention relates to human mimetibodies andligand-binding fragments, as described herein, which are modified by thecovalent attachment of an organic moiety. Such modification can producea GLP-1 mimetibody or ligand-binding fragment with improvedpharmacokinetic properties (e.g., increased in vivo serum half-life).The organic moiety can be a linear or branched hydrophilic polymericgroup, fatty acid group, or fatty acid ester group. In particularembodiments, the hydrophilic polymeric group can have a molecular weightof about 800 to about 120,000 Daltons and can be a polyalkane glycol(e.g., polyethylene glycol (PEG), polypropylene glycol (PPG)),carbohydrate polymer, amino acid polymer or polyvinyl pyrolidone, andthe fatty acid or fatty acid ester group can comprise from about eightto about forty carbon atoms.

The modified mimetibodies and ligand-binding fragments of the inventioncan comprise one or more organic moieties that are covalently bonded,directly or indirectly, to the GLP-1 mimetibody or specified portion orvariant. Each organic moiety that is bonded to a GLP-1 mimetibody orligand-binding fragment of the invention can independently be ahydrophilic polymeric group, a fatty acid group or a fatty acid estergroup. As used herein, the term “fatty acid” encompasses mono-carboxylicacids and di-carboxylic acids. A “hydrophilic polymeric group,” as theterm is used herein, refers to an organic polymer that is more solublein water than in octane. For example, polylysine is more soluble inwater than in octane. Thus, a GLP-1 mimetibody modified by the covalentattachment of polylysine is encompassed by the invention. Hydrophilicpolymers suitable for modifying mimetibodies of the invention can belinear or branched and include, for example, polyalkane glycols (e.g.,PEG, monomethoxy-polyethylene glycol (mPEG), PPG and the like),carbohydrates (e.g., dextran, cellulose, oligosaccharides,polysaccharides and the like), polymers of hydrophilic amino acids(e.g., polylysine, polyarginine, polyaspartate and the like), polyalkaneoxides (e.g., polyethylene oxide, polypropylene oxide and the like) andpolyvinyl pyrolidone. Preferably, the hydrophilic polymer that modifiesthe GLP-1 mimetibody of the invention has a molecular weight of about800 to about 150,000 Daltons as a separate molecular entity. Forexample, PEG₂₅₀₀, PEG₅₀₀₀, PEG₇₅₀₀, PEG₉₀₀₀, PEG₁₀₀₀₀, PEG₁₂₅₀₀,PEG₁₅₀₀₀, and PEG_(20,000), wherein the subscript is the averagemolecular weight of the polymer in Daltons, can be used.

The hydrophilic polymeric group can be substituted with one to about sixalkyl, fatty acid or fatty acid ester groups. Hydrophilic polymers thatare substituted with a fatty acid or fatty acid ester group can beprepared by employing suitable methods. For example, a polymercomprising an amine group can be coupled to a carboxylate of the fattyacid or fatty acid ester, and an activated carboxylate (e.g., activatedwith N,N-carbonyl diimidazole) on a fatty acid or fatty acid ester canbe coupled to a hydroxyl group on a polymer.

Fatty acids and fatty acid esters suitable for modifying mimetibodies ofthe invention can be saturated or can contain one or more units ofunsaturation. Fatty acids that are suitable for modifying mimetibodiesof the invention include, for example, n-dodecanoate (C₁₂, laurate),n-tetradecanoate (C₁₄, myristate), n-octadecanoate (C₁₈, stearate),n-eicosanoate (C₂₀, arachidate), n-docosanoate (C₂₂, behenate),n-triacontanoate (C₃₀), n-tetracontanoate (C₄₀), cis-Δ9-octadecanoate(C₁₈, oleate), all cis-Δ5,8,11,14-eicosatetraenoate (C₂₀, arachidonate),octanedioic acid, tetradecanedioic acid, octadecanedioic acid,docosanedioic acid, and the like. Suitable fatty acid esters includemonoesters of dicarboxylic acids that comprise a linear or branchedlower alkyl group. The lower alkyl group can comprise from one to abouttwelve, preferably one to about six, carbon atoms.

The modified human mimetibodies and ligand-binding fragments can beprepared using suitable methods, such as by reaction with one or moremodifying agents. A “modifying agent” as the term is used herein, refersto a suitable organic group (e.g., hydrophilic polymer, a fatty acid, afatty acid ester) that comprises an activating group. An “activatinggroup” is a chemical moiety or functional group that can, underappropriate conditions, react with a second chemical group therebyforming a covalent bond between the modifying agent and the secondchemical group. For example, amine-reactive activating groups includeelectrophilic groups such as tosylate, mesylate, halo (chloro, bromo,fluoro, iodo), N-hydroxysuccinimidyl esters (NHS), and the like.Activating groups that can react with thiols include, for example,maleimide, iodoacetyl, acrylolyl, pyridyl disulfides,5-thiol-2-nitrobenzoic acid thiol (TNB-thiol), and the like. An aldehydefunctional group can be coupled to amine- or hydrazide-containingmolecules, and an azide group can react with a trivalent phosphorousgroup to form phosphoramidate or phosphorimide linkages. Suitablemethods to introduce activating groups into molecules are known in theart (see for example, Hermanson, G. T., Bioconjugate Techniques,Academic Press: San Diego, Calif. (1996)). An activating group can bebonded directly to the organic group (e.g., hydrophilic polymer, fattyacid, fatty acid ester), or through a linker moiety, for example adivalent C₁-C₁₂ group wherein one or more carbon atoms can be replacedby a heteroatom such as oxygen, nitrogen or sulfur. Suitable linkermoieties include, for example, tetraethylene glycol, —(CH₂)₃—,—NH—(CH₂)₆—NH—, —(CH₂)₂—NH— and —CH₂—O—CH₂—CH₂—O—CH₂—CH₂—O—CH—NH—.Modifying agents that comprise a linker moiety can be produced, forexample, by reacting a mono-Boc-alkyldiamine (e.g.,mono-Boc-ethylenediamine, mono-Boc-diaminohexane) with a fatty acid inthe presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) toform an amide bond between the free amine and the fatty acidcarboxylate. The Boc protecting group can be removed from the product bytreatment with trifluoroacetic acid (TFA) to expose a primary amine thatcan be coupled to another carboxylate as described, or can be reactedwith maleic anhydride and the resulting product cyclized to produce anactivated maleimido derivative of the fatty acid. (See, for example,Thompson, et al., WO 92/16221 the entire teachings of which areincorporated herein by reference.)

The modified mimetibodies of the invention can be produced by reactingan human GLP-1 mimetibody or ligand-binding fragment with a modifyingagent. For example, the organic moieties can be bonded to the GLP-1mimetibody in a non-site specific manner by employing an amine-reactivemodifying agent, for example, an NHS ester of PEG. Modified humanmimetibodies or ligand-binding fragments can also be prepared byreducing disulfide bonds (e.g., intra-chain disulfide bonds) of a GLP-1mimetibody or ligand-binding fragment. The reduced GLP-1 mimetibody orligand-binding fragment can then be reacted with a thiol-reactivemodifying agent to produce the modified GLP-1 mimetibody of theinvention. Modified human mimetibodies and ligand-binding fragmentscomprising an organic moiety that is bonded to specific sites of a GLP-1mimetibody or specified portion or variant of the present invention canbe prepared using suitable methods, such as reverse proteolysis (Fischet al., Bioconjugate Chem., 3:147-153 (1992); Werlen et al.,Bioconjugate Chem., 5:411-417 (1994); Kumaran et al., Protein Sci.6(10):2233-2241 (1997); Itoh et al., Bioorg. Chem., 24(1): 59-68 (1996);Capellas et al., Biotechnol. Bioeng., 56(4):456-463 (1997)), and themethods described in Hermanson, G. T., Bioconjugate Techniques, AcademicPress: San Diego, Calif. (1996).

GLP-1 MIMETIBODY COMPOSITIONS. The present invention also provides atleast one GLP-1 mimetibody or specified portion or variant compositioncomprising at least one, at least two, at least three, at least four, atleast five, at least six or more mimetibodies or specified portions orvariants thereof, as described herein and/or as known in the art thatare provided in a non-naturally occurring composition, mixture or form.Such composition percentages are by weight, volume, concentration,molarity, or molarity as liquid or dry solutions, mixtures, suspension,emulsions or colloids, as known in the art or as described herein.

Such compositions can comprise 0.00001-99.9999 percent by weight,volume, concentration, molarity, or molarity as liquid, gas, or drysolutions, mixtures, suspension, emulsions or colloids, as known in theart or as described herein, on any range or value therein, such as butnot limited to 0.00001, 0.00003, 0.00005, 0.00009, 0.0001, 0.0003,0.0005, 0.0009, 0.001, 0.003, 0.005, 0.009, 0.01, 0.02, 0.03, 0.05,0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3,1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7,2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.3,4.5, 4.6, 4.7, 4.8, 4.9, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45,50, 55, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1,99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9%. Such compositions ofthe present invention thus include but are not limited to 0.00001-100mg/ml and/or 0.00001-100 mg/g.

The composition can optionally further comprise an effective amount ofat least one compound or protein selected from at least one of adiabetes or insuling metabolism related drug, an anti-infective drug, acardiovascular (CV) system drug, a central nervous system (CNS) drug, anautonomic nervous system (ANS) drug, a respiratory tract drug, agastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid orelectrolyte balance, a hematologic drug, an antineoplactic, animmunomodulation drug, an ophthalmic, otic or nasal drug, a topicaldrug, a nutritional drug or the like. Such drugs are well known in theart, including formulations, indications, dosing and administration foreach presented herein (see e.g., Nursing 2001 Handbook of Drugs, 21^(st)edition, Springhouse Corp., Springhouse, Pa., 2001; HealthProfessional's Drug Guide 2001, ed., Shannon, Wilson, Stang,Prentice-Hall, Inc, Upper Saddle River, N.J.; Pharmcotherapy Handbook,Wells et al., ed., Appleton & Lange, Stamford, Conn., each entirelyincorporated herein by reference).

The diabetes related drug can be at least one of glitazones, insulin andderivatives, sulfonylureas, meglitinides, biguanides, alpha-glucosidaseinhibitors, protein tyrosine phosphastase-1B, glycogen synthase kinase3, gluconeogenesis inhibitors, pyruvate dehydrogenase kinase (PDH)inhibitors, lipolysis inhibitors, fat oxidation inhibitors, carnitinepalmitoyltransferase I and/or II inhibitors, beta-3 adrenoceptoragonists, sodium and glucose cotransporter (SGLT) inhibitors, orcompounds that act on one or more of at least one of: autoimmunesuppression, immune regulation, activation, proliferation, migrationand/or suppressor cell function of T-cells, inhibition of T cellreceptor/peptide/MHC-II interaction, Induction of T cell anergy,deletion of autoreactive T cells, reduction of trafficking across bloodbrain barrier, alteration of balance of pro-inflammatory (Th1) andimmunomodulatory (Th2) cytokines, inhibition of matrix metalloproteaseinhibitors, neuroprotection, reduction of gliosis, promotion ofre-myelination.

The anti-infective drug can be at least one selected from amebicides orantiprotozoals, anthelmintics, antifungals, antimalarials,antituberculotics or antileprotics, aminoglycosides, penicillins,cephalosporins, tetracyclines, sulfonamides, fluoroquinolones,antivirals, macrolide anti-infectives and miscellaneous anti-infectives.The CV drug can be at least one selected from inotropics,antiarrhythmics, antianginals, antihypertensives, antilipemics andmiscellaneous cardiovascular drugs. The CNS drug can be at least oneselected from normarcotic analgesics or at least one selected fromantipyretics, nonsteroidal anti-inflammatory drugs, narcotic or opiodanalgesics, sedative-hypnotics, anticonvulsants, antidepressants,antianxiety drugs, antipsychotics, central nervous system stimulants,antiparkinsonians and miscellaneous central nervous system drugs. TheANS drug can be at least one selected from cholinergics(parasympathomimetics), anticholinergics, adrenergics(sympathomimetics), adrenergic blockers (sympatholytics), skeletalmuscle relaxants and neuromuscular blockers. The respiratory tract drugcan be at least one selected from antihistamines, bronchodilators,expectorants or antitussives and miscellaneous respiratory drugs. The GItract drug can be at least one selected from antacids, adsorbents,antiflatulents, digestive enzymes, gallstone solubilizers,antidiarrheals, laxatives, antiemetics and antiulcer drugs. The hormonaldrug can be at least one selected from corticosteroids, androgens,anabolic steroids, estrogens, progestins, gonadotropins, antidiabeticdrugs, at least one glucagon, thyroid hormones, thyroid hormoneantagonists, pituitary hormones and parathyroid-like drugs. The drug forfluid and electrolyte balance can be at least one selected fromdiuretics, electrolytes, replacement solutions, acidifiers andalkalinizers. The hematologic drug can be at least one selected fromhematinics, anticoagulants, blood derivatives and thrombolytic enzymes.The antineoplastics can be at least one selected from alkylating drugs,antimetabolites, antibiotic antineoplastics, antineoplastics that alterhormone balance and miscellaneous antineoplastics. The immunomodulationdrug can be at least one selected from immunosuppressants, vaccines,toxoids, antitoxins, antivenins, immune serums and biological responsemodifiers. The ophthalmic, otic, and nasal drugs can be at least oneselected from ophthalmic anti-infectives, ophthalmicanti-inflammatories, miotics, mydriatics, ophthalmic vasoconstrictorsand miscellaneous ophthalmics, otics, nasal drugs. The topical drug canbe at least one selected from local anti-infectives, scabicides,pediculicides and topical corticosteroids. The nutritional drug can beat least one selected from vitamins, minerals and calorics. See, e.g.,contents of Nursing 2001 Drug Handbook, supra.

The at least one amebicide or antiprotozoal can be at least one selectedfrom atovaquone, chloroquine hydrochloride, chloroquine phosphate,metronidazole, metronidazole hydrochloride and pentamidine isethionate.The at least one anthelmintic can be at least one selected frommebendazole, pyrantel pamoate and thiabendazole. The at least oneantifungal can be at least one selected from amphotericin B,amphotericin B cholesteryl sulfate complex, amphotericin B lipidcomplex, amphotericin B liposomal, fluconazole, flucytosine,griseofulvin microsize, griseofulvin ultramicrosize, itraconazole,ketoconazole, nystatin and terbinafine hydrochloride. The at least oneantimalarial can be at least one selected from chloroquinehydrochloride, chloroquine phosphate, doxycycline, hydroxychloroquinesulfate, mefloquine hydrochloride, primaquine phosphate, pyrimethamineand pyrimethamine with sulfadoxine. The at least one antituberculotic orantileprotic can be at least one selected from clofazimine, cycloserine,dapsone, ethambutol hydrochloride, isoniazid, pyrazinamide, rifabutin,rifampin, rifapentine and streptomycin sulfate. The at least oneaminoglycoside can be at least one selected from amikacin sulfate,gentamicin sulfate, neomycin sulfate, streptomycin sulfate andtobramycin sulfate. The at least one penicillin can be at least oneselected from amoxicillin/clavulanate potassium, amoxicillin trihydrate,ampicillin, ampicillin sodium, ampicillin trihydrate, ampicillinsodium/sulbactam sodium, cloxacillin sodium, dicloxacillin sodium,mezlocillin sodium, nafcillin sodium, oxacillin sodium, penicillin Gbenzathine, penicillin G potassium, penicillin G procaine, penicillin Gsodium, penicillin V potassium, piperacillin sodium, piperacillinsodium/tazobactam sodium, ticarcillin disodium and ticarcillindisodium/clavulanate potassium. The at least one cephalosporin can be atleast one selected from at least one of cefaclor, cefadroxil, cefazolinsodium, cefdinir, cefepime hydrochloride, cefixime, cefmetazole sodium,cefonicid sodium, cefoperazone sodium, cefotaxime sodium, cefotetandisodium, cefoxitin sodium, cefpodoxime proxetil, cefprozil,ceftazidime, ceftibuten, ceftizoxime sodium, ceftriaxone sodium,cefuroxime axetil, cefuroxime sodium, cephalexin hydrochloride,cephalexin monohydrate, cephradine, loracarbef. The at least onetetracycline can be at least one selected from demeclocyclinehydrochloride, doxycycline calcium, doxycycline hyclate, doxycyclinehydrochloride, doxycycline monohydrate, minocycline hydrochloride,tetracycline hydrochloride. The at least one sulfonamide can be at leastone selected from co-trimoxazole, sulfadiazine, sulfamethoxazole,sulfisoxazole, sulfisoxazole acetyl. The at least one fluoroquinolonecan be at least one selected from alatrofloxacin mesylate,ciprofloxacin, enoxacin, levofloxacin, lomefloxacin hydrochloride,nalidixic acid, norfloxacin, ofloxacin, sparfloxacin, trovafloxacinmesylate. The at least one fluoroquinolone can be at least one selectedfrom alatrofloxacin mesylate, ciprofloxacin, enoxacin, levofloxacin,lomefloxacin hydrochloride, nalidixic acid, norfloxacin, ofloxacin,sparfloxacin, trovafloxacin mesylate. The at least one antiviral can beat least one selected from abacavir sulfate, acyclovir sodium,amantadine hydrochloride, amprenavir, cidofovir, delavirdine mesylate,didanosine, efavirenz, famciclovir, fomivirsen sodium, foscarnet sodium,ganciclovir, indinavir sulfate, lamivudine, lamivudine/zidovudine,nelfinavir mesylate, nevirapine, oseltamivir phosphate, ribavirin,rimantadine hydrochloride, ritonavir, saquinavir, saquinavir mesylate,stavudine, valacyclovir hydrochloride, zalcitabine, zanamivir,zidovudine. The at least one macroline anti-infective can be at leastone selected from azithromycin, clarithromycin, dirithromycin,erythromycin base, erythromycin estolate, erythromycin ethylsuccinate,erythromycin lactobionate, erythromycin stearate. The at least onemiscellaneous anti-infective can be at least one selected fromaztreonam, bacitracin, chloramphenicol sodium sucinate, clindamycinhydrochloride, clindamycin palmitate hydrochloride, clindamycinphosphate, imipenem and cilastatin sodium, meropenem, nitrofurantoinmacrocrystals, nitrofurantoin microcrystals, quinupristin/dalfopristin,spectinomycin hydrochloride, trimethoprim, vancomycin hydrochloride.(See, e.g., pp. 24-214 of Nursing 2001 Drug Handbook.)

The at least one inotropic can be at least one selected from aminonelactate, digoxin, milrinone lactate. The at least one antiarrhythmic canbe at least one selected from adenosine, amiodarone hydrochloride,atropine sulfate, bretylium tosylate, diltiazem hydrochloride,disopyramide, disopyramide phosphate, esmolol hydrochloride, flecamideacetate, ibutilide fumarate, lidocaine hydrochloride, mexiletinehydrochloride, moricizine hydrochloride, phenyloin, phenyloin sodium,procainamide hydrochloride, propafenone hydrochloride, propranololhydrochloride, quinidine bisulfate, quinidine gluconate, quinidinepolygalacturonate, quinidine sulfate, sotalol, tocamide hydrochloride,verapamil hydrochloride. The at least one antianginal can be at leastone selected from amlodipidine besylate, amyl nitrite, bepridilhydrochloride, diltiazem hydrochloride, isosorbide dinitrate, isosorbidemononitrate, nadolol, nicardipine hydrochloride, nifedipine,nitroglycerin, propranolol hydrochloride, verapamil, verapamilhydrochloride. The at least one antihypertensive can be at least oneselected from acebutolol hydrochloride, amlodipine besylate, atenolol,benazepril hydrochloride, betaxolol hydrochloride, bisoprolol fumarate,candesartan cilexetil, captopril, carteolol hydrochloride, carvedilol,clonidine, clonidine hydrochloride, diazoxide, diltiazem hydrochloride,doxazosin mesylate, enalaprilat, enalapril maleate, eprosartan mesylate,felodipine, fenoldopam mesylate, fosinopril sodium, guanabenz acetate,guanadrel sulfate, guanfacine hydrochloride, hydralazine hydrochloride,irbesartan, isradipine, labetalol hydrochloride, lisinopril, losartanpotassium, methyldopa, methyldopate hydrochloride, metoprolol succinate,metoprolol tartrate, minoxidil, moexipril hydrochloride, nadolol,nicardipine hydrochloride, nifedipine, nisoldipine, nitroprussidesodium, penbutolol sulfate, perindopril erbumine, phentolamine mesylate,pindolol, prazosin hydrochloride, propranolol hydrochloride, quinaprilhydrochloride, ramipril, telmisartan, terazosin hydrochloride, timololmaleate, trandolapril, valsartan, verapamil hydrochloride The at leastone antilipemic can be at least one selected from atorvastatin calcium,cerivastatin sodium, cholestyramine, colestipol hydrochloride,fenofibrate (micronized), fluvastatin sodium, gemfibrozil, lovastatin,niacin, pravastatin sodium, simvastatin. The at least one miscellaneousCV drug can be at least one selected from abciximab, alprostadil,arbutamine hydrochloride, cilostazol, clopidogrel bisulfate,dipyridamole, eptifibatide, midodrine hydrochloride, pentoxifylline,ticlopidine hydrochloride, tirofiban hydrochloride. (See, e.g., pp.215-336 of Nursing 2001 Drug Handbook.)

The at least one normarcotic analgesic or antipyretic can be at leastone selected from acetaminophen, aspirin, choline magnesiumtrisalicylate, diflunisal, magnesium salicylate. The at least onenonsteroidal anti-inflammatory drug can be at least one selected fromcelecoxib, diclofenac potassium, diclofenac sodium, etodolac, fenoprofencalcium, flurbiprofen, ibuprofen, indomethacin, indomethacin sodiumtrihydrate, ketoprofen, ketorolac tromethamine, nabumetone, naproxen,naproxen sodium, oxaprozin, piroxicam, rofecoxib, sulindac. The at leastone narcotic or opiod analgesic can be at least one selected fromalfentanil hydrochloride, buprenorphine hydrochloride, butorphanoltartrate, codeine phosphate, codeine sulfate, fentanyl citrate, fentanyltransdermal system, fentanyl transmucosal, hydromorphone hydrochloride,meperidine hydrochloride, methadone hydrochloride, morphinehydrochloride, morphine sulfate, morphine tartrate, nalbuphinehydrochloride, oxycodone hydrochloride, oxycodone pectinate, oxymorphonehydrochloride, pentazocine hydrochloride, pentazocine hydrochloride andnaloxone hydrochloride, pentazocine lactate, propoxyphene hydrochloride,propoxyphene napsylate, remifentanil hydrochloride, sufentanil citrate,tramadol hydrochloride. The at least one sedative-hypnotic can be atleast one selected from chloral hydrate, estazolam, flurazepamhydrochloride, pentobarbital, pentobarbital sodium, phenobarbitalsodium, secobarbital sodium, temazepam, triazolam, zaleplon, zolpidemtartrate. The at least one anticonvulsant can be at least one selectedfrom acetazolamide sodium, carbamazepine, clonazepam, clorazepatedipotassium, diazepam, divalproex sodium, ethosuximde, fosphenytoinsodium, gabapentin, lamotrigine, magnesium sulfate, phenobarbital,phenobarbital sodium, phenyloin, phenyloin sodium, phenyloin sodium(extended), primidone, tiagabine hydrochloride, topiramate, valproatesodium, valproic acid. The at least one antidepressant can be at leastone selected from amitriptyline hydrochloride, amitriptyline pamoate,amoxapine, bupropion hydrochloride, citalopram hydrobromide,clomipramine hydrochloride, desipramine hydrochloride, doxepinhydrochloride, fluoxetine hydrochloride, imipramine hydrochloride,imipramine pamoate, mirtazapine, nefazodone hydrochloride, nortriptylinehydrochloride, paroxetine hydrochloride, phenelzine sulfate, sertralinehydrochloride, tranylcypromine sulfate, trimipramine maleate,venlafaxine hydrochloride. The at least one antianxiety drug can be atleast one selected from alprazolam, buspirone hydrochloride,chlordiazGLP-1xide, chlordiazGLP-1xide hydrochloride, clorazepatedipotassium, diazepam, doxepin hydrochloride, hydroxyzine embonate,hydroxyzine hydrochloride, hydroxyzine pamoate, lorazepam, mephrobamate,midazolam hydrochloride, oxazepam. The at least one antipsychotic drugcan be at least one selected from chlorpromazine hydrochloride,clozapine, fluphenazine decanoate, fluephenazine enanthate, fluphenazinehydrochloride, haloperidol, haloperidol decanoate, haloperidol lactate,loxapine hydrochloride, loxapine succinate, mesoridazine besylate,molindone hydrochloride, olanzapine, perphenazine, pimozide,prochlorperazine, quetiapine fumarate, risperidone, thioridazinehydrochloride, thiothixene, thiothixene hydrochloride, trifluoperazinehydrochloride. The at least one central nervous system stimulant can beat least one selected from amphetamine sulfate, caffeine,dextroamphetamine sulfate, doxapram hydrochloride, methamphetaminehydrochloride, methylphenidate hydrochloride, modafinil, pemoline,phentermine hydrochloride. The at least one antiparkinsonian can be atleast one selected from amantadine hydrochloride, benztropine mesylate,biperiden hydrochloride, biperiden lactate, bromocriptine mesylate,carbidopa-levodopa, entacapone, levodopa, pergolide mesylate,pramipexole dihydrochloride, ropinirole hydrochloride, selegilinehydrochloride, tolcapone, trihexyphenidyl hydrochloride. The at leastone miscellaneous central nervous system drug can be at least oneselected from bupropion hydrochloride, donepezil hydrochloride,droperidol, fluvoxamine maleate, lithium carbonate, lithium citrate,naratriptan hydrochloride, nicotine polacrilex, nicotine transdermalsystem, propofol, rizatriptan benzoate, sibutramine hydrochloridemonohydrate, sumatriptan succinate, tacrine hydrochloride, zolmitriptan.(See, e.g., pp. 337-530 of Nursing 2001 Drug Handbook.)

The at least one cholinergic (e.g., parasymathomimetic) can be at leastone selected from bethanechol chloride, edrophonium chloride,neostigmine bromide, neostigmine methylsulfate, physostigminesalicylate, pyridostigmine bromide. The at least one anticholinergicscan be at least one selected from atropine sulfate, dicyclominehydrochloride, glycopyrrolate, hyoscyamine, hyoscyamine sulfate,propantheline bromide, scopolamine, scopolamine butylbromide,scopolamine hydrobromide. The at least one adrenergics(sympathomimetics) can be at least one selected from dobutaminehydrochloride, dopamine hydrochloride, metaraminol bitartrate,norepinephrine bitartrate, phenylephrine hydrochloride, pseudoephedrinehydrochloride, pseudoephedrine sulfate. The at least one adrenergicblocker (sympatholytic) can be at least one selected fromdihydroergotamine mesylate, ergotamine tartrate, methysergide maleate,propranolol hydrochloride. The at least one skeletal muscle relaxant canbe at least one selected from baclofen, carisoprodol, chlorzoxazone,cyclobenzaprine hydrochloride, dantrolene sodium, methocarbamol,tizanidine hydrochloride. The at least one neuromuscular blockers can beat least one selected from atracurium besylate, cisatracurium besylate,doxacurium chloride, mivacurium chloride, pancuronium bromide,pipecuronium bromide, rapacuronium bromide, rocuronium bromide,succinylcholine chloride, tubocurarine chloride, vecuronium bromide.(See, e.g., pp. 531-84 of Nursing 2001 Drug Handbook.)

The at least one antihistamine can be at least one selected frombrompheniramine maleate, cetirizine hydrochloride, chlorpheniraminemaleate, clemastine fumarate, cyproheptadine hydrochloride,diphenhydramine hydrochloride, fexofenadine hydrochloride, loratadine,promethazine hydrochloride, promethazine theoclate, triprolidinehydrochloride. The at least one bronchodilators can be at least oneselected from albuterol, albuterol sulfate, aminophylline, atropinesulfate, ephedrine sulfate, epinephrine, epinephrine bitartrate,epinephrine hydrochloride, ipratropium bromide, isoproterenol,isoproterenol hydrochloride, isoproterenol sulfate, levalbuterolhydrochloride, metaproterenol sulfate, oxtriphylline, pirbuterolacetate, salmeterol xinafoate, terbutaline sulfate, theophylline. The atleast one expectorants or antitussives can be at least one selected frombenzonatate, codeine phosphate, codeine sulfate, dextramethorphanhydrobromide, diphenhydramine hydrochloride, guaifenesin, hydromorphonehydrochloride. The at least one miscellaneous respiratory drug can be atleast one selected from acetylcysteine, beclomethasone dipropionate,beractant, budesonide, calfactant, cromolyn sodium, dornase alfa,GLP-1prostenol sodium, flunisolide, fluticasone propionate, montelukastsodium, nedocromil sodium, palivizumab, triamcinolone acetonide,zafirlukast, zileuton. (See, e.g., pp. 585-642 of Nursing 2001 DrugHandbook.)

The at least one antacid, adsorbents, or antiflatulents can be at leastone selected from aluminum carbonate, aluminum hydroxide, calciumcarbonate, magaldrate, magnesium hydroxide, magnesium oxide,simethicone, and sodium bicarbonate. The at least one digestive enymesor gallstone solubilizers can be at least one selected from pancreatin,pancrelipase, and ursodiol. The at least one antidiarrheal can be atleast one selected from attapulgite, bismuth subsalicylate, calciumpolycarbophil, diphenoxylate hydrochloride or atropine sulfate,loperamide, octreotide acetate, opium tincture, opium tincure(camphorated). The at least one laxative can be at least one selectedfrom bisocodyl, calcium polycarbophil, cascara sagrada, cascara sagradaaromatic fluidextract, cascara sagrada fluidextract, castor oil,docusate calcium, docusate sodium, glycerin, lactulose, magnesiumcitrate, magnesium hydroxide, magnesium sulfate, methylcellulose,mineral oil, polyethylene glycol or electrolyte solution, psyllium,senna, sodium phosphates. The at least one antiemetic can be at leastone selected from chlorpromazine hydrochloride, dimenhydrinate,dolasetron mesylate, dronabinol, granisetron hydrochloride, meclizinehydrochloride, metocloproamide hydrochloride, ondansetron hydrochloride,perphenazine, prochlorperazine, prochlorperazine edisylate,prochlorperazine maleate, promethazine hydrochloride, scopolamine,thiethylperazine maleate, trimethobenzamide hydrochloride. The at leastone antiulcer drug can be at least one selected from cimetidine,cimetidine hydrochloride, famotidine, lansoprazole, misoprostol,nizatidine, omeprazole, rabeprozole sodium, rantidine bismuth citrate,ranitidine hydrochloride, sucralfate. (See, e.g., pp. 643-95 of Nursing2001 Drug Handbook.) The at least one coricosteroids can be at least oneselected from betamethasone, betamethasone acetate or betamethasonesodium phosphate, betamethasone sodium phosphate, cortisone acetate,dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate,fludrocortisone acetate, hydrocortisone, hydrocortisone acetate,hydrocortisone cypionate, hydrocortisone sodium phosphate,hydrocortisone sodium succinate, methylprednisolone, methylprednisoloneacetate, methylprednisolone sodium succinate, prednisolone, prednisoloneacetate, prednisolone sodium phosphate, prednisolone tebutate,prednisone, triamcinolone, triamcinolone acetonide, triamcinolonediacetate. The at least one androgen or anabolic steroids can be atleast one selected from danazol, fluoxymesterone, methyltestosterone,nandrolone decanoate, nandrolone phenpropionate, testosterone,testosterone cypionate, testosterone enanthate, testosterone propionate,testosterone transdermal system. The at least one estrogen or progestincan be at least one selected from esterified estrogens, estradiol,estradiol cypionate, estradiol/norethindrone acetate transdermal system,estradiol valerate, estrogens (conjugated), estropipate, ethinylestradiol, ethinyl estradiol and desogestrel, ethinyl estradiol andethynodiol diacetate, ethinyl estradiol and desogestrel, ethinylestradiol and ethynodiol diacetate, ethinyl estradiol andlevonorgestrel, ethinyl estradiol and norethindrone, ethinyl estradioland norethindrone acetate, ethinyl estradiol and norgestimate, ethinylestradiol and norgestrel, ethinyl estradiol and norethindrone andacetate and ferrous fumarate, levonorgestrel, medroxyprogesteroneacetate, mestranol and norethindron, norethindrone, norethindroneacetate, norgestrel, progesterone. The at least one gonadroptropin canbe at least one selected from ganirelix acetate, gonadoreline acetate,histrelin acetate, menotropins. The at least one antidiabetic or glucaoncan be at least one selected from acarbose, chlorpropamide, glimepiride,glipizide, glucagon, glyburide, insulins, metformin hydrochloride,miglitol, pioglitazone hydrochloride, repaglinide, rosiglitazonemaleate, troglitazone. The at least one thyroid hormone can be at leastone selected from levothyroxine sodium, liothyronine sodium, liotrix,thyroid. The at least one thyroid hormone antagonist can be at least oneselected from methimazole, potassium iodide, potassium iodide (saturatedsolution), propylthiouracil, radioactive iodine (sodium iodide ¹³¹I),strong iodine solution. The at least one pituitary hormone can be atleast one selected from corticotropin, cosyntropin, desmophressinacetate, leuprolide acetate, rGLP-1sitory corticotropin, somatrem,somatropin, vasopressin. The at least one parathyroid-like drug can beat least one selected from calcifediol, calcitonin (human), calcitonin(salmon), calcitriol, dihydrotachysterol, etidronate disodium. (See,e.g., pp. 696-796 of Nursing 2001 Drug Handbook.)

The at least one diuretic can be at least one selected fromacetazolamide, acetazolamide sodium, amiloride hydrochloride,bumetanide, chlorthalidone, ethacrynate sodium, ethacrynic acid,furosemide, hydrochlorothiazide, indapamide, mannitol, metolazone,spironolactone, torsemide, triamterene, urea. The at least oneelectrolyte or replacement solution can be at least one selected fromcalcium acetate, calcium carbonate, calcium chloride, calcium citrate,calcium glubionate, calcium gluceptate, calcium gluconate, calciumlactate, calcium phosphate (dibasic), calcium phosphate (tribasic),dextran (high-molecular-weight), dextran (low-molecular-weight),hetastarch, magnesium chloride, magnesium sulfate, potassium acetate,potassium bicarbonate, potassium chloride, potassium gluconate, Ringer'sinjection, Ringer's injection (lactated), sodium chloride. The at leastone acidifier or alkalinizer can be at least one selected from sodiumbicarbonate, sodium lactate, tromethamine. (See, e.g., pp. 797-833 ofNursing 2001 Drug Handbook.)

The at least one hematinic can be at least one selected from ferrousfumarate, ferrous gluconate, ferrous sulfate, ferrous sulfate (dried),iron dextran, iron sorbitol, polysaccharide-iron complex, sodium ferricgluconate complex. The at least one anticoagulant can be at least oneselected from ardeparin sodium, dalteparin sodium, danaparoid sodium,enoxaparin sodium, heparin calcium, heparin sodium, warfarin sodium. Theat least one blood derivative can be at least one selected from albumin5%, albumin 25%, antihemophilic factor, anti-inhibitor coagulantcomplex, antithrombin III (human), factor IX (human), factor IX complex,plasma protein fractions. The at least one thrombolytic enzyme can be atleast one selected from alteplase, anistreplase, reteplase(recombinant), streptokinase, urokinase. (See, e.g., pp. 834-66 ofNursing 2001 Drug Handbook.)

The at least one alkylating drug can be at least one selected frombusulfan, carboplatin, carmustine, chlorambucil, cisplatin,cyclophosphamide, ifosfamide, lomustine, mechlorethamine hydrochloride,melphalan, melphalan hydrochloride, streptozocin, temozolomide,thiotepa. The at least one antimetabolite can be at least one selectedfrom capecitabine, cladribine, cytarabine, floxuridine, fludarabinephosphate, fluorouracil, hydroxyurea, mercaptopurine, methotrexate,methotrexate sodium, thioguanine. The at least one antibioticantineoplastic can be at least one selected from bleomycin sulfate,dactinomycin, daunorubicin citrate liposomal, daunorubicinhydrochloride, doxorubicin hydrochloride, doxorubicin hydrochlorideliposomal, epirubicin hydrochloride, idarubicin hydrochloride,mitomycin, pentostatin, plicamycin, valrubicin. The at least oneantineoplastics that alter hormone balance can be at least one selectedfrom anastrozole, bicalutamide, estramustine phosphate sodium,exemestane, flutamide, goserelin acetate, letrozole, leuprolide acetate,megestrol acetate, nilutamide, tamoxifen citrate, testolactone,toremifene citrate. The at least one miscellaneous antineoplastic can beat least one selected from asparaginase, bacillus Calmette-Guerin (BCG)(live intravesical), dacarbazine, docetaxel, etoposide, etoposidephosphate, gemcitabine hydrochloride, irinotecan hydrochloride,mitotane, mitoxantrone hydrochloride, paclitaxel, pegaspargase, porfimersodium, procarbazine hydrochloride, rituximab, teniposide, topotecanhydrochloride, trastuzumab, tretinoin, vinblastine sulfate, vincristinesulfate, vinorelbine tartrate. (See, e.g., pp. 867-963 of Nursing 2001Drug Handbook.)

The at least one immunosuppressant can be at least one selected fromazathioprine, basiliximab, cyclosporine, daclizumab, lymphocyte immuneglobulin, muromonab-CD3, mycophenolate mofetil, mycophenolate mofetilhydrochloride, sirolimus, tacrolimus. The at least one vaccine or toxoidcan be at least one selected from BCG vaccine, cholera vaccine,diphtheria and tetanus toxoids (adsorbed), diphtheria and tetanustoxoids and acellular pertussis vaccine adsorbed, diphtheria and tetanustoxoids and whole-cell pertussis vaccine, Haemophilus b conjugatevaccines, hepatitis A vaccine (inactivated), hepatisis B vaccine(recombinant), influenza virus vaccine 1999-2000 trivalent types A & B(purified surface antigen), influenza virus vaccine 1999-2000 trivalenttypes A & B (subvirion or purified subvirion), influenza virus vaccine1999-2000 trivalent types A & B (whole virion), Japanese encephalitisvirus vaccine (inactivated), Lyme disease vaccine (recombinant OspA),measles and mumps and rubella virus vaccine (live), measles and mumpsand rubella virus vaccine (live attenuated), measles virus vaccine (liveattenuated), meningococcal polysaccharide vaccine, mumps virus vaccine(live), plague vaccine, pneumococcal vaccine (polyvalent), poliovirusvaccine (inactivated), poliovirus vaccine (live, oral, trivalent),rabies vaccine (adsorbed), rabies vaccine (human diploid cell), rubellaand mumps virus vaccine (live), rubella virus vaccine (live,attenuated), tetanus toxoid (adsorbed), tetanus toxoid (fluid), typhoidvaccine (oral), typhoid vaccine (parenteral), typhoid Vi polysaccharidevaccine, varicella virus vaccine, yellow fever vaccine. The at least oneantitoxin or antivenin can be at least one selected from black widowspider antivenin, Crotalidae antivenom (polyvalent), diphtheriaantitoxin (equine), Micrurus fulvius antivenin). The at least one immuneserum can be at least one selected from cytomegalovirus immune globulin(intraveneous), hepatitis B immune globulin (human), immune globulinintramuscular, immune globulin intravenous, rabies immune globulin(human), respiratory syncytial virus immune globulin intravenous(human), Rh₀(D) immune globulin (human), Rh₀(D) immune globulinintravenous (human), tetanus immune globulin (human), varicella-zosterimmune globulin. The at least one biological response modifiers can beat least one selected from aldesleukin, GLP-1etin alfa, filgrastim,glatiramer acetate for injection, interferon alfacon-1, interferonalfa-2a (recombinant), interferon alfa-2b (recombinant), interferonbeta-1a, interferon beta-1b (recombinant), interferon gamma-1b,levamisole hydrochloride, oprelvekin, sargramostim. (See, e.g., pp.964-1040 of Nursing 2001 Drug Handbook.)

The at least one ophthalmic anti-infectives can be selected formbacitracin, chloramphenicol, ciprofloxacin hydrochloride, erythromycin,gentamicin sulfate, ofloxacin 0.3%, polymyxin B sulfate, sulfacetamidesodium 10%, sulfacetamide sodium 15%, sulfacetamide sodium 30%,tobramycin, vidarabine. The at least one ophthalmic anti-inflammatoriescan be at least one selected from dexamethasone, dexamethasone sodiumphosphate, diclofenac sodium 0.1%, fluorometholone, flurbiprofen sodium,ketorolac tromethamine, prednisolone acetate (suspension) prednisolonesodium phosphate (solution). The at least one miotic can be at least oneselected from acetylocholine chloride, carbachol (intraocular),carbachol (topical), echothiophate iodide, pilocarpine, pilocarpinehydrochloride, pilocarpine nitrate. The at least one mydriatic can be atleast one selected from atropine sulfate, cyclopentolate hydrochloride,epinephrine hydrochloride, epinephryl borate, homatropine hydrobromide,phenylephrine hydrochloride, scopolamine hydrobromide, tropicamide. Theat least one ophthalmic vasoconstrictors can be at least one selectedfrom naphazoline hydrochloride, oxymetazoline hydrochloride,tetrahydrozoline hydrochloride. The at least one miscellaneousophthalmics can be at least one selected from apraclonidinehydrochloride, betaxolol hydrochloride, brimonidine tartrate, carteololhydrochloride, dipivefrin hydrochloride, dorzolamide hydrochloride,emedastine difumarate, fluorescein sodium, ketotifen fumarate,latanoprost, levobunolol hydrochloride, metipranolol hydrochloride,sodium chloride (hypertonic), timolol maleate. The at least one otic canbe at least one selected from boric acid, carbamide peroxide,chloramphenicol, triethanolamine polypeptide oleate-condensate. The atleast one nasal drug can be at least one selected from beclomethasonedipropionate, budesonide, ephedrine sulfate, epinephrine hydrochloride,flunisolide, fluticasone propionate, naphazoline hydrochloride,oxymetazoline hydrochloride, phenylephrine hydrochloride,tetrahydrozoline hydrochloride, triamcinolone acetonide, xylometazolinehydrochloride. (See, e.g., pp. 1041-97 of Nursing 2001 Drug Handbook.)

The at least one local anti-infectives can be at least one selected fromacyclovir, amphotericin B, azelaic acid cream, bacitracin, butoconazolenitrate, clindamycin phosphate, clotrimazole, econazole nitrate,erythromycin, gentamicin sulfate, ketoconazole, mafenide acetate,metronidazole (topical), miconazole nitrate, mupirocin, naftifinehydrochloride, neomycin sulfate, nitrofurazone, nystatin, silversulfadiazine, terbinafine hydrochloride, terconazole, tetracyclinehydrochloride, tioconazole, tolnaftate. The at least one scabicide orpediculicide can be at least one selected from crotamiton, lindane,permethrin, and pyrethrins. The at least one topical corticosteroid canbe at least one selected from betamethasone dipropionate, betamethasonevalerate, clobetasol propionate, desonide, desoximetasone,dexamethasone, dexamethasone sodium phosphate, diflorasone diacetate,fluocinolone acetonide, fluocinonide, flurandrenolide, fluticasonepropionate, halcionide, hydrocortisone, hydrocortisone acetate,hydrocortisone butyrate, hydrocorisone valerate, mometasone furoate,triamcinolone acetonide. (See, e.g., pp. 1098-1136 of Nursing 2001 DrugHandbook.)

The at least one vitamin or mineral can be at least one selected fromvitamin A, vitamin B complex, cyanocobalamin, folic acid,hydroxocobalamin, leucovorin calcium, niacin, niacinamide, pyridoxinehydrochloride, riboflavin, thiamine hydrochloride, vitamin C, vitamin D,cholecalciferol, ergocalciferol, vitamin D analogue, doxercalciferol,paricalcitol, vitamin E, vitamin K analogue, phytonadione, sodiumfluoride, sodium fluoride (topical), trace elements, chromium, copper,iodine, manganese, selenium, zinc. The at least one calorics can be atleast one selected from amino acid infusions (crystalline), amino acidinfusions in dextrose, amino acid infusions with electrolytes, aminoacid infusions with electrolytes in dextrose, amino acid infusions forhepatic failure, amino acid infusions for high metabolic stress, aminoacid infusions for renal failure, dextrose, fat emulsions, medium-chaintriglycerides. (See, e.g., pp. 1137-63 of Nursing 2001 Drug Handbook.)

The present invention also provides at least one of any suitable and/oreffective amount of a composition or pharmaceutical compositioncomprising at least one GLP-1 mimetibody or specified portion orvariant, optionally further comprise an effective amount of at least onefurther compound, protein or composition selected from at least one TNFantagonist (e.g., but not limited to a TNF chemical or proteinantagonist, TNF monoclonal or polyclonal antibody or fragment, a solubleTNF receptor (e.g., p55, p70 or p85) or fragment, fusion polypeptidesthereof, or a small molecule TNF antagonist, e.g., TNF binding protein Ior II (TBP-1 or TBP-II), nerelimonmab, infliximab, enteracept, CDP-571,CDP-870, afelimomab, lenercept, and the like), an antirheumatic (e.g.,methotrexate, auranofin, aurothioglucose, azathioprine, etanercept, goldsodium thiomalate, hydroxychloroquine sulfate, leflunomide,sulfasalzine), a muscle relaxant, a narcotic, a non-steroid inflammatorydrug (NSAID), an analgesic, an anesthetic, a sedative, a localanethetic, a neuromuscular blocker, an antimicrobial (e.g.,aminoglycoside, an antifungal, an antiparasitic, an antiviral, acarbapenem, cephalosporin, a fluororquinolone, a macrolide, apenicillin, a sulfonamide, a tetracycline, another antimicrobial), anantipsoriatic, a corticosteriod, an anabolic steroid, a diabetes relatedagent, a mineral, a nutritional, a thyroid agent, a vitamin, a calciumrelated hormone, an antidiarrheal, an antitussive, an antiemetic, anantiulcer, a laxative, an anticoagulant, an erythropieitin (e.g.,epoetin alpha), a filgrastim (e.g., G-CSF, Neupogen), a sargramostim(GM-CSF, Leukine), an immunization, an immunoglobulin, animmunosuppressive (e.g., basiliximab, cyclosporine, daclizumab), agrowth hormone, a hormone replacement drug, an estrogen receptormodulator, a mydriatic, a cycloplegic, an alkylating agent, anantimetabolite, a mitotic inhibitor, a radiopharmaceutical, anantidepressant, antimanic agent, an antipsychotic, an anxiolytic, ahypnotic, a sympathomimetic, a stimulant, donepezil, tacrine, an asthmamedication, a beta agonist, an inhaled steroid, a leukotriene inhibitor,a methylxanthine, a cromolyn, an epinephrine or analog, dornase alpha(Pulmozyme), a cytokine or a cytokine antagonist. Non-limiting examplesof such cytokines include, but are not limited to, any of IL-1 to IL-23.Suitable dosages are well known in the art. See, e.g., Wells et al.,eds., Pharmacotherapy Handbook, 2^(nd) Edition, Appleton and Lange,Stamford, Conn. (2000); PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000),each of which references are entirely incorporated herein by reference.

Such compositions can also include toxin molecules that are associated,bound, co-formulated or co-administered with at least one antibody orpolypeptide of the present invention. The toxin can optionally act toselectively kill the pathologic cell or tissue. The pathologic cell canbe a cancer or other cell. Such toxins can be, but are not limited to,purified or recombinant toxin or toxin fragment comprising at least onefunctional cytotoxic domain of toxin, e.g., selected from at least oneof ricin, diphtheria toxin, a venom toxin, or a bacterial toxin. Theterm toxin also includes both endotoxins and exotoxins produced by anynaturally occurring, mutant or recombinant bacteria or viruses which maycause any pathological condition in humans and other mammals, includingtoxin shock, which can result in death. Such toxins may include, but arenot limited to, enterotoxigenic E. coli heat-labile enterotoxin (LT),heat-stable enterotoxin (ST), Shigella cytotoxin, Aeromonasenterotoxins, toxic shock syndrome toxin-1 (TSST-1), Staphylococcalenterotoxin A (SEA), B (SEB), or C (SEC), Streptococcal enterotoxins andthe like. Such bacteria include, but are not limited to, strains of aspecies of enterotoxigenic E. coli (ETEC), enterohemorrhagic E. coli(e.g., strains of serotype 0157:H7), Staphylococcus species (e.g.,Staphylococcus aureus, Staphylococcus pyogenes), Shigella species (e.g.,Shigella dysenteriae, Shigella flexneri, Shigella boydii, and Shigellasonnei), Salmonella species (e.g., Salmonella typhi, Salmonellacholera-suis, Salmonella enteritidis), Clostridium species (e.g.,Clostridium perfringens, Clostridium dificile, Clostridium botulinum),Camphlobacter species (e.g., Camphlobacter jejuni, Camphlobacter fetus),Heliobacter species, (e.g., Heliobacter pylori), Aeromonas species(e.g., Aeromonas sobria, Aeromonas hydrophila, Aeromonas caviae),Pleisomonas shigelloides, Yersina enterocolitica, Vibrios species (e.g.,Vibrios cholerae, Vibrios parahemolyticus), Klebsiella species,Pseudomonas aeruginosa, and Streptococci. See, e.g., Stein, ed.,INTERNAL MEDICINE, 3rd ed., pp 1-13, Little, Brown and Co., Boston,(1990); Evans et al., eds., Bacterial Infections of Humans: Epidemiologyand Control, 2d. Ed., pp 239-254, Plenum Medical Book Co., New York(1991); Mandell et al, Principles and Practice of Infectious Diseases,3d. Ed., Churchill Livingstone, New York (1990); Berkow et al, eds., TheMerck Manual, 16th edition, Merck and Co., Rahway, N.J., 1992; Wood etal, FEMS Microbiology Immunology, 76:121-134 (1991); Marrack et al,Science, 248:705-711 (1990), the contents of which references areincorporated entirely herein by reference.

GLP-1 mimetibody or specified portion or variant compositions of thepresent invention can further comprise at least one of any suitableauxiliary, such as, but not limited to, diluent, binder, stabilizer,buffers, salts, lipophilic solvents, preservative, adjuvant or the like.Pharmaceutically acceptable auxiliaries are preferred. Non-limitingexamples of, and methods of preparing such sterile solutions are wellknown in the art, such as, but limited to, Gennaro, Ed., Remington'sPharmaceutical Sciences, 18^(th) Edition, Mack Publishing Co. (Easton,Pa.) 1990. Pharmaceutically acceptable carriers can be routinelyselected that are suitable for the mode of administration, solubilityand/or stability of the GLP-1 mimetibody composition as well known inthe art or as described herein.

Pharmaceutical excipients and additives useful in the presentcomposition include but are not limited to proteins, peptides, aminoacids, lipids, and carbohydrates (e.g., sugars, includingmonosaccharides, di-, tri-, tetra-, and oligosaccharides; derivatizedsugars such as alditols, aldonic acids, esterified sugars and the like;and polysaccharides or sugar polymers), which can be present singly orin combination, comprising alone or in combination 1-99.99% by weight orvolume. Exemplary protein excipients include serum albumin such as humanserum albumin (HSA), recombinant human albumin (rHA), gelatin, casein,and the like. Representative amino acid/GLP-1 mimetibody or specifiedportion or variant components, which can also function in a bufferingcapacity, include alanine, glycine, arginine, betaine, histidine,glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine,valine, methionine, phenylalanine, aspartame, and the like. Onepreferred amino acid is glycine.

Carbohydrate excipients suitable for use in the invention include, forexample, monosaccharides such as fructose, maltose, galactose, glucose,D-mannose, sorbose, and the like; disaccharides, such as lactose,sucrose, trehalose, cellobiose, and the like; polysaccharides, such asraffinose, melezitose, maltodextrins, dextrans, starches, and the like;and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitolsorbitol (glucitol), myoinositol and the like. Preferred carbohydrateexcipients for use in the present invention are mannitol, trehalose, andraffinose.

GLP-1 mimetibody compositions can also include a buffer or a pHadjusting agent; typically, the buffer is a salt prepared from anorganic acid or base. Representative buffers include organic acid saltssuch as salts of citric acid, ascorbic acid, gluconic acid, carbonicacid, tartaric acid, succinic acid, acetic acid, or phthalic acid; Tris,tromethamine hydrochloride, or phosphate buffers. Preferred buffers foruse in the present compositions are organic acid salts such as citrate.

Additionally, the GLP-1 mimetibody or specified portion or variantcompositions of the invention can include polymeric excipients/additivessuch as polyvinylpyrrolidones, ficolls (a polymeric sugar), dextrates(e.g., cyclodextrins, such as 2-hydroxypropyl-β-cyclodextrin),polyethylene glycols, flavoring agents, antimicrobial agents,sweeteners, antioxidants, antistatic agents, surfactants (e.g.,polysorbates such as “TWEEN 20” and “TWEEN 80”), lipids (e.g.,phospholipids, fatty acids), steroids (e.g., cholesterol), and chelatingagents (e.g., EDTA).

These and additional known pharmaceutical excipients and/or additivessuitable for use in the GLP-1 mimetibody compositions according to theinvention are known in the art, e.g., as listed in “Remington: TheScience & Practice of Pharmacy”, 19^(th) ed., Williams & Williams,(1995), and in the “Physician's Desk Reference”, 52^(nd) ed., MedicalEconomics, Montvale, N.J. (1998), the disclosures of which are entirelyincorporated herein by reference. Preferrred carrier or excipientmaterials are carbohydrates (e.g., saccharides and alditols) and buffers(e.g., citrate) or polymeric agents.

Formulations. As noted above, the invention provides for stableformulations, which can preferably include a suitable buffer with salineor a chosen salt, as well as optional preserved solutions andformulations containing a preservative as well as multi-use preservedformulations suitable for pharmaceutical or veterinary use, comprisingat least one GLP-1 mimetibody or specified portion or variant in apharmaceutically acceptable formulation. Preserved formulations containat least one known preservative or optionally selected from the groupconsisting of at least one phenol, m-cresol, p-cresol, o-cresol,chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol,formaldehyde, chlorobutanol, magnesium chloride (e.g., hexahydrate),alkylparaben (methyl, ethyl, propyl, butyl and the like), benzalkoniumchloride, benzethonium chloride, sodium dehydroacetate and thimerosal,or mixtures thereof in an aqueous diluent. Any suitable concentration ormixture can be used as known in the art, such as 0.001-5%, or any rangeor value therein, such as, but not limited to 0.001, 0.003, 0.005,0.009, 0.01, 0.02, 0.03, 0.05, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7,0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1,2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5,3.6, 3.7, 3.8, 3.9, 4.0, 4.3, 4.5, 4.6, 4.7, 4.8, 4.9, or any range orvalue therein. Non-limiting examples include, no preservative, 0.1-2%m-cresol (e.g., 0.2, 0.3. 0.4, 0.5, 0.9, 1.0%), 0.1-3% benzyl alcohol(e.g., 0.5, 0.9, 1.1, 1.5, 1.9, 2.0, 2.5%), 0.001-0.5% thimerosal (e.g.,0.005, 0.01), 0.001-2.0% phenol (e.g., 0.05, 0.25, 0.28, 0.5, 0.9,1.0%), 0.0005-1.0% alkylparaben(s) (e.g., 0.00075, 0.0009, 0.001, 0.002,0.005, 0.0075, 0.009, 0.01, 0.02, 0.05, 0.075, 0.09, 0.1, 0.2, 0.3, 0.5,0.75, 0.9, 1.0%), and the like.

As noted above, the invention provides an article of manufacture,comprising packaging material and at least one vial comprising asolution of at least one GLP-1 mimetibody or specified portion orvariant with the prescribed buffers and/or preservatives, optionally inan aqueous diluent, wherein said packaging material comprises a labelthat indicates that such solution can be held over a period of 1, 2, 3,4, 5, 6, 9, 12, 18, 20, 24, 30, 36, 40, 48, 54, 60, 66, 72 hours orgreater. The invention further comprises an article of manufacture,comprising packaging material, a first vial comprising lyophilized atleast one GLP-1 mimetibody or specified portion or variant, and a secondvial comprising an aqueous diluent of prescribed buffer or preservative,wherein said packaging material comprises a label that instructs apatient to reconstitute the at least one GLP-1 mimetibody or specifiedportion or variant in the aqueous diluent to form a solution that can beheld over a period of twenty-four hours or greater.

The at least one GLP-1 mimetibody or specified portion or variant usedin accordance with the present invention can be produced by recombinantmeans, including from mammalian cell or transgenic preparations, or canbe purified from other biological sources, as described herein or asknown in the art.

The range of amounts of at least one GLP-1 mimetibody or specifiedportion or variant in the product of the present invention includesamounts yielding upon reconstitution, if in a wet/dry system,concentrations from about 1.0 μg/ml to about 1000 mg/ml, although lowerand higher concentrations are operable and are dependent on the intendeddelivery vehicle, e.g., solution formulations will differ fromtransdermal patch, pulmonary, transmucosal, or osmotic or micro pumpmethods.

Preferably, the aqueous diluent optionally further comprises apharmaceutically acceptable preservative. Preferred preservativesinclude those selected from the group consisting of phenol, m-cresol,p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkylparaben (methyl,ethyl, propyl, butyl and the like), benzalkonium chloride, benzethoniumchloride, sodium dehydroacetate and thimerosal, or mixtures thereof. Theconcentration of preservative used in the formulation is a concentrationsufficient to yield an anti-microbial effect. Such concentrations aredependent on the preservative selected and are readily determined by theskilled artisan.

Other excipients, e.g. isotonicity agents, buffers, antioxidants,preservative enhancers, can be optionally and preferably added to thediluent. An isotonicity agent, such as glycerin, is commonly used atknown concentrations. A physiologically tolerated buffer is preferablyadded to provide improved pH control. The formulations can cover a widerange of pHs, such as from about pH 4 to about pH 10, and preferredranges from about pH 5 to about pH 9, and a most preferred range ofabout 6.0 to about 8.0. Preferably the formulations of the presentinvention have pH between about 6.8 and about 7.8. Preferred buffersinclude phosphate buffers, most preferably sodium phosphate,particularly phosphate buffered saline (PBS).

Other additives, such as a pharmaceutically acceptable solubilizers likeTween 20 (polyoxyethylene (20) sorbitan monolaurate), Tween 40(polyoxyethylene (20) sorbitan monopalmitate), Tween 80 (polyoxyethylene(20) sorbitan monooleate), Pluronic F68 (polyoxyethylenepolyoxypropylene block copolymers), and PEG (polyethylene glycol) ornon-ionic surfactants such as polysorbate 20 or 80 or poloxamer 184 or188, Pluronic® polyls, other block co-polymers, and chelators such asEDTA and EGTA can optionally be added to the formulations orcompositions to reduce aggregation. These additives are particularlyuseful if a pump or plastic container is used to administer theformulation. The presence of pharmaceutically acceptable surfactantmitigates the propensity for the protein to aggregate.

The formulations of the present invention can be prepared by a processwhich comprises mixing at least one GLP-1 mimetibody or specifiedportion or variant and a preservative selected from the group consistingof phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol,alkylparaben, (methyl, ethyl, propyl, butyl and the like), benzalkoniumchloride, benzethonium chloride, sodium dehydroacetate and thimerosal ormixtures thereof in an aqueous diluent. Mixing the at least one GLP-1mimetibody or specified portion or variant and preservative in anaqueous diluent is carried out using conventional dissolution and mixingprocedures. To prepare a suitable formulation, for example, a measuredamount of at least one GLP-1 mimetibody or specified portion or variantin buffered solution is combined with the desired preservative in abuffered solution in quantities sufficient to provide the protein andpreservative at the desired concentrations. Variations of this processwould be recognized by one of ordinary skill in the art. For example,the order the components are added, whether additional additives areused, the temperature and pH at which the formulation is prepared, areall factors that may be optimized for the concentration and means ofadministration used.

The claimed formulations can be provided to patients as clear solutionsor as dual vials comprising a vial of lyophilized at least one GLP-1mimetibody or specified portion or variant that is reconstituted with asecond vial containing water, a preservative and/or excipients,preferably a phosphate buffer and/or saline and a chosen salt, in anaqueous diluent. Either a single solution vial or dual vial requiringreconstitution can be reused multiple times and can suffice for a singleor multiple cycles of patient treatment and thus can provide a moreconvenient treatment regimen than currently available.

The present claimed articles of manufacture are useful foradministration over a period of immediately to twenty-four hours orgreater. Accordingly, the presently claimed articles of manufactureoffer significant advantages to the patient. Formulations of theinvention can optionally be safely stored at temperatures of from about2 to about 40° C. and retain the biologically activity of the proteinfor extended periods of time, thus, allowing a package label indicatingthat the solution can be held and/or used over a period of 6, 12, 18,24, 36, 48, 72, or 96 hours or greater. If preserved diluent is used,such label can include use up to at least one of 1-12 months, one-half,one and a half, and/or two years.

The solutions of at least one GLP-1 mimetibody or specified portion orvariant in the invention can be prepared by a process that comprisesmixing at least one GLP-1 mimetibody or specified portion or variant inan aqueous diluent. Mixing is carried out using conventional dissolutionand mixing procedures. To prepare a suitable diluent, for example, ameasured amount of at least one GLP-1 mimetibody or specified portion orvariant in water or buffer is combined in quantities sufficient toprovide the protein and optionally a preservative or buffer at thedesired concentrations. Variations of this process would be recognizedby one of ordinary skill in the art. For example, the order thecomponents are added, whether additional additives are used, thetemperature and pH at which the formulation is prepared, are all factorsthat may be optimized for the concentration and means of administrationused.

The claimed products can be provided to patients as clear solutions oras dual vials comprising a vial of lyophilized at least one GLP-1mimetibody or specified portion or variant that is reconstituted with asecond vial containing the aqueous diluent. Either a single solutionvial or dual vial requiring reconstitution can be reused multiple timesand can suffice for a single or multiple cycles of patient treatment andthus provides a more convenient treatment regimen than currentlyavailable.

The claimed products can be provided indirectly to patients by providingto pharmacies, clinics, or other such institutions and facilities, clearsolutions or dual vials comprising a vial of lyophilized at least oneGLP-1 mimetibody or specified portion or variant that is reconstitutedwith a second vial containing the aqueous diluent. The clear solution inthis case can be up to one liter or even larger in size, providing alarge reservoir from which smaller portions of the at least one GLP-1mimetibody or specified portion or variant solution can be retrieved oneor multiple times for transfer into smaller vials and provided by thepharmacy or clinic to their customers and/or patients.

Recognized devices comprising these single vial systems include thosepen-injector devices for delivery of a solution such as Humaject®,NovoPen®, B-D® Pen, AutoPen®, and OptiPen®. Recognized devicescomprising a dual vial system include those pen-injector systems forreconstituting a lyophilized drug in a cartridge for delivery of thereconstituted solution such as the HumatroPen®.

The products presently claimed include packaging material. The packagingmaterial provides, in addition to the information required by theregulatory agencies, the conditions under which the product can be used.The packaging material of the present invention provides instructions tothe patient to reconstitute the at least one GLP-1 mimetibody orspecified portion or variant in the aqueous diluent to form a solutionand to use the solution over a period of 2-24 hours or greater for thetwo vial, wet/dry, product. For the single vial, solution product, thelabel indicates that such solution can be used over a period of 2-24hours or greater. The presently claimed products are useful for humanpharmaceutical product use.

The formulations of the present invention can be prepared by a processthat comprises mixing at least one GLP-1 mimetibody or specified portionor variant and a selected buffer, preferably a phosphate buffercontaining saline or a chosen salt. Mixing the at least one GLP-1mimetibody or specified portion or variant and buffer in an aqueousdiluent is carried out using conventional dissolution and mixingprocedures. To prepare a suitable formulation, for example, a measuredamount of at least one GLP-1 mimetibody or specified portion or variantin water or buffer is combined with the desired buffering agent in waterin quantities sufficient to provide the protein and buffer at thedesired concentrations. Variations of this process would be recognizedby one of ordinary skill in the art. For example, the order thecomponents are added, whether additional additives are used, thetemperature and pH at which the formulation is prepared, are all factorsthat can be optimized for the concentration and means of administrationused.

The claimed stable or preserved formulations can be provided to patientsas clear solutions or as dual vials comprising a vial of lyophilized atleast one GLP-1 mimetibody or specified portion or variant that isreconstituted with a second vial containing a preservative or buffer andexcipients in an aqueous diluent. Either a single solution vial or dualvial requiring reconstitution can be reused multiple times and cansuffice for a single or multiple cycles of patient treatment and thusprovides a more convenient treatment regimen than currently available.

At least one GLP-1 mimetibody or specified portion or variant in eitherthe stable or preserved formulations or solutions described herein, canbe administered to a patient in accordance with the present inventionvia a variety of delivery methods including SC or IM injection;transdermal, pulmonary, transmucosal, implant, osmotic pump, cartridge,micro pump, or other means appreciated by the skilled artisan, aswell-known in the art.

Therapeutic Applications. The present invention for mimetibodies alsoprovides a method for modulating or treating diabetes, type I or type IIdiabetes mellitus, including adult onset or juvenile, insulin dependent,non-insulin dependent, and the like, including the associated signs andsymptoms, such as but not limited to, insulin resistance, hyperglycemia,hypoglycemia, pancreatitis, Sushing's syndrome, acanthosis nigricans,lipoatrrophic diabetes, retinopathy, nephropathy, polyneuropathy,mononeuropathy, autonomic neuropathy, ulcers, foot ulcers, jointproblems, infections (e.g., fungal or bacterial), and the like, in acell, tissue, organ, animal, or patient.

The present invention also provides a method for modulating or treatingat least one diabetes associated immune related disease, in a cell,tissue, organ, animal, or patient including, but not limited to, atleast one of type I or type II diabetes mellitus, including adult onsetor juvenile, insulin dependent, non-insulin dependent, and the like,including the associated signs and symptoms, such as but not limited to,insulin resistance, hyperglycemia, hypoglycemia, pancreatitis, Sushing'ssyndrome, acanthosis nigricans, lipoatrrophic diabetes, retinopathy,nephropathy, polyneuropathy, mononeuropathy, autonomic neuropathy,ulcers, foot ulcers, joint problems, infections (e.g., fungal orbacterial), and the like. See, e.g., the Merck Manual, 12th-17thEditions, Merck & Company, Rahway, N.J. (1972, 1977, 1982, 1987, 1992,1999), Pharmacotherapy Handbook, Wells et al., eds., Second Edition,Appleton and Lange, Stamford, Conn. (1998, 2001), each entirelyincorporated by reference.

Such a method can optionally comprise administering an effective amountof at least one composition or pharmaceutical composition comprising atleast one GLP-1 mimetibody or specified portion or variant to a cell,tissue, organ, animal or patient in need of such modulation, treatmentor therapy.

The present invention also provides a method for modulating or treatingat least one cardiovascular disease in a cell, tissue, organ, animal, orpatient, including, but not limited to, at least one of cardiac stunsyndrome, myocardial infarction, congestive heart failure, stroke,ischemic stroke, hemorrhage, arteriosclerosis, atherosclerosis, diabeticateriosclerotic disease, hypertension, arterial hypertension,renovascular hypertension, syncope, shock, syphilis of thecardiovascular system, heart failure, cor pulmonale, primary pulmonaryhypertension, cardiac arrhythmias, atrial ectopic beats, atrial flutter,atrial fibrillation (sustained or paroxysmal), chaotic or multifocalatrial tachycardia, regular narrow QRS tachycardia, specific arrythmias,ventricular fibrillation, His bundle arrythmias, atrioventricular block,bundle branch block, myocardial ischemic disorders, coronary arterydisease, angina pectoris, myocardial infarction, cardiomyopathy, dilatedcongestive cardiomyopathy, restrictive cardiomyopathy, valvular heartdiseases, endocarditis, pericardial disease, cardiac tumors, aordic andperipheral aneuryisms, aortic dissection, inflammation of the aorta,occulsion of the abdominal aorta and its branches, peripheral vasculardisorders, occulsive arterial disorders, peripheral atherloscleroticdisease, thromboangitis obliterans, functional peripheral arterialdisorders, Raynaud's phenomenon and disease, acrocyanosis,erythromelalgia, venous diseases, venous thrombosis, varicose veins,arteriovenous fistula, lymphederma, lipedema, unstable angina,reperfusion injury, post pump syndrome, ischemia-reperfusion injury, andthe like. Such a method can optionally comprise administering aneffective amount of a composition or pharmaceutical compositioncomprising at least one GLP-1 mimetibody or specified portion or variantto a cell, tissue, organ, animal or patient in need of such modulation,treatment or therapy.

Any method of the present invention can comprise administering aneffective amount of a composition or pharmaceutical compositioncomprising at least one GLP-1 mimetibody or specified portion or variantto a cell, tissue, organ, animal or patient in need of such modulation,treatment or therapy. Such a method can optionally further compriseco-administration or combination therapy for treating such immunediseases, wherein the administering of said at least one GLP-1mimetibody, specified portion or variant thereof, further comprisesadministering, before concurrently, and/or after, at least one selectedfrom at least one TNF antagonist (e.g., but not limited to a TNFantibody or fragment, a soluble TNF receptor or fragment, fusionproteins thereof, or a small molecule TNF antagonist), an antirheumatic,a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug(NSAID), an analgesic, an anesthetic, a sedative, a local anethetic, aneuromuscular blocker, an antimicrobial (e.g., aminoglycoside, anantifungal, an antiparasitic, an antiviral, a carbapenem, cephalosporin,a fluororquinolone, a macrolide, a penicillin, a sulfonamide, atetracycline, another antimicrobial), an antipsoriatic, acorticosteriod, an anabolic steroid, a diabetes related agent, amineral, a nutritional, a thyroid agent, a vitamin, a calcium relatedhormone, an antidiarrheal, an antitussive, an antiemetic, an antiulcer,a laxative, an anticoagulant, an erythropieitin (e.g., GLP-1etin alpha),a filgrastim (e.g., G-CSF, Neupogen), a sargramostim (GM-CSF, Leukine),an immunization, an immunoglobulin, an immunosuppressive (e.g.,basiliximab, cyclosporine, daclizumab), a growth hormone, a hormonereplacement drug, an estrogen receptor modulator, a mydriatic, acycloplegic, an alkylating agent, an antimetabolite, a mitoticinhibitor, a radiopharmaceutical, an antidepressant, antimanic agent, anantipsychotic, an anxiolytic, a hypnotic, a sympathomimetic, astimulant, donepezil, tacrine, an asthma medication, a beta agonist, aninhaled steroid, a leukotriene inhibitor, a methylxanthine, a cromolyn,an epinephrine or analog, dornase alpha (Pulmozyme), a cytokine or acytokine antagonist. Suitable dosages are well known in the art. See,e.g., Wells et al., eds., Pharmacotherapy Handbook, 2^(nd) Edition,Appleton and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia, TarasconPocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, LomaLinda, Calif. (2000), each of which references are entirely incorporatedherein by reference.

Mimetibodies can also be used ex vivo, such as in autologous marrowculture. Briefly, bone marrow is removed from a patient prior tochemotherapy and treated with TPO and/or GLP-1, optionally incombination with mimetibodies, optionally in combination with one ormore additional cytokines. The treated marrow is then returned to thepatient after chemotherapy to speed the recovery of the marrow. Inaddition, TPO, alone and in combination with GLP-1 mimetibodies and/orGLP-1, can also be used for the ex vivo expansion of marrow orperipheral blood progenitor (PBPC) cells. Prior to chemotherapytreatment, marrow can be stimulated with stem cell factor (SCF) or G-CSFto release early progenitor cells into peripheral circulation. Theseprogenitors are optionally collected and concentrated from peripheralblood and then treated in culture with TPO and mimetibodies, optionallyin combination with one or more other cytokines, including but notlimited to SCF, G-CSF, IL-3, GM-CSF, IL-6 or IL-11, to differentiate andproliferate into high-density megakaryocyte cultures, which areoptionally then be returned to the patient following high-dosechemotherapy. Doses of TPO for ex vivo treatment of bone marrow will bein the range of 100 pg/ml to 10 ng/ml, preferably 500 pg/ml to 3 ng/ml.Doses of mimetibodies will be equivalent in activity to GLP-1 which canbe used from 0.1 units/ml to 20 units/ml, preferably from 0.5 units/mlto 2 units/ml, or any range or value therein.

TNF antagonists suitable for compositions, combination therapy,co-administration, devices and/or methods of the present invention(further comprising at least one anti body, specified portion andvariant thereof, of the present invention), include, but are not limitedto, anti-TNF antibodies, ligand-binding fragments thereof, and receptormolecules which bind specifically to TNF; compounds which prevent and/orinhibit TNF synthesis, TNF release or its action on target cells, suchas thalidomide, tenidap, phosphodiesterase inhibitors (e.g,pentoxifylline and rolipram), A2b adenosine receptor agonists and A2badenosine receptor enhancers; compounds which prevent and/or inhibit TNFreceptor signalling, such as mitogen activated protein (MAP) kinaseinhibitors; compounds which block and/or inhibit membrane TNF cleavage,such as metalloproteinase inhibitors; compounds which block and/orinhibit TNF activity, such as angiotensin converting enzyme (ACE)inhibitors (e.g., captopril); and compounds which block and/or inhibitTNF production and/or synthesis, such as MAP kinase inhibitors.

As used herein, a “tumor necrosis factor antibody,” “TNF antibody,”“TNFα antibody,” or fragment and the like decreases, blocks, inhibits,abrogates or interferes with TNFα activity in vitro, in situ and/orpreferably in vivo. For example, a suitable TNF human antibody of thepresent invention can bind TNFα and includes anti-TNF antibodies,antigen-binding fragments thereof, and specified mutants or domainsthereof that bind specifically to TNFα. A suitable TNF antibody orfragment can also decrease block, abrogate, interfere, prevent and/orinhibit TNF RNA, DNA or protein synthesis, TNF release, TNF receptorsignaling, membrane TNF cleavage, TNF activity, TNF production and/orsynthesis.

Chimeric antibody cA2 consists of the antigen binding variable region ofthe high-affinity neutralizing mouse anti-human TNFα IgG1 antibody,designated A2, and the constant regions of a human IgG1, kappaimmunoglobulin. The human IgG1 Fc region improves allogeneic antibodyeffector function, increases the circulating serum half-life anddecreases the immunogenicity of the antibody. The avidity and epitopespecificity of the chimeric antibody cA2 is derived from the variableregion of the murine antibody A2. In a particular embodiment, apreferred source for nucleic acids encoding the variable region of themurine antibody A2 is the A2 hybridoma cell line.

Chimeric A2 (cA2) neutralizes the cytotoxic effect of both natural andrecombinant human TNFα in a dose dependent manner. From binding assaysof chimeric antibody cA2 and recombinant human TNFα, the affinityconstant of chimeric antibody cA2 was calculated to be 1.04×10¹⁰M⁻¹.Preferred methods for determining monoclonal antibody specificity andaffinity by competitive inhibition can be found in Harlow, et al.,Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press,Cold Spring Harbor, N.Y., 1988; Colligan et al., eds., Current Protocolsin Immunology, Greene Publishing Assoc. and Wiley Interscience, NewYork, (1992-2003); Kozbor et al., Immunol. Today, 4:72-79 (1983);Ausubel et al., eds. Current Protocols in Molecular Biology, WileyInterscience, New York (1987-2003); and Muller, Meth. Enzymol.,92:589-601 (1983), which references are entirely incorporated herein byreference.

Additional examples of monoclonal anti-TNF antibodies that can be usedin the present invention are described in the art (see, e.g., U.S. Pat.No. 5,231,024; Möller, A. et al., Cytokine 2(3):162-169 (1990); U.S.application Ser. No. 07/943,852 (filed Sep. 11, 1992); Rathjen et al.,International Publication No. WO 91/02078 (published Feb. 21, 1991);Rubin et al., GLP-1 Patent Publication No. 0 218 868 (published Apr. 22,1987); Yone et al., GLP-1 Patent Publication No. 0 288 088 (Oct. 26,1988); Liang, et al., Biochem. Biophys. Res. Comm. 137:847-854 (1986);Meager, et al., Hybridoma 6:305-311 (1987); Fendly et al., Hybridoma6:359-369 (1987); Bringman, et al., Hybridoma 6:489-507 (1987); andHirai, et al., J. Immunol. Meth. 96:57-62 (1987), which references areentirely incorporated herein by reference).

TNF Receptor Molecules. Preferred TNF receptor molecules useful in thepresent invention are those that bind TNFα with high affinity (see,e.g., Feldmann et al., International Publication No. WO 92/07076(published Apr. 30, 1992); Schall et al., Cell 61:361-370 (1990); andLoetscher et al., Cell 61:351-359 (1990), which references are entirelyincorporated herein by reference) and optionally possess lowimmunogenicity. In particular, the 55 kDa (p55 TNF-R) and the 75 kDa(p75 TNF-R) TNF cell surface receptors are useful in the presentinvention. Truncated forms of these receptors, comprising theextracellular domains (ECD) of the receptors or functional portionsthereof (see, e.g., Corcoran et al., Eur. J. Biochem. 223:831-840(1994)), are also useful in the present invention. Truncated forms ofthe TNF receptors, comprising the ECD, have been detected in urine andserum as 30 kDa and 40 kDa TNFα inhibitory binding proteins (Engelmann,H. et al., J. Biol. Chem. 265:1531-1536 (1990)). TNF receptor multimericmolecules and TNF immunoreceptor fusion molecules, and derivatives andfragments or portions thereof, are additional examples of TNF receptormolecules which are useful in the methods and compositions of thepresent invention. The TNF receptor molecules which can be used in theinvention are characterized by their ability to treat patients forextended periods with good to excellent alleviation of symptoms and lowtoxicity. Low immunogenicity and/or high affinity, as well as otherundefined properties, may contribute to the therapeutic resultsachieved.

TNF receptor multimeric molecules useful in the present inventioncomprise all or a functional portion of the ECD of two or more TNFreceptors linked via one or more polypeptide linkers or other nonpeptidelinkers, such as polyethylene glycol (PEG). The multimeric molecules canfurther comprise a signal peptide of a secreted protein to directexpression of the multimeric molecule. These multimeric molecules andmethods for their production have been described in U.S. applicationSer. No. 08/437,533 (filed May 9, 1995), the content of which isentirely incorporated herein by reference.

TNF immunoreceptor fusion molecules useful in the methods andcompositions of the present invention comprise at least one portion ofone or more immunoglobulin molecules and all or a functional portion ofone or more TNF receptors. These immunoreceptor fusion molecules can beassembled as monomers, or hetero- or homo-multimers. The immunoreceptorfusion molecules can also be monovalent or multivalent. An example ofsuch a TNF immunoreceptor fusion molecule is TNF receptor/IgG fusionprotein. TNF immunoreceptor fusion molecules and methods for theirproduction have been described in the art (Lesslauer et al., Eur. J.Immunol. 21:2883-2886 (1991); Ashkenazi et al., Proc. Natl. Acad. Sci.USA 88:10535-10539 (1991); Peppel et al., J. Exp. Med. 174:1483-1489(1991); Kolls et al., Proc. Natl. Acad. Sci. USA 91:215-219 (1994);Butler et al., Cytokine 6(6):616-623 (1994); Baker et al., Eur. J.Immunol. 24:2040-2048 (1994); Beutler et al., U.S. Pat. No. 5,447,851;and U.S. application Ser. No. 08/442,133 (filed May 16, 1995), each ofwhich references are entirely incorporated herein by reference). Methodsfor producing immunoreceptor fusion molecules can also be found in Caponet al., U.S. Pat. No. 5,116,964; Capon et al., U.S. Pat. No. 5,225,538;and Capon et al., Nature 337:525-531 (1989), which references areentirely incorporated herein by reference.

A functional equivalent, derivative, fragment or region of TNF receptormolecule refers to the portion of the TNF receptor molecule, or theportion of the TNF receptor molecule sequence which encodes TNF receptormolecule, that is of sufficient size and sequences to functionallyresemble TNF receptor molecules that can be used in the presentinvention (e.g., bind TNFα with high affinity and possess lowimmunogenicity). A functional equivalent of TNF receptor molecule alsoincludes modified TNF receptor molecules that functionally resemble TNFreceptor molecules that can be used in the present invention (e.g., bindTNFα with high affinity and possess low immunogenicity). For example, afunctional equivalent of TNF receptor molecule can contain a “SILENT”codon or one or more amino acid substitutions, deletions or additions(e.g., substitution of one acidic amino acid for another acidic aminoacid; or substitution of one codon encoding the same or differenthydrophobic amino acid for another codon encoding a hydrophobic aminoacid). See Ausubel et al., Current Protocols in Molecular Biology,Greene Publishing Assoc. and Wiley-Interscience, New York (1987-2003).

Cytokines include, but are not limited to all known cytokines. See,e.g., CopewithCytokines.com. Cytokine antagonists include, but are notlimited to, any antibody, fragment or mimetic, any soluble receptor,fragment or mimetic, any small molecule antagonist, or any combinationthereof.

Any method of the present invention can comprise a method for treating aprotein mediated disorder, comprising administering an effective amountof a composition or pharmaceutical composition comprising at least oneGLP-1 mimetibody or specified portion or variant to a cell, tissue,organ, animal or patient in need of such modulation, treatment ortherapy. Such a method can optionally further comprise co-administrationor combination therapy for treating such immune diseases, wherein theadministering of said at least one GLP-1 mimetibody, specified portionor variant thereof, further comprises administering, beforeconcurrently, and/or after, at least one selected from at least oneother cytokines such as IL-3, -6 and -11; stem cell factor; G-CSF andGM-CSF.

Typically, treatment of pathologic conditions is effected byadministering an effective amount or dosage of at least one GLP-1mimetibody composition that total, on average, a range from at leastabout 0.0001 to 500 milligrams of at least one GLP-1 mimetibody orspecified portion or variant/kilogram of patient per dose, andpreferably from at least about 0.001 to 100 milligrams GLP-1 mimetibodyor specified portion or variant/kilogram of patient per single ormultiple administration, depending upon the specific activity ofcontained in the composition. Alternatively, the effective serumconcentration can comprise 0.001-5000 μg/ml serum concentration persingle or multiple administration. Suitable dosages are known to medicalpractitioners and will, of course, depend upon the particular diseasestate, specific activity of the composition being administered, and theparticular patient undergoing treatment. In some instances, to achievethe desired therapeutic amount, it can be necessary to provide forrepeated administration, i.e., repeated individual administrations of aparticular monitored or metered dose, where the individualadministrations are repeated until the desired daily dose or effect isachieved.

Preferred doses can optionally include 0.0001, 0.0002, 0.0003, 0.0004,0.0005. 0.0006, 0.0007, 0.0008, 00009, 0.001, 0.002, 0.003, 0.004,0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05. 0.06,0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, and/or 30 mg/kg/administration, or anyrange, value or fraction thereof, or to achieve a serum concentration of0.0001, 0.0002, 0.0003, 0.0004, 0.0005. 0.0006, 0.0007, 0.0008, 00009,0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01,0.02, 0.03, 0.04, 0.05. 0.06, 0.07, 0.08, 0.09, 0.1, 0.5, 0.9, 1.0, 1.1,1.2, 1.5, 1.9, 2.0, 2.5, 2.9, 3.0, 3.5, 3.9, 4.0, 4.5, 4.9, 5.0, 5.5,5.9, 6.0, 6.5, 6.9, 7.0, 7.5, 7.9, 8.0, 8.5, 8.9, 9.0, 9.5, 9.9, 10,10.5, 10.9, 11, 11.5, 11.9, 20, 12.5, 12.9, 13.0, 13.5, 13.9, 14.0,14.5, 4.9, 5.0, 5.5, 5.9, 6.0, 6.5, 6.9, 7.0, 7.5, 7.9, 8.0, 8.5, 8.9,9.0, 9.5, 9.9, 10, 10.5, 10.9, 11, 11.5, 11.9, 12, 12.5, 12.9, 13.0,13.5, 13.9, 14, 14.5, 15, 15.5, 15.9, 16, 16.5, 16.9, 17, 17.5, 17.9,18, 18.5, 18.9, 19, 19.5, 19.9, 20, 20.5, 20.9, 21, 22, 23, 24, 25, 26,27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 96, 100,200, 300, 400, and/or 500 μg/ml serum concentration per single ormultiple administration, or any range, value or fraction thereof.

Alternatively, the dosage administered can vary depending upon knownfactors, such as the pharmacodynamic characteristics of the particularagent, and its mode and route of administration; age, health, and weightof the recipient; nature and extent of symptoms, kind of concurrenttreatment, frequency of treatment, and the effect desired. Usually adosage of active ingredient can be about 0.0001 to 100 milligrams perkilogram of body weight. Ordinarily 0.001 to 10, and preferably 0.001 to1 milligrams per kilogram per administration or in sustained releaseform is effective to obtain desired results.

As a non-limiting example, treatment of humans or animals can beprovided as a one-time or periodic dosage of at least one GLP-1mimetibody or specified portion or variant of the present invention0.0001 to 100 mg/kg, such as 0.0002, 0.0003, 0.0004, 0.0005. 0.0006,0.0007, 0.0008, 00009, 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007,0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05. 0.06, 0.07, 0.08, 0.09, 0.1,0.2, 0.3, 0.4, 0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10mg/kg, per day, on at least one of day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, or alternatively, atleast one of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19 or 20, or any combination thereof, using single, infusion orrepeated doses.

Dosage forms (composition) suitable for internal administrationgenerally contain from about 0.0001 milligram to about 500 milligrams ofactive ingredient per unit or container. In these pharmaceuticalcompositions the active ingredient will ordinarily be present in anamount of about 0.5-99.999% by weight based on the total weight of thecomposition.

For parenteral administration, the GLP-1 mimetibody or specified portionor variant can be formulated as a solution, suspension, emulsion orlyophilized powder in association, or separately provided, with apharmaceutically acceptable parenteral vehicle. Examples of suchvehicles are water, saline, Ringer's solution, dextrose solution, and 5%human serum albumin. Liposomes and nonaqueous vehicles such as fixedoils may also be used. The vehicle or lyophilized powder may containadditives that maintain isotonicity (e.g., sodium chloride, mannitol)and chemical stability (e.g., buffers and preservatives). Theformulation is sterilized by known or suitable techniques.

Suitable pharmaceutical carriers are described in the most recentedition of Remington's Pharmaceutical Sciences, A. Osol, a standardreference text in this field.

Therapeutic Administration. Many known and developed modes of can beused for administering pharmaceutically effective amounts of at leastone GLP-1 mimetibody or specified portion or variant according to thepresent invention. A GLP-1 mimetibody of the present invention can bedelivered in a carrier, as a solution, emulsion, colloid, or suspension,or as a powder, using any of a variety of devices and methods suitablefor administration by inhalation or other modes described here within orknown in the art.

Parenteral Formulations and Administration. Formulations for parenteraladministration can contain as common excipients sterile water or saline,polyalkylene glycols such as polyethylene glycol, oils of vegetableorigin, hydrogenated naphthalenes and the like. Aqueous or oilysuspensions for injection can be prepared by using an appropriateemulsifier or humidifier and a suspending agent, according to knownmethods. Agents for injection can be a non-toxic, non-orallyadministrable diluting agent such as aqueous solution or a sterileinjectable solution or suspension in a solvent. As the usable vehicle orsolvent, water, Ringer's solution, isotonic saline, etc. are allowed; asan ordinary solvent, or suspending solvent, sterile involatile oil canbe used. For these purposes, any kind of involatile oil and fatty acidcan be used, including natural or synthetic or semisynthetic fatty oilsor fatty acids; natural or synthetic or semisynthtetic mono- or di- ortri-glycerides. Parental administration is known in the art andincludes, but is not limited to, conventional means of injections, a gaspressured needle-less injection device as described in U.S. Pat. No.5,851,198, and a laser perforator device as described in U.S. Pat. No.5,839,446 entirely incorporated herein by reference.

Alternative Delivery. The invention further relates to theadministration of at least one GLP-1 mimetibody or specified portion orvariant by parenteral, subcutaneous, intramuscular, intravenous, bolus,vaginal, rectal, buccal, sublingual, intranasal, or transdermal means.Protein, GLP-1 mimetibody or specified portion or variant compositionscan be prepared for use for parenteral (subcutaneous, intramuscular orintravenous) administration particularly in the form of liquid solutionsor suspensions; for use in vaginal or rectal administration particularlyin semisolid forms such as creams and suppositories; for buccal, orsublingual administration particularly in the form of tablets orcapsules; or intranasally particularly in the form of powders, nasaldrops or aerosols or certain agents; or transdermally particularly inthe form of a gel, ointment, lotion, suspension or patch delivery systemwith chemical enhancers such as dimethyl sulfoxide to either modify theskin structure or to increase the drug concentration in the transdermalpatch (Junginger, et al. In “Drug Permeation Enhancement”; Hsieh, D. S.,Eds., pp. 59-90 (Marcel Dekker, Inc. New York 1994, entirelyincorporated herein by reference), or with oxidizing agents that enablethe application of formulations containing proteins and peptides ontothe skin (WO 98/53847), or applications of electric fields to createtransient transport pathways such as electroporation, or to increase themobility of charged drugs through the skin such as iontophoresis, orapplication of ultrasound such as sonophoresis (U.S. Pat. Nos. 4,309,989and 4,767,402) (the above publications and patents being entirelyincorporated herein by reference).

Pulmonary/Nasal Administration. For pulmonary administration, preferablyat least one GLP-1 mimetibody or specified portion or variantcomposition is delivered in a particle size effective for reaching thelower airways of the lung or sinuses. According to the invention, atleast one GLP-1 mimetibody or specified portion or variant can bedelivered by any of a variety of inhalation or nasal devices known inthe art for administration of a therapeutic agent by inhalation. Thesedevices capable of dGLP-1siting aerosolized formulations in the sinuscavity or alveoli of a patient include metered dose inhalers,nebulizers, dry powder generators, sprayers, and the like. Other devicessuitable for directing the pulmonary or nasal administration of GLP-1mimetibody or specified portion or variants are also known in the art.All such devices can use of formulations suitable for the administrationfor the dispensing of GLP-1 mimetibody or specified portion or variantin an aerosol. Such aerosols can be comprised of either solutions (bothaqueous and non aqueous) or solid particles. Metered dose inhalers likethe Ventolin® metered dose inhaler, typically use a propellent gas andrequire actuation during inspiration (See, e.g., WO 94/16970, WO98/35888). Dry powder inhalers like Turbuhaler™ (Astra), Rotahaler®(Glaxo), Diskus® (Glaxo), Spiros™ inhaler (Dura), devices marketed byInhale Therapeutics, and the Spinhaler® powder inhaler (Fisons), usebreath-actuation of a mixed powder (U.S. Pat. No. 4,668,218 Astra, EP237507 Astra, WO 97/25086 Glaxo, WO 94/08552 Dura, U.S. Pat. No.5,458,135 Inhale, WO 94/06498 Fisons, entirely incorporated herein byreference). Nebulizers like AERx™ Aradigm, the Ultravent® nebulizer(Mallinckrodt), and the Acorn II® nebulizer (Marquest Medical Products)(U.S. Pat. No. 5,404,871 Aradigm, WO 97/22376), the above referencesentirely incorporated herein by reference, produce aerosols fromsolutions, while metered dose inhalers, dry powder inhalers, etc.generate small particle aerosols. These specific examples ofcommercially available inhalation devices are intended to be arepresentative of specific devices suitable for the practice of thisinvention, and are not intended as limiting the scope of the invention.Preferably, a composition comprising at least one GLP-1 mimetibody orspecified portion or variant is delivered by a dry powder inhaler or asprayer. There are a several desirable features of an inhalation devicefor administering at least one GLP-1 mimetibody or specified portion orvariant of the present invention. For example, delivery by theinhalation device is advantageously reliable, reproducible, andaccurate. The inhalation device can optionally deliver small dryparticles, e.g. less than about 10 μm, preferably about 1-5 μm, for goodrespirability.

Administration of GLP-1 mimetibody or specified portion or variantCompositions as a Spray. A spray including GLP-1 mimetibody or specifiedportion or variant composition protein can be produced by forcing asuspension or solution of at least one GLP-1 mimetibody or specifiedportion or variant through a nozzle under pressure. The nozzle size andconfiguration, the applied pressure, and the liquid feed rate can bechosen to achieve the desired output and particle size. An electrospraycan be produced, for example, by an electric field in connection with acapillary or nozzle feed. Advantageously, particles of at least oneGLP-1 mimetibody or specified portion or variant composition proteindelivered by a sprayer have a particle size less than about 10 μm,preferably in the range of about 1 μm to about 5 μm, and most preferablyabout 2 μm to about 3 μm.

Formulations of at least one GLP-1 mimetibody or specified portion orvariant composition protein suitable for use with a sprayer typicallyinclude GLP-1 mimetibody or specified portion or variant compositionprotein in an aqueous solution at a concentration of about 1 mg to about20 mg of at least one GLP-1 mimetibody or specified portion or variantcomposition protein per ml of solution. The formulation can includeagents such as an excipient, a buffer, an isotonicity agent, apreservative, a surfactant, and, preferably, zinc. The formulation canalso include an excipient or agent for stabilization of the GLP-1mimetibody or specified portion or variant composition protein, such asa buffer, a reducing agent, a bulk protein, or a carbohydrate. Bulkproteins useful in formulating GLP-1 mimetibody or specified portion orvariant composition proteins include albumin, protamine, or the like.Typical carbohydrates useful in formulating GLP-1 mimetibody orspecified portion or variant composition proteins include sucrose,mannitol, lactose, trehalose, glucose, or the like. The GLP-1 mimetibodyor specified portion or variant composition protein formulation can alsoinclude a surfactant, which can reduce or prevent surface-inducedaggregation of the GLP-1 mimetibody or specified portion or variantcomposition protein caused by atomization of the solution in forming anaerosol. Various conventional surfactants can be employed, such aspolyoxyethylene fatty acid esters and alcohols, and polyoxyethylenesorbitol fatty acid esters. Amounts will generally range between 0.001and 14% by weight of the formulation. Especially preferred surfactantsfor purposes of this invention are polyoxyethylene sorbitan monooleate,polysorbate 80, polysorbate 20, or the like. Additional agents known inthe art for formulation of a protein such as mimetibodies, or specifiedportions or variants, can also be included in the formulation.

Administration of GLP-1 mimetibody or specified portion or variantcompositions by a Nebulizer. GLP-1 mimetibody or specified portion orvariant composition protein can be administered by a nebulizer, such asjet nebulizer or an ultrasonic nebulizer. Typically, in a jet nebulizer,a compressed air source is used to create a high-velocity air jetthrough an orifice. As the gas expands beyond the nozzle, a low-pressureregion is created, which draws a solution of GLP-1 mimetibody orspecified portion or variant composition protein through a capillarytube connected to a liquid reservoir. The liquid stream from thecapillary tube is sheared into unstable filaments and droplets as itexits the tube, creating the aerosol. A range of configurations, flowrates, and baffle types can be employed to achieve the desiredperformance characteristics from a given jet nebulizer. In an ultrasonicnebulizer, high-frequency electrical energy is used to createvibrational, mechanical energy, typically employing a piezoelectrictransducer. This energy is transmitted to the formulation of GLP-1mimetibody or specified portion or variant composition protein eitherdirectly or through a coupling fluid, creating an aerosol including theGLP-1 mimetibody or specified portion or variant composition protein.Advantageously, particles of GLP-1 mimetibody or specified portion orvariant composition protein delivered by a nebulizer have a particlesize less than about 10 μm, preferably in the range of about 1 μm toabout 5 μm, and most preferably about 2 μm to about 3 μm.

Formulations of at least one GLP-1 mimetibody or specified portion orvariant suitable for use with a nebulizer, either jet or ultrasonic,typically include GLP-1 mimetibody or specified portion or variantcomposition protein in an aqueous solution at a concentration of about 1mg to about 20 mg of at least one GLP-1 mimetibody or specified portionor variant protein per ml of solution. The formulation can includeagents such as an excipient, a buffer, an isotonicity agent, apreservative, a surfactant, and, preferably, zinc. The formulation canalso include an excipient or agent for stabilization of the at least oneGLP-1 mimetibody or specified portion or variant composition protein,such as a buffer, a reducing agent, a bulk protein, or a carbohydrate.Bulk proteins useful in formulating at least one GLP-1 mimetibody orspecified portion or variant composition proteins include albumin,protamine, or the like. Typical carbohydrates useful in formulating atleast one GLP-1 mimetibody or specified portion or variant includesucrose, mannitol, lactose, trehalose, glucose, or the like. The atleast one GLP-1 mimetibody or specified portion or variant formulationcan also include a surfactant, which can reduce or preventsurface-induced aggregation of the at least one GLP-1 mimetibody orspecified portion or variant caused by atomization of the solution informing an aerosol. Various conventional surfactants can be employed,such as polyoxyethylene fatty acid esters and alcohols, andpolyoxyethylene sorbital fatty acid esters. Amounts will generally rangebetween 0.001 and 4% by weight of the formulation. Especially preferredsurfactants for purposes of this invention are polyoxyethylene sorbitanmono-oleate, polysorbate 80, polysorbate 20, or the like. Additionalagents known in the art for formulation of a protein such as at leastone GLP-1 mimetibody or specified portion or variant protein can also beincluded in the formulation.

Administration of GLP-1 mimetibody or specified portion or variantcompositions By A Metered Dose Inhaler. In a metered dose inhaler (MDI),a propellant, at least one GLP-1 mimetibody or specified portion orvariant, and any excipients or other additives are contained in acanister as a mixture including a liquefied compressed gas. Actuation ofthe metering valve releases the mixture as an aerosol, preferablycontaining particles in the size range of less than about 10 μm,preferably about 1 μm to about 5 μm, and most preferably about 2 μm toabout 3 μm. The desired aerosol particle size can be obtained byemploying a formulation of GLP-1 mimetibody or specified portion orvariant composition protein produced by various methods known to thoseof skill in the art, including jet-milling, spray drying, critical pointcondensation, or the like. Preferred metered dose inhalers include thosemanufactured by 3M or Glaxo and employing a hydrofluorocarbonpropellant.

Formulations of at least one GLP-1 mimetibody or specified portion orvariant for use with a metered-dose inhaler device will generallyinclude a finely divided powder containing at least one GLP-1 mimetibodyor specified portion or variant as a suspension in a non-aqueous medium,for example, suspended in a propellant with the aid of a surfactant. Thepropellant can be any conventional material employed for this purpose,such as chlorofluorocarbon, a hydrochlorofluorocarbon, ahydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane,dichlorodifluoromethane, dichlorotetrafluoroethanol and1,1,1,2-tetrafluoroethane, HFA-134a (hydrofluoroalkane-134a), HFA-227(hydrofluoroalkane-227), or the like. Preferably the propellant is ahydrofluorocarbon. The surfactant can be chosen to stabilize the atleast one GLP-1 mimetibody or specified portion or variant as asuspension in the propellant, to protect the active agent againstchemical degradation, and the like. Suitable surfactants includesorbitan trioleate, soya lecithin, oleic acid, or the like. In somecases solution aerosols are preferred using solvents such as ethanol.Additional agents known in the art for formulation of a protein such asprotein can also be included in the formulation.

One of ordinary skill in the art will recognize that the methods of thecurrent invention can be achieved by pulmonary administration of atleast one GLP-1 mimetibody or specified portion or variant compositionsvia devices not described herein.

Mucosal Formulations and Administration. For absorption through mucosalsurfaces, compositions and methods of administering at least one GLP-1mimetibody or specified portion or variant include an emulsioncomprising a plurality of submicron particles, a mucoadhesivemacromolecule, a bioactive peptide, and an aqueous continuous phase,which promotes absorption through mucosal surfaces by achievingmucoadhesion of the emulsion particles (U.S. Pat. No. 5,514,670). Mucoussurfaces suitable for application of the emulsions of the presentinvention can include corneal, conjunctival, buccal, sublingual, nasal,vaginal, pulmonary, stomachic, intestinal, and rectal routes ofadministration. Formulations for vaginal or rectal administration, e.g.suppositories, can contain as excipients, for example,polyalkyleneglycols, vaseline, cocoa butter, and the like. Formulationsfor intranasal administration can be solid and contain as excipients,for example, lactose or can be aqueous or oily solutions of nasal drops.For buccal administration excipients include sugars, calcium stearate,magnesium stearate, pregelinatined starch, and the like (U.S. Pat. No.5,849,695).

Oral Formulations and Administration. Formulations for oral rely on theco-administration of adjuvants (e.g., resorcinols and nonionicsurfactants such as polyoxyethylene oleyl ether andn-hexadecylpolyethylene ether) to increase artificially the permeabilityof the intestinal walls, as well as the co-administration of enzymaticinhibitors (e.g., pancreatic trypsin inhibitors,diisopropylfluorophosphate (DFF) and trasylol) to inhibit enzymaticdegradation. The active constituent compound of the solid-type dosageform for oral administration can be mixed with at least one additive,including sucrose, lactose, cellulose, mannitol, trehalose, raffinose,maltitol, dextran, starches, agar, arginates, chitins, chitosans,pectins, gum tragacanth, gum arabic, gelatin, collagen, casein, albumin,synthetic or semisynthetic polymer, and glyceride. These dosage formscan also contain other type(s) of additives, e.g., inactive dilutingagent, lubricant such as magnesium stearate, paraben, preserving agentsuch as sorbic acid, ascorbic acid, alpha-tocopherol, antioxidant suchas cysteine, disintegrator, binder, thickener, buffering agent,sweetening agent, flavoring agent, perfuming agent, etc.

Tablets and pills can be further processed into enteric-coatedpreparations. The liquid preparations for oral administration includeemulsion, syrup, elixir, suspension and solution preparations allowablefor medical use. These preparations may contain inactive diluting agentsordinarily used in said field, e.g., water. Liposomes have also beendescribed as drug delivery systems for insulin and heparin (U.S. Pat.No. 4,239,754). More recently, microspheres of artificial polymers ofmixed amino acids (proteinoids) have been used to deliverpharmaceuticals (U.S. Pat. No. 4,925,673). Furthermore, carriercompounds described in U.S. Pat. No. 5,879,681 and U.S. Pat. No.5,871,753 are used to deliver biologically active agents orally areknown in the art.

Transdermal Formulations and Administration. For transdermaladministration, the at least one GLP-1 mimetibody or specified portionor variant is encapsulated in a delivery device such as a liposome orpolymeric nanoparticles, microparticle, microcapsule, or microspheres(referred to collectively as microparticles unless otherwise stated). Anumber of suitable devices are known, including microparticles made ofsynthetic polymers such as polyhydroxy acids such as polylactic acid,polyglycolic acid and copolymers thereof, polyorthoesters,polyanhydrides, and polyphosphazenes, and natural polymers such ascollagen, polyamino acids, albumin and other proteins, alginate andother polysaccharides, and combinations thereof (U.S. Pat. No.5,814,599).

Prolonged Administration and Formulations. It can be sometimes desirableto deliver the compounds of the present invention to the subject overprolonged periods of time, for example, for periods of one week to oneyear from a single administration. Various slow release, dGLP-1t orimplant dosage forms can be utilized. For example, a dosage form cancontain a pharmaceutically acceptable non-toxic salt of the compoundsthat has a low degree of solubility in body fluids, for example, (a) anacid addition salt with a polybasic acid such as phosphoric acid,sulfuric acid, citric acid, tartaric acid, tannic acid, pamoic acid,alginic acid, polyglutamic acid, naphthalene mono- or di-sulfonic acids,polygalacturonic acid, and the like; (b) a salt with a polyvalent metalcation such as zinc, calcium, bismuth, barium, magnesium, aluminum,copper, cobalt, nickel, cadmium and the like, or with an organic cationformed from e.g., N,N′-dibenzyl-ethylenediamine or ethylenediamine; or(c) combinations of (a) and (b) e.g. a zinc tannate salt. Additionally,the compounds of the present invention or, preferably, a relativelyinsoluble salt such as those just described, can be formulated in a gel,for example, an aluminum monostearate gel with, e.g. sesame oil,suitable for injection. Particularly preferred salts are zinc salts,zinc tannate salts, pamoate salts, and the like. Another type of slowrelease dGLP-1t formulation for injection would contain the compound orsalt dispersed for encapsulated in a slow degrading, non-toxic,non-antigenic polymer such as a polylactic acid/polyglycolic acidpolymer for example as described in U.S. Pat. No. 3,773,919. Thecompounds or, preferably, relatively insoluble salts such as thosedescribed above can also be formulated in cholesterol matrix silasticpellets, particularly for use in animals. Additional slow release,dGLP-1t or implant formulations, e.g. gas or liquid liposomes are knownin the literature (U.S. Pat. No. 5,770,222 and “Sustained and ControlledRelease Drug Delivery Systems”, J. R. Robinson ed., Marcel Dekker, Inc.,N.Y., 1978).

Having generally described the invention, the same will be more readilyunderstood by reference to the following examples, which are provided byway of illustration and are not intended as limiting.

Example 1 Cloning and Expression of a GLP-1 mimetibody in MammalianCells

A typical mammalian expression vector contains at least one promoterelement, which mediates the initiation of transcription of mRNA, theGLP-1 mimetibody or specified portion or variant coding sequence, andsignals required for the termination of transcription andpolyadenylation of the transcript. Additional elements includeenhancers, Kozak sequences and intervening sequences flanked by donorand acceptor sites for RNA splicing. Highly efficient transcription canbe achieved with the early and late promoters from SV40, the longterminal repeats (LTRS) from Retroviruses, e.g., RSV, HTLVI, HIVI andthe early promoter of the cytomegalovirus (CMV). However, cellularelements can also be used (e.g., the human actin promoter). Suitableexpression vectors for use in practicing the present invention include,for example, vectors such as pIRES1neo, pRetro-Off, pRetro-On, PLXSN, orpLNCX (Clonetech Labs, Palo Alto, Calif.), pcDNA3.1 (+/−), pcDNA/Zeo(+/−) or pcDNA3.1/Hygro (+/−) (Invitrogen), PSVL and PMSG (Pharmacia,Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146) andpBC12MI (ATCC 67109). Mammalian host cells that could be used includehuman Hela 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1,Cos 7 and CV 1, quail QC1-3 cells, mouse L cells and Chinese hamsterovary (CHO) cells.

Alternatively, the gene can be expressed in stable cell lines thatcontain the gene integrated into a chromosome. The co-transfection witha selectable marker such as dhfr, gpt, neomycin, or hygromycin allowsthe identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts ofthe encoded GLP-1 mimetibody or specified portion or variant. The DHFR(dihydrofolate reductase) marker is useful to develop cell lines thatcarry several hundred or even several thousand copies of the gene ofinterest. Another useful selection marker is the enzyme glutaminesynthase (GS) (Murphy, et al., Biochem. J. 227:277-279 (1991);Bebbington, et al., Bio/Technology 10:169-175 (1992)). Using thesemarkers, the mammalian cells are grown in selective medium and the cellswith the highest resistance are selected. These cell lines contain theamplified gene(s) integrated into a chromosome. Chinese hamster ovary(CHO) and NSO cells are often used for the production of GLP-1mimetibody or specified portion or variants.

The expression vectors pC1 and pC4 contain the strong promoter (LTR) ofthe Rous Sarcoma Virus (Cullen, et al., Molec. Cell. Biol. 5:438-447(1985)) plus a fragment of the CMV-enhancer (Boshart, et al., Cell41:521-530 (1985)). Multiple cloning sites, e.g., with the restrictionenzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning ofthe gene of interest. The vectors contain in addition the 3′ intron, thepolyadenylation and termination signal of the rat preproinsulin gene.

Cloning and Expression in CHO Cells. The vector pC4 is used for theexpression of GLP-1 mimetibody or specified portion or variant. PlasmidpC4 is a derivative of the plasmid pSV2-dhfr (ATCC Accession No. 37146).The plasmid contains the mouse DHFR gene under control of the SV40 earlypromoter. Chinese hamster ovary- or other cells lacking dihydrofolateactivity that are transfected with these plasmids can be selected bygrowing the cells in a selective medium (e.g., alpha minus MEM, LifeTechnologies, Gaithersburg, Md.) supplemented with the chemotherapeuticagent methotrexate. The amplification of the DHFR genes in cellsresistant to methotrexate (MTX) has been well documented (see, e.g., F.W. Alt, et al., J. Biol. Chem. 253:1357-1370 (1978); J. L. Hamlin and C.Ma, Biochem. et Biophys. Acta 1097:107-143 (1990); and M. J. Page and M.A. Sydenham, Biotechnology 9:64-68 (1991)). Cells grown in increasingconcentrations of MTX develop resistance to the drug by overproducingthe target enzyme, DHFR, as a result of amplification of the DHFR gene.If a second gene is linked to the DHFR gene, it is usually co-amplifiedand over-expressed. It is known in the art that this approach can beused to develop cell lines carrying more than 1,000 copies of theamplified gene(s). Subsequently, when the methotrexate is withdrawn,cell lines are obtained that contain the amplified gene integrated intoone or more chromosome(s) of the host cell.

Plasmid pC4 contains for expressing the gene of interest the strongpromoter of the long terminal repeat (LTR) of the Rous Sarcoma Virus(Cullen, et al., Molec. Cell. Biol. 5:438-447 (1985)) plus a fragmentisolated from the enhancer of the immediate early gene of humancytomegalovirus (CMV) (Boshart, et al., Cell 41:521-530 (1985)).Downstream of the promoter are BamHI, XbaI, and Asp718 restrictionenzyme cleavage sites that allow integration of the genes. Behind thesecloning sites the plasmid contains the 3′ intron and polyadenylationsite of the rat preproinsulin gene. Other high efficiency promoters canalso be used for the expression, e.g., the human b-actin promoter, theSV40 early or late promoters or the long terminal repeats from otherretroviruses, e.g., HIV and HTLVI. Clontech's Tet-Off and Tet-On geneexpression systems and similar systems can be used to express the GLP-1in a regulated way in mammalian cells (M. Gossen, and H. Bujard, Proc.Natl. Acad. Sci. USA 89: 5547-5551 (1992)). For the polyadenylation ofthe mRNA other signals, e.g., from the human growth hormone or globingenes can be used as well. Stable cell lines carrying a gene of interestintegrated into the chromosomes can also be selected uponco-transfection with a selectable marker such as gpt, G418 orhygromycin. It is advantageous to use more than one selectable marker inthe beginning, e.g., G418 plus methotrexate.

The plasmid pC4 is digested with restriction enzymes and thendephosphorylated using calf intestinal phosphatase by procedures knownin the art. The vector is then isolated from a 1% agarose gel.

The DNA sequence encoding the complete GLP-1 mimetibody or specifiedportion or variant is used, corresponding to HC and LC variable regionsof a GLP-1 mimetibody of the present invention, according to knownmethod steps. Isolated nucleic acid encoding a suitable human constantregion (i.e., HC and LC regions) is also used in this construct.

The isolated variable and constant region encoding DNA and thedephosphorylated vector are then ligated with T4 DNA ligase. E. coliHB101 or XL-1 Blue cells are then transformed and bacteria areidentified that contain the fragment inserted into plasmid pC4 using,for instance, restriction enzyme analysis.

Chinese hamster ovary (CHO) cells lacking an active DHFR gene are usedfor transfection. 5 μg of the expression plasmid pC4 is cotransfectedwith 0.5 μg of the plasmid pSV2-neo using lipofectin. The plasmidpSV2neo contains a dominant selectable marker, the neo gene from Tn5encoding an enzyme that confers resistance to a group of antibioticsincluding G418. The cells are seeded in alpha minus MEM supplementedwith 1 μg/ml G418. After 2 days, the cells are trypsinized and seeded inhybridoma cloning plates (Greiner, Germany) in alpha minus MEMsupplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 μg/ml G418.After about 10-14 days single clones are trypsinized and then seeded in6-well petri dishes or 10 ml flasks using different concentrations ofmethotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing atthe highest concentrations of methotrexate are then transferred to new6-well plates containing even higher concentrations of methotrexate (1mM, 2 mM, 5 mM, 10 mM, 20 mM). The same procedure is repeated untilclones are obtained that grow at a concentration of 100-200 mM.Expression of the desired gene product is analyzed, for instance, bySDS-PAGE and Western blot or by reverse phase HPLC analysis.

Example 2 Non-Limiting Example of a GLP-1 mimetibody of the Invention

GLP-1 is a 37-amino acid peptide secreted from the L-cells of theintestine following an oral glucose challenge. A mimetibody constructincorporating a biologically active GLP-1 (7-37) peptide, variant orderivative is expected to prolong the in vivo lifetime of the peptideand provide a novel therapy for lowering blood glucose in Type 2diabetic patients. Peptides encoding the native GLP-1 (7-37) peptide ora DPP-IV resistant analogue can be incorporated into the mimetibodyscaffold. Several of these molecules have been made, and the resultingmimetibodies have demonstrated activity in functional in vitrocell-based assays. It should be noted that different in vitro assays andin vivo models can be used in these studies and the potencies may not becomparable to each other or to results presented herein.

To generate GLP-1 mimetibody variants, the GLP-1 peptide, the linker,the hinge, or the CH2 and CH3 sequences in the mimetibody could bedeleted, added, substituted, mutated or modified to improve expression,potency, stability, or effector functions.

The wild-type GLP-1 sequence (GLP-1MMB of SEQ ID NO: 69), as well asDPP-IV resistant GLP-1 variants, such as GLP-1MMB of SEQ ID NO: 71 (A2S)or GLP-1MMB of SEQ ID NO: 70 (A2G) can be incorporated into a mimetibodyscaffold. Mutations of the peptide could be made to improve theproperties of a GLP-1 mimetibody. For example mutations in the aminoterminal residues may improve signaling while mutations in the helicaldomain may stabilize the helix and thereby improve binding to thereceptor and/or stability of the mimetibody.

The length and composition of the linker could be mutated to vary theflexibility or stability of the attachment between the GLP-1 peptide andthe Fc region. Different isotypes could be incorporated into the hingeregion of the molecule. In addition, mutations could be made within thehinge region of the mimetibody to stabilize the molecule. For example,the human IgG4 hinge could be mutated to make the Ser²²⁸->Pro variant,to stabilize the interchain disulfide bonds in the mimetibody.Variations within the Fc portion of the mimetibody could be made toimprove the stability of the molecule and to change effector functionssuch as FcR binding. For example, one could use human or murine isotypes(or variations of these molecules) such as IgG4 with Ala/Ala mutations.

GLP-1 mimetibody of the Present Invention. A specific, non-limiting,example of this invention is the GLP-1 mimetibody construct (SEQ IDNO:2) according to Formula (I):

((P(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t),

where P is a single copy of the bioactive GLP-1 peptide (7-36), L is atandem repeat of either Gly-Ser or Gly-Gly-Gly-Ser (SEQ ID NO: 16)flexible linker, V is the C-terminal of V_(H) sequence, i.e., the Jregion of a naturally occurring IgG, His the complete IgG4 hinge regionand CH2 & CH3 are of the IgG4 isotype subclass. It is expected that thehalf-life of this construct will be many times that of the GLP-1 peptidealone or its variant or derivative and similar to that of an IgG.

In addition to the basic structure described above, variants withpotentially favorable biological characteristics are described. Theseinclude constructs that may have a decreased tendency to self-associate,reduced immune effector functions or decreased immunogenicity. Othermodifications that confer desired characteristics such as improvedconformation of the biologically active peptide, and transfer across theblood-brain barrier are envisioned. The proposed variants andmodifications may be combined in any fashion to yield constructs withdesired activities.

Using recombinant DNA methods, the GLP-1 peptide was inserted into anintermediate vector between an immunoglobulin signal peptide and a humanJ sequence. This was done using complementary synthetic oligonucletideswith ends compatible with the restriction sites present in the vector.These oligonucleotides comprised coding sequences for the GLP-1 peptide,and a flexible linker composed of two GGGS (SEQ ID NO: 16) repeats. Arestriction fragment containing the above-mentioned functional elementswas then transferred into an expression vector. This vector containedthe anti-CD4 immunoglobulin promoter and enhancer, and the codingsequence for the human IgG4 hinge sequence, HC constant region 2 (CH2)and constant region 3 (CH3) as well as the necessary elements forplasmid replication and selection in bacteria and selection for stableexpressers in mammalian cells.

This plasmid was introduced into the HEK293E cells and expression of thewt GLP-1 MMB was achieved in transiently transfected cells. Purificationof GLP-1 MMB was accomplished by standard protein A and Superose 12affinity chromatography, yielding approximately 1.5 mg/L of transfectedcells. This protein was the starting material for the experimentsdescribed below.

The amino acid sequence of a GLP-1 mimetibody is shown in FIG. 1.Functional domains are annotated above the peptide coding sequence. Itis thought that the J sequence will provide even more flexibility toallow the GLP-1 segment to assume the proper conformation and allow thepeptides to protrude from the globular structure of the immunoglobulinenabling appropriate orientation for binding to the GLP-1 receptor. CH2and CH3 regions constitute the bulk of the protein. One of the reasonsthat immunoglobulins are believed to have a long serum half-life istheir ability to bind the FcRn that extends the serum half-life byreturning pinocytosed immunoglobulin back to the extracellular space.The binding site of the FcRn overlaps the junction of the CH2 and CH3regions (Sheilds et al, 2001, J. Biol. Chem., vol. 276 (9), 6591-6604).

It is well known that two IgG heavy chains are assembled during cellularprocessing via disulfide bonds between cysteines located in the hingeregion to form a homodimer. It is expected that this will also occurbetween the modified peptides to form the assembled GLP-1 mimetibodyconstruct. The expected structure of a GLP-1 mimetibody contains twoGLP-1 peptides.

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 3 FACS Binding Assay

The activity of a GLP-1 mimetibody was tested in an in vitro FACSbinding assay. To determine whether the GLP-1 MMB binds the GLP-1R,HEK293 cells (1×10⁶ cells) over-expressing the GLP-1R were incubatedwith GLP-1 MMB of SEQ ID NO: 69 (20 nM) for 2 hours at 4° C. The cellswere washed, and a fluorescently labeled secondary detection antibody (1μg/mL goat anti-human IgG, Fc gamma specific) was added for 30 minutesat 4° C. The fluorescence intensity of the cells was monitored via flowcytometry. FIG. 2A shows that GLP-1 MMB of SEQ ID NO: 69 binds to HEK293cells over-expressing the GLP-1R (grey, GLP-1 MMB of SEQ ID NO: 69 butno secondary; black, secondary only; red, negative control MMB andsecondary; blue, GLP-1 MMB and secondary). FIG. 2B shows that the GLP-1MMB of SEQ ID NO: 69 does not bind to the control HEK293 cells (grey,GLP-1 MMB of SEQ ID NO: 69 but no secondary; black, secondary only;blue, GLP-1 MMB of SEQ ID NO: 69 and secondary). FIG. 2C shows that aGLP-1 peptide analogue (A2S) is able to compete with GLP-1 MMB of SEQ IDNO: 69 for binding to HEK293 cells over-expressing the GLP-1R (grey,GLP-1 MMB of SEQ ID NO: 69 but no secondary; black, GLP-1 MMB of SEQ IDNO: 69 and secondary; orange, GLP-1 MMB of SEQ ID NO: 69, 0.2 nMcompetitor, secondary; blue, GLP-1 MMB of SEQ ID NO: 69, 20 nMcompetitor, secondary; red, GLP-1 MMB of SEQ ID NO: 69, 100 nMcompetitor, secondary).

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 4 cAMP Assay

GLP-1 binds to its receptor, a G-protein coupled receptor, resulting ina dose-dependent increase in the signaling molecule, 3′,5′-cyclic AMP(cAMP). cAMP can be measured with an in vitro assay in cells expressingthe GLP-1R (Applied Biosystems). Briefly, Rinm cells (100,000 cells)were incubated with increasing concentrations of GLP-1 peptide (0-30 nM)or A GLP-1 MMB (0-100 nM). The cells were lysed, and the amount of cAMPwas determined using a competitive assay that employs analkaline-phosphatase labeled cAMP conjugate and a chemiluminescentsubstrate (Tropix® CDPD®). The concentration dependent cAMP activity forthe wt GLP-1 MMB of SEQ ID NO: 69 (FIG. 3A) is comparable to the GLP-1peptide (FIG. 3B) (EC₅₀=11 nM vs. 0.4 nM, respectively). In a similarexperiment, GLP-1 MMB of SEQ ID NO: 70 (A2G) in an IgG4 scaffold (FIG.3C) and GLP-1 MMB of SEQ ID NO: 71 (A2S) in an IgG4 scaffold (FIG. 3D)both increased cAMP levels in Rinm cells to a significantly higher levelthan wt GLP-1 MMB of SEQ ID NO: 69 in an IgG4 scaffold.

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 5 In Vitro Activity of GLP-1MMB as Measured by cAMP

A LANCE™ cAMP assay was used to measure the functional activity ofGLP-1MMB in INS-1E cells, a rat insulinoma cell line expressing the ratGLP-1 receptor.

-   -   Materials/Methods: INS-1E cells were cultured in RPMI 1640/10%        FBS/1% L-glutamine/1% Sodium Pyruvate/1% Non-essential Amino        Acids/50 μM β-Mercaptoethanol and maintained at 37° C. in a        humidified incubator with 5% CO₂. LANCE cAMP kits were purchased        from Perkin Elmer (Boston, Mass.). The GLP-1 peptide was        purchased from Sigma (St Louis, Mo.). Data was analyzed in        GraphPad PRISM, version 4.03.    -   cAMP Assay: INS-1E cells were plated at 100,000 cells/well in        96-well plates (Costar 3610) and allowed to recover 4 days in        normal growth media. Media was aspirated from the wells and 24        μl of Alexa Fluor 647 anti-cAMP antibody (LANCE cAMP Kit, Perkin        Elmer, Boston, Mass.) was added followed by 24 μl of GLP-1MMB of        SEQ ID NO 4 (in PBS/0.5% BSA/0.5 mM IBMX). The cells were        stimulated at room temperature for 7 minutes and lysed per the        manufacture's protocol. The plates were incubated at room        temperature for 1 hour and the fluorescence intensity was        measured at 665 nm. cAMP concentrations were determined using a        standard curve.    -   Results: The concentration of cAMP was plotted against the        concentration of GLP-1MMB of SEQ ID NO 4 (nM) and the points        were fit to a hyperbola, providing an EC₅₀ of 8.7 nM (FIG. 18A).        The data obtained with GLP-1 peptide was plotted in the same        manner, providing an EC₅₀ of 0.11 nM (FIG. 18B).

Example 6 DPP-IV Cleavage Assay

Since GLP-1 is rapidly inactivated by DPP-IV, an in vitro assay wasestablished to quantitate intact (i.e. uncleaved) GLP-1 MMB of SEQ IDNO: 69. Briefly, GLP-1 MMB of SEQ ID NO: 69 or peptide (1.2 nM) wasincubated at room temperature with DPP-IV (1 μg/mL, R&D Systems). Aftervarious times (0, 5, 10, 15, 20, 30, 40 minutes), a DPP-IV inhibitor(100 μM, Linco) was added to quench the reaction. The amount of intactGLP-1 MMB of SEQ ID NO: 69 or peptide was measured using the GLP-1Active ELISA (Linco) and the GLP-1 MMB of SEQ ID NO: 69 or peptides forthe respective standard curves. FIG. 4 shows that the GLP-1 MMB of SEQID NO: 69 was significantly more resistant to cleavage by DPP-IV,relative to the GLP-1 peptide.

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 7

Human Serum Stability Assay

The stability of the GLP-1 MMB in serum was also measured to ensure thatother serum proteases were not able to cleave and inactivate the GLP-1MMB. Briefly, GLP1 peptide or the GLP-1 MMB of SEQ ID NO: 71 (30 nM) wasincubated in human serum at 37° C. After various times, the reactionswere quenched with a DPP-IV inhibitor (100 μM, Linco), and the sampleswere analyzed using the GLP-1 Active ELISA from Linco. FIG. 5 shows thatthe GLP-1 MMB of SEQ ID NO: 71 is stable in human serum for 24 hourswhile the peptide is decayed rapidly.

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 8 GLP-1 MMB Causes Insulin Secretion in RINm Cells

To test the effect of GLP-1 MMB in insulin secretion, RINm cells weretreated with increasing concentrations of GLP-1 (7-36) peptide (0-5 nM),exendin-4 peptide (0-5 nM), or various GLP-1 mimetibodies (5 or 50 nM)and the amount of insulin secreted was measured via ELISA. All GLP-1MMBs tested had activities in stimulating insulin secretion in RINmcells (FIG. 6). At 50 nM, the MMBs had activities comparable to that ofthe wide-type GLP-1 (7-36) peptide.

Example 9 In vitro Activity of GLP-1MMB as Measured by Insulin Secretion

A further insulin secretion assay was developed to measure functional invitro activity of the GLP-1MMB of SEQ ID NO 4.

-   -   Cell culture: INS-1E cells were cultured in RPMI 1640/10% FBS/1%        L-glutamine/1% Sodium Pyruvate/1% Non-essential Amino Acids/50        μM β-Mercaptoethanol and maintained at 37° C. in a humidified        incubator with 5% CO₂. Data was analyzed in GraphPad PRISM,        version 4.03.    -   Insulin Secretion Assay: INS-1E cells were plated at 100,000        cells/well in 96-well plates (Costar 3610) and allowed to        recover 4 days in normal growth media. The cells were washed        twice and 0.1 ml of KRBH buffer/3 mM glucose was added. The        cells were allowed to equilibrate in this buffer for 2 hours.        The media was removed and 0.12 ml of GLP-1MMB of SEQ ID NO 4 in        KRBH with 6.5 mM glucose was added per well. Twenty microliters        of supernatant was removed per well for the T=0 time point. The        cells were incubated for two hours at 37° C. at 5% CO₂ and        twenty microliters of supernatant were removed per well.        Supernatants were frozen at −20° C. until the insulin ELISA was        performed. Insulin concentrations were determined using a the        Ultra Sensitive Rat Insulin ELISA kit (Crystal Chem).    -   Results: The data was plotted as the amount of insulin secreted        at each concentration of GLP-1MMB of SEQ ID NO 4 (FIG. 19).        GLP-1MMB of SEQ ID NO 4 (25 nM) significantly increased the        amount of insulin secreted into the supernatant.

Example 10 GLP-1 MMB Lowers Glucose level in db/db mice

Six week old db/db mice were fasted for two hours and then dosedintravenously with vehicle, GLP-1 peptide, or GLP-1 MMB of SEQ ID NO: 71(A2S). Blood glucose was monitored 0.5, 1, 2, 3, and 4 hourspost-dosing. The GLP-1 peptide lowered blood glucose at 30 minutes, butby 60 minutes, the blood glucose began to increase again likely due tothe short half-life of the GLP-1 peptide. In comparison, GLP-1 MMB ofSEQ ID NO: 71 (A2S) at a dose 100-fold lower than the GLP-1 peptide doseinduced a decrease in blood glucose throughout the entire 4 hour period(FIG. 7A). In addition, the decrease in blood glucose was dose dependent(FIG. 7B).

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 11 Pharmacokinetics of GLP-1 MMBs in Mice and in CynomolgusMonkeys

To measure the pharmacokinetics of four GLP-1 mimetibodies (A2G, A2S,exedin-cap, and wt) (SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, andSEQ ID NO: 69, respectively), C57/B16 mice were intravenously dosed with1 mg/kg of the MMBs. Plasma was obtained via cardiac puncture aftersacrificing mice at different time point. Various ELISAs were used tomeasure Fc, total MMB, active MMB, and active peptide as they weremetabolized in the animal. Active MMB reflects the intact N-terminus ofthe peptide still attached to the Fc region of the mimetibody.Substitution of the second amino acid in the peptide (alanine) witheither a serine or a glycine prolonged the lifetime of the active MMB incirculation.

Cynomolgus monkey were injected intravenously with 1.0 mg/kg of fourdifferent GLP-1 MMB constructs and serum samples were taken at differenttime points from 10 minutes to 5 days following dosing. Serum sampleswere evaluated by ELISA to quantify intact MMB. As illustrated in FIG.8, all four MMBs exhibit a rapid distribution phase, followed by aslower clearance phase. Pharmacokinetic constants were calculated foreach of the constructs to indicate a T½ of approximately 3 days withsimilar exposure determined by AUC from T=0 to T=120 hours.

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 12 Pharmacokinetic Characterization of GLP-1MMB in Rats andMonkeys

GLP-1MMB was engineered to maintain the bioactivity of GLP-1 whileextending its pharmacokinetic (PK) profile.

Pharmacokinetics in rats: Sprague-Dawley-derived rats were treated witha single subcutaneous or intravenous dose of GLP-1 MMB of SEQ ID NO 4(3.0 mg/kg, lot #8833173) (1). Approximately 300 μl of blood werecollected at various times following dosing in sodium citrate (3.8%)containing protease inhibitors (Roche Complete EDTA free, Roche AppliedScience, Indianapolis, Ind.) and DPP4 inhibitors (Linco, St. Charles,Mo.). Plasma was isolated and stored at −80° until samples could beanalyzed. The concentration of intact GLP-1 MMB of SEQ ID NO 4 wasmeasured using a mesoscale discovery (MSD) technology [3-7]. Briefly,plasma samples were serially diluted by BioMek Fx for a total of 4dilutions, neat, 1:8, 1:64 and 1:512. Identical standard curves in neatplasma were included on each plate. GLP-1MMB of SEQ ID NO 4 was capturedon MSD plates by biotinylated monoclonal antibody (CNTO1626) designed todetect intact N-terminus of GLP-1MMB of SEQ ID NO 4. Ruthenium labeledmonoclonal antibody recognizing linker region on GLP-1MMB of SEQ ID NO 4(CNTO712) were added for detection and the luminescence responses weredetermined using the MSD sector imager 6000 reader. GLP-1MMB of SEQ IDNO 4 level was calculated using sigmoidal dose-response curve (GraphPadPRISM).

Pharmacokinetics in monkeys: Cynomolgus monkeys were dosed intravenouslywith GLP-1MMB of SEQ ID NO 4 (1.0 mg/kg, lot #8833013) at DiabetesResearch Institute, University of Miami (2). The monkeys were chemicallyrestrained with ketamine HCl (100 mg/mL, 10 mg/kg) prior to dosing andblood collections. GLP-1MMB of SEQ ID NO 4 was administered at a dosevolume of 2.2 mL/kg at a rate of 1 mL/minute. Approximately 2 mL ofblood was collected at various time points following dosing in sodiumcitrate (3.8%) containing protease inhibitors (Roche Complete EDTA free,Roche Applied Science, Indianapolis, Ind.) and DPP4 inhibitors (Linco,St. Charles, Mo.). Plasma was isolated and stored at −80° until samplescould be analyzed. GLP-1MMB of SEQ ID NO 4 concentrations in the plasmawas measured as described above.

Data analysis: Non-compartmental analysis (NCA) was employed tocalculate the pharmacokinetic parameters of GLP-1MMB of SEQ ID NO 4(WinNonlin, Version 5.1, Pharsight Corporation, Mountain View, Calif.).The maximum serum concentration, Cmax and the time to reach Cmax (Tmax),were obtained from inspection of the serum concentration vs. timeprofiles. The area under the concentration curve (AUC) from time 0 tothe last time point with quantifiable levels of GLP-1MMB of SEQ ID NO 4was calculated (AUC (0-7d) for rat, AUC (0-21d) for monkey), as well asthe AUC from time 0 to infinity. The AUC values were obtained by lineartrapezoidal integration. The terminal rate constant (λz) was determinedby least-squares regression analysis of the log-linear portion of theterminal phase. The terminal half-life, t½, was calculated from theratio of 0.693 and λz.

Results: Pharmocokinetics in rats: The plasma pharmacokinetic profile ofGLP-1MMB of SEQ ID NO 4 in rats after a single sc and iv administrationis shown (FIG. 20A). The full pharmacokinetic analysis from the rat datais summarized in Table 1. The terminal half-life of GLP-1MMB of SEQ IDNO 4 was modeled to be 1.5 days following iv dosing and 1.7 daysfollowing sc dosing. The bioavalibility of GLP-1MMB of SEQ ID NO 4following sc administration was approximately 22%.

TABLE 2 Pharmacokinetic characteristics of GLP-1MMB of SEQ ID NO 4 in SDrats following single sc and iv administration (3 mg/kg). Cmax Tmax AUC(0-7 d) AUCinf Cl Vss t½ Material (route) ug/mL day day * ug/mL day *ug/mL mL/day/kg mL/kg day F % GLP-1MMB (iv) mean 53.91 na 23.61 23.86125.90 110.07 1.48 na of SEQ ID NO 4 sd 5.03 na 1.11 1.06 5.59 7.32 0.49na % CV 9.3 na 4.7 4.4 4.4 6.7 33.0 na GLP-1MMB (sc) mean 2.29 0.83 5.045.20 na na 1.73 21.85 of SEQ ID NO 4 sd 0.10 0.29 0.20 0.30 na na 1.101.85 % CV 4.5 34.6 4.0 5.7 na na 63.7 8.5 GLP-1MMB mean 53.91 na 23.6123.86 125.90 110.07 1.48 na of SEQ ID NO 4 (iv) sd 5.03 na 1.11 1.065.59 7.32 0.49 na % CV 9.3 na 4.7 4.4 4.4 6.7 33.0 na GLP-1MMB mean 2.290.83 5.04 5.20 na na 1.73 21.85 of SEQ ID NO 4 (sc) sd 0.10 0.29 0.200.30 na na 1.10 1.85 % CV 4.5 34.6 4.0 5.7 na na 63.7 8.5

Pharmocokinetics in monkeys: The plasma pharmacokinetic profile ofGLP-1MMB in monkeys following a single iv administration is shown (FIG.20B). The full pharmacokinetics analysis is summarized in Table 2. Theterminal half-life of GLP-1MMB in monkey was modeled to be 2.9 days.

TABLE 3 Pharmacokinetic characteristics of GLP-1MMB of SEQ ID NO 4 incynomolgus monkeys following single iv administration (1 mg/kg). meanconc PK Parameters (ug/mL) sd % CV Cmax ug/mL 40.09 9.28 23.1 AUC(0-21)day*ug/mL 41.92 10.25 24.4 AUCinf day*ug/mL 42.05 10.29 24.5 ClmL/day/kg 24.81 6.38 25.7 Vss mL/kg 50.18 19.07 38.0 Vz mL/kg 105.4034.92 33.1 t½ day 2.93 0.37 12.7

Example 13 Effects of GLP-1 MMB during an Oral Glucose Tolerance Test inDiabetic Mice

Eight-week old diabetic db/db mice were fasted for 6 hours prior to asubcutaneous injection of the GLP-1 MMB of SEQ ID NO: 71 (0.02 to 2mg/kg). Following dosing, mice were fasted for an additional six hoursand a baseline fasting blood glucose was measured. At t=0, mice weregiven an oral gavage of 1.0 mg/g glucose, and blood glucose was measuredat various times. Results shown in FIG. 9 indicate that the GLP-1 MMB ofSEQ ID NO: 71 was effective in lowering the glucose excursion during anoral glucose tolerance test at all doses tested.

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 14 Effects of GLP-1 MMB on Fasting Blood Glucose During ChronicDosing to Diabetic Mice

Ten-week old diabetic db/db mice were subcutaneously dosed daily withvehicle or GLP-1 MMB of SEQ ID NO: 71 (1 mg/kg) for six weeks. Fastingblood glucose was measured twice per week during the course of thestudy. The fasting blood glucose was reduced in the treated animalsrelative to the controls throughout the study (FIG. 10), and by sixweeks, the difference was more than 200 mg/dL (466 vs 221 mg/dL, controland treated animals respectively).

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 15 Effects of GLP-1 MMB on Oral Glucose Tolerance Test afterChronic Dosing to Diabetic Mice

As in Example 11, ten-week old diabetic db/db mice were dosed daily withvehicle or GLP-1 MMB of SEQ ID NO: 71 (1 mg/kg) for six weeks. After 40days of dosing, the mice were given an oral glucose tolerance test.Briefly, at t=0, mice were given an oral gavage of 1.0 mg/g glucose, andblood glucose was measured at various times. Results shown in FIG. 11indicate that the GLP-1 MMB of SEQ ID NO: 71 was effective in loweringthe glucose excursion during an oral glucose tolerance test suggestingthat mice treated chronically with GLP-1 MMB of SEQ ID NO: 71 are ableto dispose of a glucose load more efficiently relative to controlanimals.

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 16 Effects of GLP-1 MMB on reducing HbA1c after Chronic Dosingto Diabetic Mice

As in Examples 11 and 12, ten-week old diabetic db/db mice were doseddaily with vehicle or GLP-1 MMB of SEQ ID NO: 71 (1 mg/kg) for sixweeks. Before and after six-weeks of dosing, whole blood samples weretaken and analyzed for percent HbA1c. As shown in FIG. 12, the HbA1C ofthe GLP-1 treated animals increased by 109 percent during the six-weekperiod whereas the control treated animals increased by 142 percent.This data suggests that the treated animals are better able to regulatetheir blood glucose over a chronic period relative to the controls.

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 17 Effects of GLP-1 MMB on an Oral Glucose Tolerance Test inNormal Cynomolgus Monkeys

An oral glucose tolerance test (OGTT) was done in normal cynomolgusmonkeys prior to and six days after a single dose of the GLP-1 MMB ofSEQ ID NO: 71 (1 mg/kg). Briefly, at t=0, monkeys were given an oralgavage of 2.0 mg/g glucose, and blood glucose was measured at varioustimes. The blood glucose levels were significantly reduced in the OGTTdone six days after dosing (FIG. 13A), and the insulin levels weresignificantly increased (FIG. 13B). This suggests the GLP-1 MMB of SEQID NO: 71 is causing insulin secretion from the pancreas at elevatedglucose concentrations.

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 18 Effects of GLP-1 MMB on Insulin Staining in Islets ofDiabetic Mice (db/db) after a Single Dose

Twelve-week old diabetic mice (db/db) were treated with a singlesubcutaneous dose of the GLP-1 MMB of SEQ ID NO: 71 (1.5 mg/kg), and thepancreata were harvested four weeks later. The pancreata were sectionedand stained for the presence of insulin. As shown in FIG. 14, there wassignificantly more insulin staining in the treated animals relative tothe control animals.

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 19 GLP-1 MMB Delays Gastric Emptying in Normal Dogs

A gastric cannula was surgically implanted into female beagle dogs(10-15 kg) under general anesthesia and allowed to recover for at least2 weeks. Dogs were fasted for 24 hours after which water was freelyavailable. The gastric cannula was opened and gastric juice and foodremnants were removed with 40-50 ml of lukewarm water. Groups of sixdogs were dosed subcutaneously with lidamidine, an alpha2 agonist (0.63mg/kg), 60 minutes before the meal, a positive control for delay ofgastric emptying. Dogs dosed with the vehicle control or GLP-1 MMB ofSEQ ID NO: 70 (0.1 mg/kg) were dosed intravenously in the cephalic vein15 minutes before the meal. Five minutes before the meal, the gastriccannula was opened to determine the amount of fluid present in stomachfor baseline value and fluid was promptly reintroduced. Then a test mealconsisting of 250 ml of a glucose solution (5 g/l) was administered viathe cannula and allowed to remain in the stomach for 30 minutes. Gastriccontents were drained from the stomach to measure total volume after 30minutes. One ml of gastric contents was retained for analysis and theremaining volume was reintroduced into the stomach via the cannula.Assessment of the gastric content volume and retrieval of samples wasrepeated at 60, 90, and 120 minutes. Glucose concentrations wereevaluated for collected samples and used to determine the absoluteamount of glucose remaining in the stomach at each time point. Thepercentage of glucose retained in the stomach was determined from thestarting value and the concentration of glucose at each time point andplotted as a function of time. The time at which 50% of the gastriccontents were retained was determined by fitting of the curves to asingle exponential. As shown in FIG. 15, 50% of the gastric contentswere emptied in dogs dosed with vehicle in 12.35±3.69 minutes followingwhile the lidamidine positive control and GLP-1 MMB of SEQ ID NO: 70dosed dogs showed a significant delay in gastric emptying (30.60±6.47and 59.23±14.46, respectively).

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO 4 andsimilar results were obtained.

Example 20 GLP-1 MMB Lowers Blood Glucose following an Oral GlucoseTolerance Test (OGTT) in Diet Induced Obese Mice

To develop a murine model of diet induced obesity, mice were maintainedon a high fat diet for at least 27 weeks. Mice became obese and weredetermined to be diabetic when fasting blood glucose values exceeded 120mg/dl. To evaluate the effect of GLP-1 MMB therapy on postprandial bloodglucose levels, diet induced obese mice were fasted overnight and dosedsubcutaneously with 0.02, 0.2, or 2 mg/kg GLP-1 MMB of SEQ ID NO: 71 orvehicle control. Six hours after dosing, mice were given a 1.5 mg/ggastric gavage of glucose. Blood glucose levels were determined prior toMMB dosing, at t=0, 15, 30, 60, 90, 120, 150, and 180 minutes using tailvein blood. As shown in FIG. 16, GLP-1 MMB of SEQ ID NO: 71 dosedependent decrease in fasting blood glucose values was observed at t=0and all subsequent time points. Areas under the curve were calculatedbetween t=0 and t=180 demonstrating a significant lowering in glucosedisposal at all doses.

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 21

GLP-1 MMB Lowers Blood Glucose in an Intraperitoneal Glucose ToleranceTest (IPGTT) in db/db Mice

Male db/db mice of approximately 13-15 weeks of age were randomized intotreatment groups of six mice based on fasting blood glucose levels. Micewere dosed with either 0.02 mg/kg or 0.1 mg/kg of GLP-1 MMB of SEQ IDNO: 71 or 0.1 mg/kg of negative control MMB six hours prior to theglucose tolerance test. Five minutes before the glucose tolerance test,a glucose measurement was taken with a hand held glucometer from tailvein blood. Mice were then dosed intraperitoneally with 1 mg/g ofD-glucose and blood glucose levels were monitored at 10 min, 20 min, 30min, 60 min, 90 min, 120 min, 150 min, and 180 min. As illustrated inFIG. 17A, blood glucose levels were significant lower in both groupstreated with GLP-1 MMB of SEQ ID NO: 71 over the full time course.Additional groups of animals treated in the same manner were sacrificedfor measurement of insulin levels at t=10 minutes. There is a dosedependent increase in the amount of insulin released 10 minutesfollowing GLP-1 MMB of SEQ ID NO: 71 dosing.

Similar experiments were repeated for the GLP-1 MMB of SEQ ID NO:4 andsimilar results were obtained.

Example 22 Acute Pharmodynamic Study with GLP-1MMB

To demonstrate biological activity of a GLP-1 MMB of SEQ ID NO 4, anintraperetoneal glucose tolerance test (ipGTT) was performed indiet-induced obese (DIO) mice.

Materials/Methods: D-glucose was purchased from Sigma. The studiesdescribed below used diet-induced obese (DIO) C57B1/6J mice that werestarted on a diet containing 60.9% fat (Purina TestDiets 58126) at 4weeks of age. All animals achieved three consecutive weeks of diabeticfasting blood glucose values (>120 mg/dL) prior to their inclusion inthe study. ipGTT: Thirty-five mice were fasted overnight (16 hr) andwere randomized into 7 groups (n=5) based upon their fasting glucoseconcentrations. Ten minutes prior to the glucose tolerance test, micewere dosed i.v. with PBS or GLP1 MMB of SEQ ID NO 4 (0.003, 0.01, 0.03,0.1, 0.3, and 1.0 mg/kg). Five minutes prior to the glucose tolerancetest, a fasting glucose measurement was made from tail vein blood. AtT=0 min, mice were dosed i.p. with D-glucose (1.0 mg/g). Blood glucoselevels were measured at 15, 30, 60, 90, 120, 150 and 180 min using tailvein blood.

Results: The blood glucose levels measured during the glucose tolerancetest were plotted as a function of time (FIG. 21A). The area under thecurve was calculated and was significantly reduced in a dose dependentmanner in five of the groups treated with GLP-1 MMB of SEQ ID NO 4(0.01, 0.03, 0.1, 0.3, 1 mg/kg) relative to the PBS-treated group (FIG.21B). The AUC vs GLP-1 MMB of SEQ ID NO 4 concentration was fit to ahyperbola, providing an ED₅₀ of 14 μg/kg (FIG. 21C). Data was plottedand analyzed in GraphPad PRISM, version 4.03.

Example 23 Effect of a GLP-1 MMB on Food Intake, Glycemic Control andGastric Emptying in GLP-1R−/− and Wild-Type Mice

The purpose of this study was to evaluate if a GLP-1 MMB affectsglycemic control, food intake and gastric emptying in a GLP-1receptor-dependent manner. Single intravenous (iv) administration of aGLP-1 MMB of SEQ ID NO 4 improved glucose tolerance, reduced food intakeand inhibited gastric emptying in wild type, but not in GLP-1 receptorknock out mice. The results demonstrate that the effect of a GLP-1 MMBof SEQ ID NO 4 on glucose and energy metabolism is mediated via theGLP-1 receptor.

Materials/Methods: Animals: Male GLP-1R−/− and age matched wild typemice were randomized into three treatment groups (n=5) based on bodyweight and fasting blood glucose.Food intake: Mice were fasted overnight and injected with a singleintravenous (iv) dose of a GLP-1 MMB of SEQ ID NO 4 (1 mg/kg), CNTO 1996(1 mg/kg) (CNTO1996 was used in the study as a negative control since itlacks the GLP-1 peptide and an equimolar dose of exendin-4 (0.07 mg/kg,purchased from Sigma). Food and water intake was measured 4, 6, 24 and48 h post dosing.Glucose tolerance test (ipGTT): Mice were fasted overnight and dosedintravenously as discussed above. Fasting glucose was measured via tailsnips using a hand-held glucometer (LifeScan). At t=0 min, mice weredosed i.p. with D-glucose (1.0 mg/g, Sigma) and blood glucose wasmeasured after 15, 30, 60, 90 and 120 min using tail vein bloodGastric Emptying: Mice were fasted overnight. The next morning mice werere-fed for 1 h, food intake was recorded and the mice were deprived offood for the rest of the study. Mice were dosed intravenously asdiscussed above. Two hours post-dosing mice were euthanized. The stomachwas exposed by laparotomy, ligated at both the pylorus and cardia andremoved. The stomach content wet weight was measured. Equation 1 wasused to calculate the percent of food remaining in the stomach.

(Stomach Content Wet Weight(g)/Food Intake(g))*100  Equation (1)

Results and Discussion

Food Intake Cumulative food intake for both the wild-type and GLP-1R−/−mice over a 24 hour period post drug administration was plotted (FIG.22). Both the GLP-1 MMB of SEQ ID NO 4 (1 mg/kg) and an equimolar doseof exendin-4 (0.07 mg/kg) resulted in a statistically significantreduction in food intake in wild type animals compared to the controlgroup, CNTO1996 (FIG. 22A). The GLP-1 MMB of SEQ ID NO 4 and exendin-4had no effect on food intake in GLP-1R−/− mice (FIG. 22B).

Glucose Tolerance Test: The data obtained during the ipGTT in wild typeand GLP-1R−/− mice was plotted as the concentration of blood glucoseversus time (FIGS. 23A and 23B). The area under the curve (AUC) wascalculated for each individual ipGTT curve (FIG. 23C). Singleadministration of a GLP-1 MMB of SEQ ID NO 4 and exendin-4 resulted in astatistically significant reduction in the AUC in wild type but notGLP-1R−/− animalsGastric emptying: The percent of food remaining in the stomach 2 h afterdosing in wild type and GLP-1R−/− mice was plotted (FIG. 24). The GLP-1MMB of SEQ ID NO 4 (1 mg/kg) and an equimolar dose of exendin-4 (0.07mg/kg) resulted in a statistically significant increase in stomachcontent in the wild-type mice compared to the control, CNTO1996. Thedata demonstrate that the GLP-1 MMB of SEQ ID NO 4 and exendin-4 inhibitgastric emptying in wild type animals. The GLP-1 MMB of SEQ ID NO 4 andexendin-4 had no effect on gastric emptying in the GLP-1R−/− mice.

Example 24 Correlation of the Pharmacodynamic Activity of a GLP-1 MMBwith its Pharmacokinetic Profile in DIO Mice

The purpose of this study was to correlate the effect of a GLP-1 MMB inregulating glucose tolerance with its pharmacokinetic profile indiet-induced obese (DIO) mice. Animals were dosed (iv) with a GLP-1 MMBof SEQ ID NO 4 (1 mg/kg) and glucose tolerance tests were performed atvarious time post dosing. Simultaneously, blood samples were collectedto assess GLP-1 MMB of SEQ ID NO 4 levels. The GLP-1 MMB of SEQ ID NO 4improved glucose tolerance in DIO mice with an ED₅₀ of approximately 370ng/ml.

Materials/Methods. Animals/Treatments: C57B1/6J mice were started at 4weeks of age on a diet containing 60.9% fat (Purina TestDiets 58126). Atthe time of the study start, all of the animals had achieved threeconsecutive weeks of diabetic fasting blood glucose values (>120 mg/dL).DIO mice were randomized into treatment groups based on fasting bloodglucose and were dosed (iv) with GLP-1 MMB of SEQ ID NO 4 (1 mg/kg, lot#8833173)) or PBS. At various time post-dosing, glucose tolerance testswere performed and blood samples were collected to measure GLP-1 MMB ofSEQ ID NO 4 plasma levels as described below.Glucose tolerance test (ipGTT): Mice were fasted overnight (16 hr)before the test. In the morning a fasting glucose was measured via tailsnips using a hand-held glucometer (LifeScan). At T=0 min, mice weredosed i.p. with D-glucose (1.0 mg/g, Sigma). Blood glucose was measuredafter 15, 30, 60, 90 and 120 min using tail vein blood.GLP-1 MMB plasma levels: Blood samples were collected after the ipGTTvia cardiac puncture. Approximately 300 μl of blood was collected insodium citrate (3.8%) containing protease inhibitors (Roche CompleteEDTA free, Roche Applied Science, Indianapolis, Ind.) and DPP4inhibitors (Linco, St. Charles, Mo.). The concentration of intact GLP-1MMB of SEQ ID NO 4 was measured using a mesoscale discovery (MSD)technology [2-5]. Briefly, plasma samples were serially diluted by aBioMek Fx for a total of 4 dilutions, neat, 1:8, 1:64 and 1:512.Standard curves diluted in the same manner with plasma were included oneach plate. GLP-1 MMB was captured on the MSD plates by a biotinylatedmonoclonal antibody (CNTO1626) designed to detect the intact N-terminusof the mimetibody. A ruthenium labeled monoclonal antibody recognizingthe linker region of the mimetibody (CNTO712) was added for detection,and the luminescence responses were determined using the MSD sectorimager 6000 reader. GLP-1 MMB of SEQ ID NO 4 level was calculated usingsigmoidal dose-response curve (GraphPad PRISM).Results And Discussion. Pharmacodynamics of a GLP-1 MMB: The ipGTT datafrom each time point was plotted as the concentration of blood glucoseversus time (FIG. 25). The area under the curve (AUC) was calculated foreach individual ipGTT curve (FIG. 26). Single administration of theGLP-1 MMB of SEQ ID NO 4 resulted in a statistically significantreduction in the AUC up to 6 days post injection relative to thenegative control.Pharmacokinetics of GLP-1 MMB: The plasma concentration of the GLP-1 MMBof SEQ ID NO 4 in DIO mice following each glucose tolerance test wasplotted (FIG. 27).Correlation of pharmacodynamic activity of GLP-1 MMB with its plasmalevels: The AUC for all of the ipGTT data was plotted versus the GLP-1MMB of SEQ ID NO 4 plasma levels following each glucose tolerance test(FIG. 28). The data were fit to a hyperbola to obtain the ED₅₀ (370ng/ml).

Advantages of GLP-1 Mimetibody: The use of this novel molecule as atherapeutic to treat type 2 diabetes provides several advantages overother GLP-1 analogues. For example, it is likely to prolong thehalf-life of the GLP-1 peptide. Also, the wild-type GLP-1 peptide in themimetibody scaffold is resistant to protease degradation, specificallyDPP-IV. This may allow for treatment with the wild-type GLP-1 peptiderather than a mutant peptide. Since GLP-1 is a native peptide, there maybe less immune response in patients treated with a GLP-1 mimetibody thanin patients treated with a mutated GLP-1 analogue. In addition, thelarge size of the mimetibody may preclude it from crossing the bloodbrain barrier. This may offer an advantage since nausea and anxiety havebeen associated with GLP-1 engaging the GLP-1R in the brain.Furthermore, the mimetibody platform results in expression of twopeptides on each mimetibody molecule. This may allow the GLP-1 peptidesto interact with each other, forming a dimeric ligand that couldincrease affinity to the cell surface GLP-1 receptor.

It will be clear that the invention can be practiced otherwise than asparticularly described in the foregoing description and examples.

Numerous modifications and variations of the present invention arepossible in light of the above teachings and, therefore, are within thescope of the present invention.

TABLE 1 SEQ TOTAL REGIONS ID NO AA NO FR1 FR4 47 Heavy Vh1 125 1-31 81-125 48 chain Vh2 97 1-30 80-97 49 variable Vh3a 102 1-30  80-102 50region Vh3b 102 1-30  80-102 51 Vh3c 94 1-30 80-94 52 Vh4 106 1-30 80-106 53 Vh5 97 1-30 80-97 54 Vh6 91 1-30 80-91 55 Vh7 91 1-30 80-91SEQ REGIONS ID NO AA NO hinge1 hinge2 hinge3 hinge4 CH2 CH3 CH4 56 HeavyIgA1 354 103-122  123-222 223-354 57 chain IgA2 340 103-108  109-209210-340 58 constant IgD 384 102-135  319-497 160-267 268-384 59 regionIgE 497 104-210 211-318 319-497 60 IgG1 339 99-121 122-223 224-339 61IgG2 326 99-117 118-219 220-326 62 IgG3 377 99-115 131-145 146-168169-270 271-377 63 IgG4 327 99-110 324-476 111-220 221-327 64 IgM 476105-217 218-323 324-476

1. (canceled)
 1. At least one GLP-1 CH1 deleted mimetibody nucleic acid,comprising at least one polynucleotide encoding the amino acid sequencecomprising at least one selected from SEQ ID NOS:2, 4, 6 or 7-14, or apolynucleotide complementary thereto, wherein said GLP-1 CH1 deletedmimetibody has at least one GLP-1 biological activity in vitro or invivo and further comprising at least one N-linked glycosylation site. 2.At least one GLP-1 CH1 deleted mimetibody nucleic acid according toclaim 1, comprising at least one polynucleotide encoding the amino acidsequence of SEQ ID NOS:2 or 4, or a polynucleotide complementarythereto, wherein said GLP-1 CH1 deleted mimetibody has at least oneGLP-1 biological activity in vitro or in vivo and further comprising atleast one N-linked glycosylation site.
 3. At least one GLP-1 CH1 deletedmimetibody nucleic acid, comprising at least one polynucleotide encodinga polypeptide according to Formula (I):(Pep(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), wherein P comprises at leastone bioactive GLP-1 peptide selected from SEQ ID NOS:1 or 6, L is atleast one linker sequence comprising Ser and Gly, V is at least oneportion of a C-terminus of an immunoglobulin variable region, His atleast a portion of an immunoglobulin variable hinge region, CH2 is atleast a portion of an immunoglobulin CH2 constant region, CH3 is atleast a portion of an immunoglobulin CH3 constant region, n is aninteger from 1 to 10, and o, p, q, r, s, and t can be independently aninteger from 0 to 10, wherein said GLP-1 CH1 deleted mimetibody has atleast one GLP-1 biological activity in vitro or in vivo and furthercomprising at least one N-linked glycosylation site.
 4. At least oneGLP-1 CH1 deleted mimetibody polypeptide, comprising all of thecontiguous amino acids of SEQ ID NOS:2 or 4, wherein said GLP-1 CH1deleted mimetibody polypeptide has at least one GLP-1 biologicalactivity in vitro or in vivo and further comprising at least oneN-linked glycosylation site.
 5. At least one GLP-1 CH1 deletedmimetibody polypeptide, comprising all of the contiguous amino acids ofat least one of SEQ ID NOS:7-14, wherein said GLP-1 CH1 deletedmimetibody polypeptide has at least one GLP-1 biological activity invitro or in vivo and further comprising at least one N-linkedglycosylation site.
 6. At least one GLP-1 CH1 deleted mimetibodypolypeptide, comprising a polypeptide according to Formula (I):(Pep(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), wherein P is at least onebioactive GLP-1 peptide selected from SEQ ID NO:1 and 6, L is selectedfrom GS, GGS, GGGS (SEQ ID NO:16), GSGGGS (SEQ ID NO:17), GGSGGGS (SEQID NO:18), GGSGGGSGG (SEQ ID NO:19) and GGGSGGGSGG (SEQ ID NO:20); V isselected from GTLVTVSS (SEQ ID NO:21), GTLVAVSS (SEQ ID NO:22), GTAVTVSS(SEQ ID NO:23), TVSS (SEQ ID NO:24), and AVSS (SEQ ID NO:25); H isEPKSCDKTHTCPPCPAPELLGGP (SEQ ID NO:26), CH2 isSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK (SEQ ID NO:43),CH3 is GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS LSPGK (SEQ IDNO:44), n is an integer from 1 to 10, and o, p, q, r, s, and t can beindependently an integer from 0 to 10, wherein said GLP-1 CH1 deletedmimetibody has at least one GLP-1 biological activity in vitro or invivo and further comprising at least one N-linked glycosylation site. 7.At least one GLP-1 CH1 deleted mimetibody polypeptide, comprising apolypeptide according to Formula (I):(Pep(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), wherein P is at least onebioactive GLP-1 peptide of SEQ ID NO:6, L is selected from GS, GGS, GGGS(SEQ ID NO:16), GSGGGS (SEQ ID NO:17), GGSGGGS (SEQ ID NO:18), GGSGGGSGG(SEQ ID NO:19) and GGGSGGGSGG (SEQ ID NO:20); V is selected fromGTLVTVSS (SEQ ID NO:21), GTLVAVSS (SEQ ID NO:22), GTAVTVSS (SEQ IDNO:23), TVSS (SEQ ID NO:24), and AVSS (SEQ ID NO:25); HisESKYGPPCPSCPAPEFLGGP (SEQ ID NO:27), CH2 isSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK (SEQ ID NO:45), CH3 isGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:46), n isan integer from 1 to 10, and o, p, q, r, s, and t can be independentlyan integer from 0 to 10, wherein said GLP-1 CH1 deleted mimetibody hasat least one GLP-1 biological activity in vitro or in vivo and furthercomprising at least one N-linked glycosylation site.
 8. At least oneGLP-1 CH1 deleted mimetibody polypeptide, comprising a polypeptideaccording to Formula (I):(Pep(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), wherein P is at least onebioactive GLP-1 peptide of SEQ ID NO:6, L is selected from GS, GGS, GGGS(SEQ ID NO:16), GSGGGS (SEQ ID NO:17), GGSGGGS (SEQ ID NO:18), GGSGGGSGG(SEQ ID NO:19) and GGGSGGGSGG (SEQ ID NO:20); V is selected fromGTLVTVSS (SEQ ID NO:21), GTLVAVSS (SEQ ID NO:22), GTAVTVSS (SEQ IDNO:23), TVSS (SEQ ID NO:24), and AVSS (SEQ ID NO:25); HisESKYGPPCPPCPAPEAAGGP (SEQ ID NO:28), CH2 isSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK (SEQ ID NO:45), CH3 isGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:46), n isan integer from 1 to 10, and o, p, q, r, s, and t can be independentlyan integer from 0 to 10, wherein said GLP-1 CH1 deleted mimetibody hasat least one GLP-1 biological activity in vitro or in vivo and furthercomprising at least one N-linked glycosylation site.
 9. At least oneGLP-1 CH1 deleted mimetibody polypeptide, comprising a polypeptideaccording to Formula (I):(Pep(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), wherein P is at least onebioactive GLP-1 peptide, variant or derivative, L is at least one linkersequence, which can be a polypeptide that provides structuralflexibility by allowing the mimetibody to have alternative orientationsand binding properties, V is at least one portion of a C-terminus of animmunoglobulin variable region, His at least a portion of animmunoglobulin variable hinge region, CH2 isSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK (SEQ ID NO:43),CH3 is GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS LSPGK (SEQ IDNO:44), n is an integer from 1 to 10, and o, p, q, r, s, and t can beindependently an integer from 0 to 10, wherein said GLP-1 CH1 deletedmimetibody has at least one GLP-1 biological activity in vitro or invivo and further comprising at least one N-linked glycosylation site.10. At least one GLP-1 CH1 deleted mimetibody polypeptide, comprising apolypeptide according to Formula (I):(Pep(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), wherein P is at least onebioactive GLP-1 peptide, variant or derivative, L is at least one linkersequence, which can be a polypeptide that provides structuralflexibility by allowing the mimetibody to have alternative orientationsand binding properties, V is at least one portion of a C-terminus of animmunoglobulin variable region, His at least a portion of animmunoglobulin variable hinge region, CH2 isSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK (SEQ ID NO:45), CH3 isGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:46), n isan integer from 1 to 10, and o, p, q, r, s, and t can be independentlyan integer from 0 to 10, wherein said GLP-1 CH1 deleted mimetibody hasat least one GLP-1 biological activity in vitro or in vivo and furthercomprising at least one N-linked glycosylation site.
 11. At least oneGLP-1 CH1 deleted mimetibody polypeptide, comprising a polypeptideaccording to Formula (I):(Pep(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), wherein P is at least onebioactive GLP-1 peptide of SEQ ID NO:6, L is at least one linkersequence, which can be a polypeptide that provides structuralflexibility by allowing the mimetibody to have alternative orientationsand binding properties, V is at least one portion of a C-terminus of animmunoglobulin variable region, His at least a portion of animmunoglobulin variable hinge region, CH2 is at least a portion of animmunoglobulin CH2 constant region, CH3 is at least a portion of animmunoglobulin CH3 constant region, n is an integer from 1 to 10, and o,p, q, r, s, and t can be independently an integer from 0 to 10, whereinsaid GLP-1 CH1 deleted mimetibody has at least one GLP-1 biologicalactivity in vitro or in vivo and further comprising at least oneN-linked glycosylation site.
 12. At least one GLP-1 CH1 deletedmimetibody polypeptide, comprising a polypeptide according to Formula(I):(Pep(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), wherein P is at least onebioactive GLP-1 peptide, variant or derivative, L is selected from GS,GGS, GGGS (SEQ ID NO:16), GSGGGS (SEQ ID NO:17), GGSGGGS (SEQ ID NO:18),GGSGGGSGG (SEQ ID NO:19) and GGGSGGGSGG (SEQ ID NO:20); V is at leastone portion of a C-terminus of an immunoglobulin variable region, His atleast a portion of an immunoglobulin variable hinge region, CH2 is atleast a portion of an immunoglobulin CH2 constant region, CH3 is atleast a portion of an immunoglobulin CH3 constant region, n is aninteger from 1 to 10, and o, p, q, r, s, and t can be independently aninteger from 0 to 10, wherein said GLP-1 CH1 deleted mimetibody has atleast one GLP-1 biological activity in vitro or in vivo and furthercomprising at least one N-linked glycosylation site.
 13. At least oneGLP-1 CH1 deleted mimetibody polypeptide, comprising a polypeptideaccording to Formula (I):(Pep(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), wherein P is at least onebioactive GLP-1 peptide, variant or derivative; L is at least one linkersequence, which can be a polypeptide that provides structuralflexibility by allowing the mimetibody to have alternative orientationsand binding properties; V is selected from GTLVTVSS (SEQ ID NO:21),GTLVAVSS (SEQ ID NO:22), GTAVTVSS (SEQ ID NO:23), TVSS (SEQ ID NO:24),and AVSS (SEQ ID NO:25); His at least a portion of an immunoglobulinvariable hinge region; CH2 is at least a portion of an immunoglobulinCH2 constant region; CH3 is at least a portion of an immunoglobulin CH3constant region; n is an integer from 1 to 10, and o, p, q, r, s, and tcan be independently an integer from 0 to 10, wherein said GLP-1 CH1deleted mimetibody has at least one GLP-1 biological activity in vitroor in vivo and further comprising at least one N-linked glycosylationsite.
 14. At least one GLP-1 CH1 deleted mimetibody polypeptide,comprising a polypeptide according to Formula (I):(Pep(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), wherein P is at least onebioactive GLP-1 peptide, variant or derivative, L is at least one linkersequence, which can be a polypeptide that provides structuralflexibility by allowing the mimetibody to have alternative orientationsand binding properties, V is at least one portion of a C-terminus of animmunoglobulin variable region, His selected fromEPKSCDKTHTCPPCPAPELLGGP (SEQ ID NO:26), ESKYGPPCPSCPAPEFLGGP (SEQ IDNO:27), and ESKYGPPCPPCPAPEAAGGP (SEQ ID NO:28), CH2 is at least aportion of an immunoglobulin CH2 constant region, CH3 is at least aportion of an immunoglobulin CH3 constant region, n is an integer from 1to 10, and o, p, q, r, s, and t can be independently an integer from 0to 10, wherein said GLP-1 CH1 deleted mimetibody has at least one GLP-1biological activity in vitro or in vivo and further comprising at leastone N-linked glycosylation site.
 15. At least one GLP-1 CH1 deletedmimetibody polypeptide, comprising a polypeptide according to Formula(I):(Pep(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), wherein P is at least onebioactive GLP-1 peptide, variant or derivative, L is at least one linkersequence, which can be a polypeptide that provides structuralflexibility by allowing the mimetibody to have alternative orientationsand binding properties, V is at least one portion of a C-terminus of animmunoglobulin variable region, His selected fromEPKSADKTHTCPPCPAPEAAGGP (SEQ ID NO:29), EPKSADKTHTCPPCPAPELAGGP (SEQ IDNO:30), EPKSADKTHTCPPCPAPEALGGP (SEQ ID NO:31), EPKSADKTHTCPPCPAPELEGGP(SEQ ID NO:32), EPKSSDKTHTCPPCPAPEFLGGP (SEQ ID NO:33),EPKSADKTHACPPCPAPELLGGP (SEQ ID NO:34), EPKSADKAHTCPPCPAPELLGGP (SEQ IDNO:35), and EPKSADKTHTCPPCPAPELLGGP (SEQ ID NO:36), ADKTHTCPPCPAPELLGGP(SEQ ID NO:37), THTCPPCPAPELLGGP (SEQ ID NO:38), ESKYGPPCPSCPAPEAAGGP(SEQ ID NO:39), ESKYGPPCPPCPAPELLGGP (SEQ ID NO:40), CPPCPAPELLGGP (SEQID NO:41), and CPPCPAPEAAGGP (SEQ ID NO:42), CH2 is at least a portionof an immunoglobulin CH2 constant region, CH3 is at least a portion ofan immunoglobulin CH3 constant region, n is an integer from 1 to 10, ando, p, q, r, s, and t can be independently an integer from 0 to 10,wherein said GLP-1 CH1 deleted mimetibody has at least one GLP-1biological activity in vitro or in vivo and further comprising at leastone N-linked glycosylation site.
 16. At least one GLP-1 CH1 deletedmimetibody polypeptide according to Formula (I):(Pep(n)-L(o)-V(p)-H(q)-CH2(r)-CH3(s))(t), wherein P is at least onebioactive GLP-1 peptide, variant or derivative, L is at least one linkersequence, which can be a polypeptide that provides structuralflexibility by allowing the mimetibody to have alternative orientationsand binding properties, V is at least one portion of a C-terminus of animmunoglobulin variable region, His at least a portion of animmunoglobulin variable hinge region, CH2 is at least a portion of animmunoglobulin CH2 constant region, CH3 is at least a portion of animmunoglobulin CH3 constant region, n is an integer from 1 to 10, and o,p, q, r, s, and t can be independently an integer from 0 to 10, whereinsaid GLP-1 CH1 deleted mimetibody has at least one GLP-1 biologicalactivity in vitro or in vivo and further comprising at least oneN-linked glycosylation site.
 17. A GLP-1 CH1 deleted Mimetibody GLP-1CH1 deleted mimetibody polypeptide according to any one of claims 4 or 5wherein said polypeptide has at least one activity of at least one Ppolypeptide.
 18. An anti-idiotype monoclonal or polyclonal antibody,fusion protein, or fragment thereof, that specifically binds at leastone GLP-1 CH1 deleted mimetibody polypeptide according to any one ofclaims 4 or
 5. 20. (canceled)
 19. A GLP-1 CH1 deleted mimetibody vectorcomprising at least one isolated nucleic acid according to any one ofclaims 1-3.
 20. A GLP-1 CH1 deleted mimetibody host cell comprising anisolated nucleic acid according to any one of claims 1-3.
 21. A GLP-1CH1 deleted mimetibody host cell according to claim 19, wherein saidhost cell is at least one selected from COS-1, COS-7, HEK293, BHK21,CHO, BSC-1, Hep G2, 653, SP2/0, 293, NSO, DG44 CHO, CHO K1, HeLa,myeloma, or lymphoma cells, or any derivative, immortalized ortransformed cell thereof.
 22. A method for producing at least one GLP-1CH1 deleted mimetibody polypeptide or GLP-1 CH1 deleted mimetibodyantibody, comprising translating a nucleic acid according to any one ofclaims 1-3 under conditions in vitro, in vivo or in situ, such that theGLP-1 CH1 deleted mimetibody or antibody is expressed in detectable orrecoverable amounts.
 23. A pharmaceutical composition comprising atleast one GLP-1 CH1 deleted mimetibody polypeptide according to any oneof claims 4 or
 5. 24. A pharmaceutical composition according to claim23, wherein said composition further comprises at least onepharmaceutically acceptable carrier or diluent.
 25. A pharmaceuticalcomposition according to claim 24, further comprising at least onecomposition comprising an therapeutically effective amount of at leastone compound, composition or polypeptide selected from at least one of adiabetes or insuling metabolism related drug, a detectable label orreporter, a TNF antagonist, an anti-infective drug, a cardiovascular(CV) system drug, a central nervous system (CNS) drug, an autonomicnervous system (ANS) drug, a respiratory tract drug, a gastrointestinal(GI) tract drug, a hormonal drug, a drug for fluid or electrolytebalance, a hematologic drug, an antineoplactic, an immunomodulationdrug, an ophthalmic, otic or nasal drug, a topical drug, a nutritionaldrug, a cytokine, or a cytokine antagonist.
 26. A pharmaceuticalcomposition according to claim 23, in a form of at least one selectedfrom a liquid, gas, or dry, solution, mixture, suspension, emulsion orcolloid, a lyophilized preparation, or a powder.
 27. A method fordiagnosing or treating an GLP-1 related condition in a cell, tissue,organ or animal, comprising (a) contacting or administering acomposition comprising an effective amount of at least one GLP-1 CH1deleted mimetibody, polypeptide according to any one of claims 4 or 5,with, or to, said cell, tissue, organ or animal.
 28. A method accordingto claim 27, wherein the GLP-1 related condition is diabetes orcongestive heart failure.
 29. A method according to claim 27, whereinsaid effective amount is 0.0001-50 mg of GLP-1 CH1 deleted mimetibodyantibody; 0.1-500 mg of said GLP-1 CH1 deleted mimetibody; or 0.0001-100μg of said GLP-1 CH1 deleted mimetibody nucleic acid per kilogram ofsaid cells, tissue, organ or animal.
 30. A method according to claim 27,wherein said contacting or said administrating is by at least one modeselected from parenteral, subcutaneous, intramuscular, intravenous,intrarticular, intrabronchial, intraabdominal, intracapsular,intracartilaginous, intracavitary, intracelial, intracelebellar,intracerebroventricular, intracolic, intracervical, intragastric,intrahepatic, intramyocardial, intraosteal, intrapelvic,intrapericardiac, intraperitoneal, intrapleural, intraprostatic,intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal,intrasynovial, intrathoracic, intrauterine, intravesical, intralesional,bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.31. A method according to claim 27, further comprising administering,prior, concurrently or after said (a) contacting or administering, atleast one composition comprising an effective amount of at least onecompound or polypeptide selected from at least one of a diabetes orinsuling metabolism related drug, a detectable label or reporter, a TNFantagonist, an anti-infective drug, a cardiovascular (CV) system drug, acentral nervous system (CNS) drug, an autonomic nervous system (ANS)drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, ahormonal drug, a drug for fluid or electrolyte balance, a hematologicdrug, an antineoplactic, an immunomodulation drug, an ophthalmic, oticor nasal drug, a topical drug, a nutritional drug, a cytokine, or acytokine antagonist.
 32. A device, comprising at least one isolatedGLP-1 CH1 deleted mimetibody polypeptide according to any one of claims4 or 5, wherein said device is suitable for contacting or administeringsaid at least one of said GLP-1 CH1 deleted mimetibody polypeptide,antibody or nucleic acid, by at least one mode selected from parenteral,subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial,intraabdominal, intracapsular, intracartilaginous, intracavitary,intracelial, intracelebellar, intracerebroventricular, intracolic,intracervical, intragastric, intrahepatic, intramyocardial, intraosteal,intrapelvic, intrapericardiac, intraperitoneal, intrapleural,intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal,intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical,intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal,or transdermal.
 33. An article of manufacture for human pharmaceuticalor diagnostic use, comprising packaging material and a containercomprising at least one isolated GLP-1 CH1 deleted mimetibodypolypeptide according to any one of claims 4 or
 5. 34. The article ofmanufacture of claim 33, wherein said container is a component of aparenteral, subcutaneous, intramuscular, intravenous, intrarticular,intrabronchial, intraabdominal, intracapsular, intracartilaginous,intracavitary, intracelial, intracelebellar, intracerebroventricular,intracolic, intracervical, intragastric, intrahepatic, intramyocardial,intraosteal, intrapelvic, intrapericardiac, intraperitoneal,intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal,intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine,intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual,intranasal, or transdermal delivery device or system.
 35. A method forproducing at least one isolated GLP-1 CH1 deleted mimetibody polypeptideaccording to any one of claims 4 or 5, comprising providing at least onehost cell, transgenic animal, transgenic plant, plant cell capable ofexpressing in detectable or recoverable amounts said polypeptide,antibody or nucleic acid.
 36. At least one GLP-1 CH1 deleted mimetibodypolypeptide produced by a method according to claim 35.